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Abstract 
Increases in Staphylococcus aureus resistance against existing treatment options and 
the shortage of new antibiotics signals an urgent need for new treatments for the 
ongoing battle against the development of antibiotic resistance. 
DNA gyrase is an essential bacterial type II DNA topoisomerase that manipulates DNA 
topology by performing transient double-strand breaks and DNA strand passage.  As 
gyrase is vital for bacterial survival, it is an effective antibacterial target.  By 
understanding the mechanistic differences between S. aureus gyrase and the better 
studied Escherichia coli counterpart, we aim to better utilise S. aureus gyrase as an 
antibacterial target and improve the design of future antibacterial drug. 
This study has investigated features unique to S. aureus DNA gyrase: the potassium 
glutamate (KGlu) salt-dependent and salt-specific supercoiling.  This KGlu dependency 
in S. aureus, but not E. coli gyrase, was partially attributed to the differences in the C-
terminal domain of the gyrase A-subunit (GyrA).  The discovery of the two novel 
monovalent alkali metal cation (M+) binding sites located in N-terminal domain of GyrB 
by protein crystallography has suggested a novel role of these M+ ions in the 
supercoiling functions of DNA gyrase, providing theoretical links to the unique KGlu 
dependency in S. aureus gyrase and the dependency of monovalent ions in E. coli and B. 
subtilis gyrase. 
Diospyrin, a phyto-naphthoquinone, was found to be active against S. aureus in vivo.  It 
inhibits S. aureus gyrase and topo IV in vitro, with gyrase as the preferred target.  
Further studies suggested the binding site of Diospyrin to be located in the N-terminal 
domain of GyrB.  Diospyrin also partially inhibits the ATPase activity of GyrB in an 
allosteric manner.  Diospyrin is hypothesized to bind to a novel binding site between 
the ATPase domain and the transducer domain.  Diospyrin also inhibits both the 
relaxation and the DNA cleavage ability of gyrase, suggesting it inhibits gyrase with a 
novel mechanism. 
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Chapter 1 Introduction 
1.1 Antibiotic resistance 
1.1.1 History and latest development 
Development of antibiotic resistance has been the result of the constant competition 
between humans and bacterial evolution ever since the discovery of the first 
antibiotic, penicillin.  Penicillin was first famously discovered in 1928 by Sir 
Alexander Fleming by a fortuitous accident when a mould (Penicillin rubens) 
contaminated a petri dish of Staphylococcus aureus 1.  Since then, penicillin has been 
industrially mass produced and became a prescription antibacterial for the treatment 
of a wide spectrum of bacterial infections, saving numerous lives over the past 
decades.  However, as early as the 1940s it was discovered that resistance can be 
observed in bacterial cultures incubated in the presence of penicillin 2-3. 
It was then understood that bacteria have the ability to gradually acquire resistance 
upon exposure to antibiotics and there are needs for more novel antibiotics to 
compensate for the development of bacterial resistance against older antibiotics.  
Examples of antibacterial resistance developed by bacteria are listed in figure 1.1.  
Despite the gradual development of antibiotic resistance, the boom of antibiotic 
discovery and availability of a wide range of antibiotics has led to complacency and 
developed a general misconception that bacterial infections are no longer life-
threatening diseases.  Compounded by the generally short-dosage schedule of 
antibiotics, low profitability and the rising cost of developing antibacterials in 
comparison to other human targeting drugs 4, traditional antibacterials discovery is 
deemed unprofitable and was slowly phased out over the last 2 decades 4. 
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Figure 1.1.  A schematic diagram showing of some of the mechanisms 
contributing to multi-drug resistance in bacteria via horizontal gene 
transfer.  The resistant genes transferred via a plasmid are typically capable of 
producing resistance phenotypes via: i) enzymatic degradation or modification 
of the specific antibiotic or ii) removal of antibiotics out of the intracellular 
space by efflux pumps 5. 
While discoveries of antibiotics have slowed, antibacterial resistance continues to rise, 
accelerated by years of their overuse in clinics 6.  This rise in demand for novel 
antibiotics is met with the decline in newly approved antibacterials.  With this 
ongoing trend, bacterial infections are predicted to again become the deadliest 
disease in the clinic 6.  The World Health Organisation has voiced concerns of late and 
regards antimicrobial resistance as one of the biggest threat to global health 7. 
 
1.1.2 Methicillin-resistant-Staphylococcus aureus  
Methicillin-resistant-Staphylococcus aureus (MRSA) was first isolated in 1961, shortly 
following the introduction of Methicillin in 1959 in the clinic.  MRSA developed 
Methicillin resistance by acquisition of a copy of mecA, which encodes penicillin-
binding protein PBP 2A8.  PBP 2A, unlike its wide type counterpart, does not bind to 
Methicillin and subsequently confers methicillin resistance.  In recent years, MRSA 
has become a highly prominent opportunistic hospital-acquired pathogen in western 
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countries.  This has created a huge economic burden on health-care systems 
worldwide 9-10.  As statistical studies suggested, the increasing number of MRSA cases 
are closely related to the increase in the misuse of antibiotics compounded with the 
decrease of susceptibility in S. aureus to major antibiotics in recent years 11.  Due to its 
multi-drug resistance ability, MRSA is extremely resilient to antibiotic treatment and 
is difficult to eradicate once contracted.  Its ability to survive on human skin (a high 
salt environment) 12, nose 13-14 and common antiseptic, 15 has enabled MRSA to 
spread swiftly between patient and medical staff through human contact, causing 
major outbreaks and deaths in hospitals.  Subsequent series of campaigns and media 
coverage raising concern over the rise of MRSA infection has led to establishment of stricter hygiene procedure in the UK ȋǲcleanyourhands" campaign 16) to tackle the 
spread of the bacteria in hospitals.  As an effect, the number of MRSA-related deaths 
in the UK has seen a sharp drop in the past 2-3 years (fig.1.2). 
  
Figure 1.2 Age-standardised mortality rates for deaths mentioning 
Staphylococcus aureus: by methicillin resistance in England and Wales, 
1993 to 2011 17. 
Despite the recent successes in tackling hospital-acquired MRSA in the UK and US 18, 
community-acquired MRSA cases in the USA has doubled in the past five years 19.  The 
lower number of infection cases, however, does not reflect the continual development 
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of resistance against antibiotics while they are being administrated in the clinic.  
Moreover, increasing cases of multidrug resistance development has been observed 
over a wide range of other bacterial pathogens such as Escherichia coli 20-21, 
Mycobacterium tuberculosis 22, Pseudomonas aeruginosa 23 and Clostridium difficile 24, 
etc.  This has become a major concern and there are fears about imminent outbreak of 
infections cause by these pathogenic bacteria in the hospital settings and community. 
1.1.3 Modern antibiotics discovery – strategies revised 
During the 50s-60s, the golden era of antibiotics, discoveries of new antibiotics 
primarily relied on relatively empirical, trial and error methodologies 4.  These 
included cultivation of a wide range of soil bacteria (of the genus Streptomyces) from 
world-wide sources25, and in vitro co-culture inhibition tests with the pathogenic 
bacteria.  These traditional antibacterials from natural sources have predominantly 
been found to target a narrow subset of protein targets key to limited cellular 
processes such as cell wall synthesis, protein biosynthesis, DNA and RNA replication 
etc. 26. 
The discovery of DNA, DNA sequencing and protein crystallography, and the advances 
in biology has allowed a much improved understanding of target-based medicine.  
The so-called ǲpost-genomic eraǳ of bioscience has profoundly changed the face of 
drug discovery.  There is a general belief that utilisation of advance genomic 
technology could lead to discovery of a wider range of crucial housekeeping genes in 
bacteria vital to survival.  By creating new drugs that target these novel housekeeping 
genes via chemical library screening and medicinal chemistry, it was believed we 
would be able to rapidly expand the repertoire of antibiotics at our disposal.  
However, this approach has serious disadvantages, with the limited structural 
diversity offered in existing chemical libraries and many novel targets discovered via 
genomic approaches proven to be ineffective4. 
It is argued by David et al 4 that the shift in the drug discovery strategy in the post-
genomic era has led to the inefficiency in antibiotics discovery.  To meet with the 
rising cost of drug research, exploring novel inhibitors targeting ǲoldǳ established 
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antibacterial targets is currently deemed a more economical option for 
pharmaceutical companies and has gained momentum in recent years. 
To ensure we are prepared for the battles with pathogenic bacteria in the coming 
decades, increased effort on discovery and development of novel antibiotics, narrow 
or wide spectrum, is urgently needed. 
 
 
1.2. DNA topological problems 
1.2.1 Twist, Writhe and Linking number 
The existence of DNA topoisomerases in all known cellular organisms stems from the 
inherent topological problems created by the use of DNA as a genetic information 
carrier.  DNA is a linear macromolecule consisting of two polymeric molecules 
intertwined with each other to form a double-helical spiral.  The frequencies with 
which the two strands are wound together are described quantitatively by Twist (Tw) 
and Writhe (Wr) (fig. 1.3). The variation of Tw and Wr therefore determines the 
overall topological properties of the double helix. 
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Figure 1.3 Introduction of twist and writhe in circular DNA.  The top-left and top-
right of the figure depicts close DNA circle with zero linking number.  Following double 
stranded breakage on the circular DNA (top-left), a 360° unwinding rotation on one 
end of the breakage and subsequent resealing.  The circular DNA subsequently acquires 
-1 in Linking number and a negatively supercoiled state.  The figure also illustrates 
two of the many possible topological states that the resultant -1 Lk circular DNA can 
adopt, -1 twist and 0 writhe (middle-left) and 0 twist and -1 writhe (bottom-left), both 
interchangeable to one another.  The right-side of the figure depicts an opposite 
scenario, with positive supercoiling being introduced to the circular DNA by a +1 
change in Lk number.  Figure is reproduced from Wheeler 2007 27. 
Tw describes the frequency with which one strand of the double-helix wraps around 
the other with respect to the helical axis, while Wr describes the number of times the 
double-helix crossovers itself.  In circular DNA or DNA with two ends immobilised, 
the topological system is closed.  In this situation Tw and Wr are interchangeable, as 
depicted in figure 1.3.  The sum of Tw and Wr give rise to an integral number called 
the linking number (Lk), which describes the number of times one strand of DNA 
wraps around the other: 
Lk = Tw + Wr 
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A fully relaxed segment of DNA has a topological state of the lowest energy (Lk0) and 
the linking number is approximately equal to the number of base pairs (N) divided by 
the periodicity of DNA helix (~10.5 bp/turn): 
Lk0 ≈ N / 10.5   
In a circular DNA molecule, a linking number below Lk0 mean a decrease in the sum 
of Tw and Wr, resulting in negatively supercoiled DNA with right-handed crossovers.  
The number of bp per turn may increase thus the DNA base stacking is weaker at Lk0.  
Linking numbers above Lk0 results in an increase in the sum of Tw and Wr.  Increases 
in linking numbers equate to increases in left handed positive supercoils on the DNA 
and DNA base stacking.  The majority of chromosomal DNA displays characteristics of 
a closed or semi-closed topological system due to the compact nature of the 
chromosome and the hindrance of DNA-binding proteins.  In these closed topological 
systems, protein binding and DNA unwinding during cellular processes such as DNA 
replication and transcription can produce a ǲrippleǳ of negative and positive 
supercoils.  The imbalance of the supercoiling distribution can have a major effect on the cell’s survival.  
 
1.2.2 Biological importance of DNA topology 
In order for the genetic information to be accessed and replicated, unwinding of the 
DNA double helix is necessary to allow the recognition of the internal nucleotide 
sequences by protein complexes.  In the course of DNA replication and transcription, 
protein complexes process DNA and travel downstream at a high speed 28.  As the 
transcription or the replication fork advances, the rapid DNA unwinding generates an 
enormous twist on both the downstream and upstream of the DNA strands.  The build 
up of twist generates an opposite writhe and create various forms of torodial and 
plectonemic DNA superstructure (fig. 1.3).  Downstream of the DNA fork, positive 
supercoiling can build up 29, while precatenates and negative supercoiling accumulate 
upstream of the DNA fork during replication and transcription respectively (fig. 1.3).   
Chapter 1   Introduction 
 
8 
 
  
Figure 1.4.Schematic diagram showing the build-up of secondary DNA 
structure caused by topological stress in DNA processing events.  
Precatenates and negative supercoiled DNA accumulate upstream of the DNA 
fork in DNA replication and transcription, respectively.  Positive supercoils are 
found on the downstream of the fork in both events 30. 
Accumulation of these local strains and high energy DNA structures can prevent the 
progression of transcription 29 and/or the replication fork 31 thus inhibiting cell 
growth and replication.  DNA topological problems could arise towards the end of the 
circular chromosomal DNA replication in prokaryotes as two closed, interlinked 
circular daughter DNA molecules will unavoidably be produced 32.  Unlinking of this 
catenated DNA is need for successful chromosome segregation during cell division.  
Similarly in DNA recombination events, knotted and catenated DNA could be 
generated and unlinking of these DNA structures are required prior to the partition of 
cells 33.  These topological problems often arise from DNA processing events is 
detrimental to cell survival.  Nature has therefore evolved a wide range of 
topoisomerases to perform DNA linking and unlinking reactions to solve these 
problems 34.  
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1.3. DNA topoisomerases 
1.3.1 Major types of topoisomerases 
DNA topoisomerases can be divided into two major classes, type I and type II, 
distinguished by the changes in linking number (Lk) introduced in the DNA 
substrates per reaction: type I introduces +1/-1 Lk, while type II produces +2/-2 Lk in 
each reaction 35.  They are further divided into five subtypes according to their overall 
structural distinction: IA, IB, IC, IIA and IIB (fig.1.4).   
As a result of convergent and divergent evolution, organisms have evolved and 
inherited a unique set of topoisomerases36.  In general, cellular organisms possess at 
least one type I and one type II topoisomerase.  While some organisms can possess up 
to four different topoisomerases with overlapping functions, the entire set of DNA 
topoisomerases are usually required to compensate each other for the survival of the 
organism (fig. 1.4).  In E. coli, DNA gyrase is mainly responsible for negative 
supercoiling of DNA, while topo IV is mainly responsible for DNA decatenation and 
has a minor role in DNA relaxation.  While E. coli DNA gyrase has decatenation 
activity, it is too weak to compensate for the function of topo IV in vivo 37.   
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Figure 1.5 Various classes of topoisomerases performs overlapping functions in the maintenance 
of cellular DNA topology.  Reproduced from Schoeffler & Berger 2008 38.   
 (a) DNA modifying activities of various families of DNA topoisomerase are displayed in colour coded 
arrows.  Different DNA topoisomerases are capable of carrying out DNA negative supercoil relaxation 
(left to centre), positive supercoil relaxation (right to centre), decatenation (top to centre), positive and 
negative supercoiling (centre to right and centre to left).  ATP co-factor and ssDNA requirements for 
particular activities are indicated.   
(b) Examples of topoisomerase activity complements in E. coli, S. shibatae and S. cerevisiae.  The colours 
of the triangles correspond to the colour keys displayed in (a), demonstrating the type of topoisomerases 
presence in each organism 30.  The overall topological state of the chromosome in each organism is 
highlighted with a grey box.  E. coli and S. shibatae chromosomes are topologically biased as a result of 
the presence of the DNA negative and positive supercoiling enzymes, DNA gyrase and reverse gyrase 
respectively.  S. cerevisiae does not possess DNA supercoiling enzymes; its overall supercoiled state of the 
chromosome is achieved by wrapping of DNA around histones in a positive sense.   
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1.3.2 Type I topoisomerases 
Type I topoisomerases carry out transient backbone breakage on one strand of the 
substrate DNA through a transesterification reaction and enable changes in the 
linking number of the substrate DNA by +/-1 on each round of reaction.  Type I 
topoisomerases can be further divided into IA, IB, IC.  Type IA topoisomerases include 
topo I, topo III and reverse gyrase.  They all possess a toprim fold, a protein domain 
conserved in primase and type IIA topoisomerase (topo IIA), critical for the catalytic 
function of the enzyme.  They carry out DNA unlinking reactions by enabling the 
passage of a single strand of intact DNA through the transiently broken strand.  As 
topo I and topo III reactions do not require ATP hydrolysis, they are only able to 
modify DNA towards topology with ground state energy.  The ability to carry out 
single strand DNA passage enables both topo I and topo III to remove catenated DNA.  
Unlike topo I & III, the archeae enzyme reverse gyrase utilises ATP and is the only 
topoisomerase known to produce positive supercoils 39. 
Conversely, type IB and type IC topoisomerases induce DNA topology changes 
through transient breakage of a single strand DNA backbone, followed by the rotation 
of the broken strand around the intact strand and the subsequent resealing of the 
broken strand 40.  Similar to type IA topoisomerase, this mechanism is energy free and 
the DNA substrate will result in a more relaxed state post-reaction.  Hence, the 
cellular role of most type I topoisomerases is to relax DNA. 
 
1.3.3 Type II topoisomerases 
Type )) topoisomerases utilises a ǲtwo-gateǳ DNA strand passage mechanism to 
unlink DNA 41.  This involves transient transesterification breakage on both strands of 
a DNA segment (G or Gate segment) to create a four base staggered breakage, 
followed by the passage of an intra/intermolecular DNA segment (T or transported 
segment) through the two broken ends of DNA and the subsequent resealing of the 
cleaved DNA 42.  Most type II topoisomerase reactions require ATP hydrolysis to 
induce the necessary conformational change for the passage of the T-segment DNA. 
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Type IIA topoisomerases are conserved in bacteria and eukaryotes but absent in 
archea.  This suggests that these enzymes evolved after the divergence of eubacteria.  
Type IIA topoisomerases (topo IIA) of eukaryotes consist of one dimer, whereas 
prokaryotes topo IIA consist of two pairs of dimers.  Despite the differences, both 
eukaryotic and prokaryotic topo IIA enzymes have a highly conserved domain 
organisation (fig. 1.5).  The availability of crystal structures of E. coli gyrase 43-46 and 
topo IV 47-48, and S. cerevisiae topo II fragments 49-51  showed type IIA topoisomerases 
to share highly conserved protein folds despite the difference in protein sequences. 
 
Figure 1.6 Domain structure and alignments of type IIA topoisomerases.  The yellow and 
orange colours represent the ATPase and C-terminal domains of GyrB.  Blue and cyan represents 
the NTD and the CTD of GyrA.  E. coli GyrB has an additional ~170 amino acid of unknown 
function as an insert in the CTD.  Note: domain structure display above is the monomers of each 
of the Topo IIs, a functional Topo II require two sets of monomers.  Taken from Bates and 
Maxwell, 2007 52.  
Topo VI is the only enzyme from the type IIB category and its existence is confined to 
plants, archea and plasmodia 38.   
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1.4. DNA gyrase 
DNA gyrase is a widely conserved bacterial DNA topoisomerase.  It belongs to the 
family of type IIA topoisomerases and is the only topoisomerase capable of 
generating negative DNA supercoils in an ATP-dependent manner 53.  Although its 
major function is to carry out DNA negative supercoiling and relaxation of positive 
supercoils, DNA gyrase is highly versatile and can demonstrate weak relaxation and 
decatenation activity 54.  Intriguingly, for reasons not yet known, gyrase is the only 
type II topoisomerase able to relax negatively supercoiled DNA in the absence of ATP 
55.  
A functional DNA gyrase enzyme consists of two subunits, GyrA and GyrB, which, in 
the presence of the DNA substrate, form an A2B2 tetramer-DNA complex.  The binding 
of the gate-segment (G-segment) DNA to the A2B2 tetramer is followed by the T-
segment DNA wrapping around the exterior of the cylindrical GyrA C-terminal 
domain (CTD) beta-propeller fold56 (fig. 1.6).  The wrapping motion presents a T-
segment DNA towards the N-gate, which is then captured by the N-terminal domain 
(NTD) of GyrB during a range of conformational changes coordinated by the binding 
and hydrolysis of ATP.  The capture of T-segment DNA triggers a series of events 
resulting in the transient cleavage of the backbone of both strands of DNA.  This 
creates a four base stagger, allowing the DNA-gate to open and the passage of the 
captured T-segment DNA through the cleavage.  The subsequent closure of the DNA-
gate and the exit of the T-segment DNA via the C-gate completes the reaction cycle 
and produces a change of -2 to the linking number of the DNA substrate. 
57 
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1.4.1 Structural aspects of DNA gyrase 
Each B subunit of DNA gyrase consists of the N-terminal GHKL (Gyrase, Hsp90, 
Histidine Kinase, MutL) ATPase domain (fig. 1.7) 58, the transducer domain, the 
Toprim domain and the C-terminal tail domain 59.  The ATPase activity of the GHKL 
domain requires Mg2+ as a co-factor 60 while monovalent ions such as sodium or 
potassium are implicated as a possible co-factor 61.  The conformational changes 
induced by ATP hydrolysis of this domain are transmitted towards the C-terminal 
portion of GyrB, which is essential to the strand passage and the supercoiling activity 
of gyrase 46,62.  At the C-terminus of the transducer domain is the Toprim domain.  It is 
a protein fold conserved in type IA and type II topoisomerases 63, and primases 64 , 
which plays a major role in the catalytic activity of these enzymes.  The characteristic 
DXDXD motif within the Toprim domain (D498-D502 in E. coli) can hold one Mg2+, 
while two Mg2+ ions are bound to this region in the presence of the G-segment DNA 65.  
This transition is suggested to be crucial to facilitating the DNA cleavage reunion 
reaction 66-67.  The tail domain of GyrB makes extensive contacts with GyrA.  
 
Figure 1.8. Ribbon representation of the 
crystal structure of a dimerised E. coli GyrB N-
terminal fragment in the presence of ATP.  The 
N-terminal ǲstrapsǳ ȋthe extended structures 
indicated by the two bright green dotted braces) 
from each monomer (red and green) were 
extended to bind to the other monomer to form a 
dimerised structure in the presence of ATP 
(magenta) 46.  68 
 
 
In addition, it was observed in a crystallographic study of gyrase-DNA complex that 
Ile 83369, which is surface-exposed and located in a domain equivalent to the tower 
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motif of GyrA-NTD, intercalates between +4 and +5 bases on both arms of the G-
segment DNA 51.  The intercalation appeared to induce a strong DNA distortion by 
causing a rotation of ͹Ͳ˚ of DNA on each arm of the G-segment DNA 70.  This bending 
was later confirmed in eukaryotic topo II by a FRET study 71, although the exact role 
of the bending in the function of the enzyme is yet to be established; substitution of 
the isoleucine with alanine completely abolishes relaxation activity of the enzyme.  
This intercalation appears to ǲstapleǳ the G-segment DNA to the GyrA subunit, thus 
enabling stabilisation of the catalytic complex and remotely assists the DNA-enzyme 
transesterification reaction. 
The A subunit of gyrase consists of two main separately folded domains: the NTD 
which forms part of the GyrA-GyrB interface 72 (fig. 1.8a blue) and the CTD which has 
a characteristic beta-propeller fold 57, essential for DNA wrapping (fig. 1.8a red) 73-74.  
Under physiological conditions, the GyrA subunit exists as a stable homodimer 75 and 
helix-3 of the winged-helix-domain (WHD) motif of the N-terminal domain forms a 
crucial dimer interface and ǲthe DNA gateǳ 44. The closure of this dimer interface 
allows the formation of the DNA ǲsaddleǳ 44.  This ǲsaddleǳ together with the Toprim 
domain of GyrB forms the DNA channel that accommodates the G-segment DNA.  The 
catalytic Tyr122 of GyrA is critical for the transesterification reaction 76 and is located 
in the WHD domain of GyrA.  This tyrosine is positioned adjacent to the DXDXD motif 
of the GyrB toprim domain when the A2B2 tetramer is assembled 51.   
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Figure 1.9. Domain structure organisation of DNA gyrase  
A. The crystal structure of GyrA NTD and CTD are shown in blue and red, respectively.  
B. Illustrative diagram of DNA wrapped onto the electro-positive circumference of GyrA-
CTD, in electrostatic colour-coded molecular surface (bottom left) and ribbon (bottom 
right) representations.  Reproduced from Ruthenburg et al 2005 57 
Towards the C-terminus of the N-terminal domain (NTD) of GyrA, a coiled coil motif 
protrudes out of the major globular fold to form the second dimer interface or the ǲexit gateǳ 44 (fig. 1.8a).  The CTD of GyrA is a separate a six-bladed beta-propeller 
structure57 connected with the NTD through a 15 amino acid flexible linker region 77.  
This special cylindrical fold allows the T-segment DNA to wrap around the 
electropositive surface in a positive sense (fig. 1.8b) 57, which is critical to the ability 
for gyrase to negatively supercoil DNA.  While the CTD of all gyrases were found to 
have six blades and adopt a full beta-propeller fold, the CTD of topo IVs have a 
varying number of blades and often have an incomplete beta-propeller fold 48.  The 
missing blades in the CTD of topo IV has led to its inability to wrap DNA and thus 
carry out supercoiling. 
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1.4.2 Mechanistic aspects of DNA gyrase 
1.4.2.1 Two-gate strand passage mechanism 
It was first proposed by Roca et al 78 that in order for type II DNA topoisomerases to 
function without inducing DNA damage, a ǲtwo-gateǳ mechanism is required for the 
double-stranded DNA passage to ensure the religation of the transiently cleaved DNA.  
While the gate that controls the cleavage of the DNA is open to allow the passage of 
the second DNA segment, the second gate has to be closed to ensure the integrity of 
the enzyme-DNA cleavage complex and prevent dsDNA breakage from occurring 79-80. 
In fact, DNA gyrase possesses three ǲgatesǳ in the symmetric axis of the tetramer: the 
Amino-terminal-gate (N-gate) of the NTD of the GyrB dimer, the DNA-gate that guards 
the separation of the transiently cleaved G-segment DNA, and the C-gate of protruded 
segment of the GyrA dimer (fig. 1.6).  These three gates operate sequentially during a 
strand passage reaction to allow passage of a T-segment DNA through the centre of 
the A2B2-DNA complex without disintegration of the enzyme.  
DNA gyrase can perform dsDNA strand passage (including DNA cleavage and 
religation) in the absence of the N-gate, as reconstituted mutants with the NTD of 
GyrB truncated still demonstrate weak relaxation activity 81.  This shows strand 
passage in gyrase to operate as a two-gate enzyme, albeit inefficiently.  DNA gate is 
crucial to the function of the DNA gyrase as it controls the double-stranded cleavage 
of DNA and the separation of the two transiently-cleaved DNA ends during a 
supercoiling reaction.  C-gate forms a crucial second interface between the GyrA 
dimer independent of the DNA-gate.  It is therefore proposed to be vital to the 
integrity of the the Gyrase-DNA complex during the opening of DNA-gate.  This 
strand-passage mechanism is the core function of gyrase and is conserved in topo IIA 
enzyme (including topo IV and eukaryotic topo II) across all species.  
1.4.2.2 ATP-dependent capture of the T-segment DNA in a DNA-wrapped gyrase 
complex 
Following the capture of the G-segment DNA and the assembly of the A2B2 tetramer, 
the wrapping of the end of the G-segment DNA on the CTD 82 allows the T-segment to 
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be positioned into the cleft between the two GyrB subunits in their nucleotide-
unbound state.   At this stage, the ATPase domain of GyrB is in equilibrium between 
the ATP-bound and -unbound states.  In the ATP-bound state, the ~20 amino acid N-terminal ǲstrapǳ of both B subunits bind to the binding site in the opposing B subunit 
to form the DNA clamp or the N-gate 83.  Once the T-segment DNA makes contacts 
with the B subunits, it triggers the ATP hydrolysis reaction by activating the ATPase 
activity of the GHKL domains 84-85.  Although the role of ATP hydrolysis is unclear, its 
structural homolog, topo VI, has a dramatically different conformation in the interface 
between the ATPase domain and the transducer region in the ATP- and ADP-bound 
states.   The linker helix that connects both domains is found to swing outwards by ͳͳ˚ during ATP hydrolysis (fig. 1.9) 86.  It is therefore possible that in gyrase, this 
movement induced by ATP hydrolysis could transmit strain towards the DNA gate 
activating the cleavage reaction, the opening of the DNA gate and the passage of the T-
segment.  
 
Figure 1.10. Ribbon representation of topo VI GHKL domain, homologous to type 
))A topoisomerase, demonstrating the ͷͷ˚ movement in the transducer domain 
from the ATP (grey) to the ADP (orange) bound state. 30,86 
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1.4.2.3 Phospho-tyrosyl transesterification reaction 
Prior to the passage of the T-segment, the transesterification reaction between the 
two catalytic tyrosines, one from each GyrA monomers, and the 5´phosphate group on 
both DNA backbones four bases apart from each other is needed to introduce the 
double-strand break.  Prior to the reaction, the DXDXD motif of GyrB, the reactive 
tyrosine residue of GyrA and the phosphate group of the scissile DNA backbone have 
to be in close proximity to form the pre-reaction complex 51 (fig. 1.10).  The reaction 
is then initiated by a nucleophilic attack from the activated tyrosine hydroxyl group 
onto the phosphate group.  Once the tyrosine-phosphate bond is formed, a  3´OH 
group of the backbone sugar is found after bond breakage 76.  The overall result of this 
reaction will leave a 5´ backbone phosphate on each strand of the G-segment DNA 
covalently linked with the hydroxyl tyrosine group (Tyr122 in E. coli gyrase) of each 
GyrA subunit and result in a staggered 4 base double-stranded DNA cleavage. 
 
Figure 1.11. An illustrative model of the DNA cleaving catalytic complex formed 
between residues from the DXDXD motif of GyrB (E424, D498, D500, D502), GyrA 
(R32, H78, Y122) and the scissile phosphate group from the DNA stabilised by two Mg2+ 
ions. 66 
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The DXDXD motif of GyrB is responsible for holding Mg2+ ion(s) involved in the 
stabilisation of the reaction complex 66 (fig. 1.10).  The exact molecular context of the 
Mg2+ ion(s) within the reaction complex is unclear, although it can bind to oxygen 
atoms from either the backbone phosphate, the tyrosine residue or a reactive water 
molecule, as suggested in various hypothetical models 67.  The physical properties 
(e.g., radius, charge density, hardness) of this divalent Mg2+ ion is critical to the 
equilibrium of the reaction as replacement with other divalent metal ions alters the 
nature of the reaction, e.g., calcium induce DNA cleavage as it is poor at promoting the 
DNA religation reaction 67,87.  There has been a debate over whether one or two Mg2+ 
ion(s) is/are involved in the religation reaction.  One hypothesis states that although 
two Mg2+ are involved with the reaction, only one Mg2+ is stably incorporated with the 
enzyme, while the second Mg2+ is more dynamic and could escape depending on the 
state of the reaction 65,67. 
1.4.2.4 Passage of the T-segment DNA, closure of the DNA gate and 
conformation reset 
Following the cleavage of the G-segment DNA and the opening of the DNA gate, the T-
segment DNA is passed through the two cleaved staggered ends of the G-segment 
DNA.  After the T-segment passes the DNA gate, it remains in the cavity between the 
DNA gate and the exit-gate until the DNA gate is fully shut.  It is unclear how the 
opening of the exit gate is operated, although it is proposed that it is opened after the 
closure of the DNA gate 30.  The exit gate opening allows the T-segment to escape.  The 
subsequent release of 2 ADP and 2 inorganic phosphate (Pi) ions resets the GyrB back 
to its unbound state and reopens the N-gate.  The enzyme then either continues 
another cycle of strand passage on the same DNA segment or becomes disassembled, 
depending on the supercoiled state of the DNA 88.  Processivity between reaction 
cycles is dependent on the availability of ATP 88. 
 One round of completed intra-strand passage reaction results in a more negatively 
supercoiled DNA substrate with a change of -2Lk. 
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1.4.3 Cellular role of DNA gyrase  
As mentioned previously, during DNA processing events such as replication and 
transcription, rapid DNA unwinding is required to allow access to the internal 
nucleotides.  As a result, torsional stress can accumulate up and downstream of the 
progressing DNA fork.  In this situation, DNA gyrase is employed to actively remove 
the downstream positive supercoils by introducing negative supercoils.  In the 
absence of gyrase, a torsional stress can build up on the DNA and this can become 
critical to the progression of replication and transcription 89. 
Another important function of DNA gyrase is to maintain the underwound state of the 
bacterial chromosome, especially during log phase growth 90.  Relaxed DNA requires high energy for the formation of a localised ǲDNA bubbleǳ, which contains DNA 
strands that can be readily melted and separated for the initiation of transcription 
and replication 91.  Maintaining DNA in its negatively supercoiled state allows easier formation of these ǲDNA bubblesǳ and permits greater access of protein complexes to 
chromosomal DNA during transcription and replication, thus favouring cell growth.   
The maintenance of this superhelical state is suggested to be controlled by the 
cellular ATP/ADP ratio, and this is be affected by the difference in growth conditions 
i.e., temperature92, pH and the availability of nutrients.  As gyrase activity is closely 
linked to the cellular ATP/ADP ratio 93-94, these external conditions could mediate 
changes to the hyperhelicity of the chromosome through altering gyrase activity.  
Often as a result of changes in superhelicity, gene expression patterns are affected 
and therefore gyrase can act as a gene expression regulator and controls gene 
expression in response to changes in external conditions.  For example, the aerobic 
and anaerobic growth of Salmonella typhimurium is controlled by DNA gyrase and 
topo I activity, respectively, where mutants with defective gyrases will only grow in 
anaerobic conditions 95.  In addition, the reduced gyrase activity in anaerobic growth 
of bacteria is reflected by the fact that anaerobically grown bacteria are less 
susceptible to quinolones96.  
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1.5. Topoisomerase IV 
Topo IV is another conserved bacterial type IIA topoisomerase that usually coexists 
with gyrase.  Different from DNA gyrase, it does not supercoil DNA.  Instead topo IV is 
extremely efficient at relaxing and decatenating DNA.  Topo IV is crucial to cell 
division due to its decatenation ability which assists segregation of the chromosome.  
It has a domain structure analogous to gyrase and consists of two subunits, ParC and 
ParE subunits (alternatively known as GrlA and GrlB), and forms a tetrameric A2B2 
enzyme.   
 
1.5.1 Structural differences between topo IV and DNA gyrase 
While GyrA-CTD consist of a conserved six bladed beta-propeller domain structure 
across species, the number of blades found in the CTD of ParC is more variable 48.  The 
CTD of ParC in a number of organisms has 4 or 5 blades.  In certain cases it is 
completely truncated, similar to a eukaryotic topo IIA.  Evidence from a structural 
study suggested ParC CTD appears as a broken beta-propeller and forms a partial 
cylindrical structure.  The inability to form a completed beta-propeller is suggested to 
led to topo )V’s inability to bend DNA and carry out supercoiling similar to DNA 
gyrase 97. 
 
 
Figure 1.12 Diagram showing the difference in the interfaces between blade 1 
and 6 in B. stearothermophilus ParC-CTD and B. stearothermophilus GyrA-CTD 
represented in ribbon structure.  The GyrA box is labelled in red.  Figure is reproduced 
from Hsieh et al 2004 97. 
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Despite E. coli topo IV  having a six bladed ParC-CTD, sequence comparison and 
mutant studies found ParC-CTD to lack the ǲGyrA boxǳ ȋfig. 1.11) 98, a stretch of 7 
amino acids located in blade 1.  This is consistent with the fact that the removal of the 
GyrA box in gyrase has a deleterious effect on its supercoiling activity 98.  Further 
evidence from a structural study suggests the GyrA box to form a crucial interface 
between blade 1 and blade 6 97 and as a result topo IV ParC-CTD is unable to form a 
fully cylindrical beta-propeller fold (fig. 1.11) thus can not perform DNA wrapping 
required for intra-molecular strand passage. 
 
1.5.2 Mechanistic aspects 
Similar to DNA gyrase and all topo IIA enzymes, topo IV carries out transient double-
strand breakage and dsDNA passage by utilising the ǲtwo gateǳ mechanism.  Although 
its overall protein folding and mechanistic action is somewhat similar DNA gyrase, it 
does not generate DNA supercoils but instead performs DNA relaxation and 
decatenation. 
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Figure 1.13 The differences between gyrase and topo IV in DNA substrate 
recognition.  The DNA clamp of the NTD of the B subunit is coloured yellow.  Red 
represents the CTD of the B subunit.  Blue and green is the NTD and the CTD of 
the A subunit respectively.  (a) Wrapping of DNA around the CTD of GyrA in DNA 
gyrase and the intra-strand DNA passage.  (b) Recognition of DNA hooked 
juxtaposition by topo IV ParC CTD and inter-strand DNA passage.  (c) 
Recognition of DNA hooked juxtaposition by topo IV 99. 
This difference of enzymatic function in topo )V stems from the lack of ǲGyrA boxǳ in 
the CTD of ParC as mentioned previously, which affects the preference of substrate 
DNA.  Instead of wrapping DNA around its CTD and negatively supercoiling DNA by 
intra-strand passage, the CTD of topo IV is proposed to bind to the T-segment DNA 
carrying out inter-strand DNA passage to relax and decatenate DNA efficiently in a 
ATP-dependent manner (fig. 1.12).  One hypothesis stated that topo IV ParC-CTD 
promotes preferential binding to DNA with the hooked juxtaposition100, a DNA 
geometry predicted to be ubiquitous in tightly wound, knotted or catenated DNA.  
This could explain the enzyme’s catalytic preference.  
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1.5.3 Cellular role 
Topo IV is an essential enzyme for successful chromosome segregation and cell 
division in most prokaryotes.  The replication of a circular chromosome and 
recombination events produce catenated and knotted DNA and topo IV is required to 
resolve these problems by performing DNA unlinking reactions 101.  In addition, topo 
IV is an efficient DNA relaxing enzyme and has a secondary role of supporting the 
elongation of the DNA fork during replication and transcription by removing negative 
supercoils and precatenates in the upstream region of the DNA fork 102.  
M. tuberculosis is one of the rare exceptions that lack a topo IV 103 although its DNA 
gyrase appears to function similar to a hybrid between a normal gyrase and topo 
IV104 and covers functions of both enzymes depending on its reaction conditions.  
1.6 Gyrase-targeting antibacterial agents 
The function of gyrase involves the dangerous act of cleaving and religating dsDNA.  
The completion of this process is crucial to the survival of the cell as failure to religate 
cleaved DNA can lead to permanent DNA breakage and chromosome fragmentation.  
This mechanism can be utilised to our advantage, by developing agents that inhibit 
the DNA reunion step of these enzymes and turning them into potent antibacterial 
agents.  Quinolones are a classic example of bacterial topo II ǲpoisonsǳ, which mediate 
bactericidal action by inhibition of the DNA reunion reaction and turning gyrase and topo )V into ǲpoisonsǳ, inducing cellular DNA breakage.  Due to the ubiquitous 
presence of gyrase and topo IV in prokaryotes, most of the known bacterial topo II 
inhibitors tend to be effective against a wide spectrum of bacteria. 
Despite the huge variety of quinolone analogs reaching the clinic since the first 
introduction of nalidixic acid in 1962, there has been little success in the discovery of 
other classes of gyrase/topo IV-targeting drugs.  Given the example of the clinical and 
commercial success from quinolones and the fact that bacterial topo II has been a 
relatively under-exploited target compared to other anti-bacterial strategies, 
bacterial topo II targeting agents still have enormous developmental potential.   
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1.6.1 Quinolones 
Quinolones are the most successful gyrase/topo IV inhibitors ever introduced into the 
clinic.  As a class of antibacterials, quinolones are worth almost a quarter of the entire 
antibacterial drug market, with the best selling drug Cipro (ciprofloxacin) currently 
worth over $1bn in gross annual sales.  The success of quinolones has been 
contributed by their effectiveness for treatment against a wide spectrum of bacterial 
pathogens as well as the excellent safety profile and good ADMET (absorption, 
distribution, metabolism, excretion and toxicity) properties.  In 1962 , the first 
quinolone, nalidixic acid 105, a derivative of quinoline, was discovered and found to be 
an excellent antibacterial agent.  Since then, hundreds of analogues with improved 
potency against both gram-negative and gram-positive pathogens have been 
produced (fig.1.13) and they can generally be classified into generations I, II, III and 
IV.  The first generation of quinolone was initially used for urinary tract infections 
and was mainly restricted to anti-gram-negative treatments due to its poor efficacy 
against gram-positive pathogens 106.  The second generation quinolones had 
improved serum distribution over the first generation plus improved potency against 
gram-negative organisms thus are suitable for a wider range of indication 106.  In spite 
of that they are only mildly effective against most gram-positive pathogens.  The third 
generation quinolones have an improved gram-positive coverage and potency against 
atypical pathogens 106.  The fourth generation quinolones have similar properties to 
the third generation with additional coverage against anaerobes 106. 
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Figure 1.14 Chemical structures of various quinolone drugs 
 
1.6.1.1 Quinolone-induced ternary complex, polymerase collision and oxidative 
damage 
Whilst quinolones inhibit the catalytic activity of gyrase and topo IV, their potency is 
mainly attributed to the DNA damage they induce 107.  By inhibiting the DNA 
religation process of gyrase/topo IV, quinolones trap gyrase/topo IV on DNA to form 
a stable quinolone-DNA-enzyme ternary complex 108.  As the 5´ phosphate group of 
the cleaved DNA is covalently attached to the enzyme in the ternary complex, its 
collision with the advancing replication or transcription complex can generate DNA 
double-strand breaks109.  While collisions with polymerase can occur, most of the 
advancing DNA fork is proposed to stall by the excessive torsional strain on DNA as a 
result of gyrase inhibition, before the collision happens 110.  It is suggested that the 
DNA repair mechanism recognises the stalled DNA forks and in an attempt to restore 
these DNA structures, DNA damage may be generated.  On the cellular scale, the DNA 
damage can lead to chromosome fragmentation and cell death.   
In addition, DNA damage induced by quinolones was found to generate high energy 
free radicals at each end of the broken bond 111.   They then trigger an oxidative chain 
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reaction that inflicts further damage to DNA, protein and induces the SOS responses 
111.   
1.6.1.2 Preference of quinolone drugs in targeting gyrase/topo IV 
While gyrase is the primary target of quinolones in E. coli 112 and other gram-negative 
organisms, 113-115 for the majority of quinolones developed (80-90%) the target 
preference is reversed in gram-positive bacteria such as S. aureus 116, E. faecalis and S. 
pneumoniae 117, with topo IV being the primary target.  Despite the availability of 
Quinolone binding pocket crystal structure, the reason behind such changes in target 
preference is currently unknown.  This shift in quinolone target preference has been 
suggested to have contributed to the ineffectiveness of quinolones in gram-positive 
pathogens.   
While the primary target of quinolones contributes to the most cellular damage, 
targeting of the secondary target generates significant damage and provides a synergistic effect to the drug’s potency 118.  Therefore, a dual-targeting quinolone that 
targets both gyrase and topo IV with similar minimum inhibitory concentrations 
(MICs) is often more potent than quinolones that targets gyrase predominately.  This 
dual-targeting strategy can decrease the mutant prevention concentration (MPC) of 
the drug,  as it is less likely for the bacteria to develop resistant mutations on gyrase 
and topo IV simultaneously in the same generation 119. 
1.6.1.3 Structure-activity-relationships and the evolution of quinolone 
The precise mechanism of quinolone binding remains a long-standing question 
despite its medicinal advancement over generations.  Much quinolone development 
has been dependent purely on medicinal chemistry and structural-activity 
relationship studies in vitro and in vivo.  Among all the changes across generations of 
quinolones, the quinolone bicyclic ring and the C3 and C4 groups has remained the 
most conserved feature of the quinolone pharmacophore (fig. 1.14).  The function of 
the quinolone bicyclic ring is unclear, although several lines of evidence showed it to 
be involved with DNA stacking 120.   Numerous physico-chemical studies of 
quinolones have suggested the C3 and C4 groups form a bidentate complex with a 
Chapter 1   Introduction 
 
30 
 
metal ion in solution in a 1:1 or 2:1 ratio 121-122, and Mg2+ is considered to be the most 
biologically relevant candidate for such a complex.  Alternatively, the C3/C4 group is 
conceived to contribute some form of electrostatic or H-bond interaction with the 
enzyme or the DNA substrate. 
 
Figure 1.15. Chemical structure of Ciprofloxacin with group numbers 
assigned. 
The C1/N1 (as shown in fig. 1.15, position 1) substituted group has been relatively 
unchanged throughout generations and its small molecular weight and its generally 
hydrophobic nature is regarded to be important for maintaining the potency of the 
drug 123.  However introduction of a larger group (difluorobenzene) at the C1 position 
was seen in a recent class of quinolones (i.e., trovafloxacin) with improved anti-gram-
positive activity 124.  The C5 position has remained un-substituted throughout 
chemical evolution.  The introduction of a fluorine atom on the C6 position has 
dramatically increased the potency of the drug and this feature was kept unchanged 
since the emergence of the second generation of quinolone drugs and the start of the 
fluoroquinolone era 125.   Although little is known about the function of the 
substituted fluorine, it was found to improve drug binding.  Although methoxyl substitution on the Cͺ position is found to favour the drug’s potency, the size of the 
substituted group at this position is relatively restricted.  The C7 group is the most 
flexible and the most extensively modified group in quinolone class drugs as most 
medicinal improvement of the latest generations of quinolones were achieved by 
manipulating the C7 group.  Quinolones with bulky C7 groups tend to have stronger 
resistance against efflux mechanisms 126 and prefer targeting gram-positive gyrases 
over topo IVs 126.  The addition of methyl groups to the piperazine ring of C7 groups 
enhances the activity of quinolones against mammalian topo II127-128, which suggested 
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that the C7 group might have direct interactions with the enzyme.  Ofloxacin is one of 
the few quinolones with a chiral methyl group extended from the N1 position.  
Interestingly, the potency and binding of ofloxacin displays strong chirality and its L-
enantiomer (levofloxacin) was found to bind 12-fold stronger than its D-enantiomer 
129.     
Moreover, quinolone drugs were suggested to bind to eukaryotic topoII in a similar 
fashion to other human topo II inhibitors 130.  Quinolones display a protective effect to 
mammalian cells against these cytotoxic agents 131.  As the success of novel bacterial 
topo II inhibitors is highly dependent on their cytotoxicity in eukaryotic cells, it is 
favourable to have the least interaction with human topo II.  Therefore, it is important 
to further understand the human-bacterial topo II preference of these agents as well 
as how topo II poisons induce the cleavage complex at the molecular level.  This 
knowledge can be applied to the development of antineoplastic topo II drug against 
drug-resistant cancer cells with improved potent. 
1.6.1.4 Quinolone resistance 
The trend of increasing overuse and misuse of antibiotics has led to the emergence of 
fluoroquinolone resistance in most clinically relevant bacteria and therefore the 
decreasing effectiveness of the entire class of quinolone antibiotics 132.  Numerous 
different quinolone resistance mechanisms have been discovered since the 
introduction of the drug in clinics.  These include intrinsically up-regulated efflux 
mechanisms (e.g., NorA in S. aureus) 133-134 and qnr-containing plasmid-acquired 
resistance 135, expression of DNA mimicking proteins and plasmid-encoded 
pentapeptide-repeat-proteins that can inhibit gyrase activity and prevent the binding 
of quinolone 136-137.  However, the majority of the resistant strains arise from 
mutations that occur in the quinolone resistance-determining regions (QRDR) located 
on helix 4 of gyrase/topo IV A subunits 138.  In particular, the Ser83 and Asp87 of E. 
coli gyrase 139 and the equivalent residues in gyrase and topo IV of gram-positive 
bacterial species 113-115,140 are the most frequently found sites of first-step mutations.  
These mutations as studied in vitro, were found to greatly reduce quinolone binding 
without greatly affecting the activity of the enzyme 141.  In the light of the recent 
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availability of crystal structures from quinolone-DNA gyrase complex 142, it appears 
that C3 and C4 group of quinolone chelate with a Mg2+ ion in a bidentate manner, 
while Ser83 and Asp87 of the GyrA subunits make contact with the quinolone 
chelated Mg2+ via two of its octahedrally coordinated waters.   
While mutations in GyrB 143-144 and in GyrA 145 away from the QRDR region were 
found to confer quinolone resistance, it remains difficult to establish the exact role of 
these mutations in reducing quinolone potency without understanding quinolone 
binding at the molecular level. 
1.6.1.5 Molecular details of quinolone binding 
There have been numerous studies on quinolone binding to DNA or enzyme alone, 
where quinolone was found to bind weakly to DNA alone or enzyme alone 146.  
Quinolone was shown to bind to negatively supercoiled DNA and ssDNA 147, and that 
guanine is favoured 148-149.     Intriguingly, quinolone binding to the DNA-enzyme 
complex does not require DNA cleavage 150 and this exclude the possibility of 
quinolone binding to the staggered ssDNA bases when the G-segment is cleaved.  The 
fact that quinolones have little affinity for the enzyme or DNA alone suggests that 
quinolones might bind to both gyrase and DNA in a cooperative manner 151.  One 
possibility is that the localised DNA bubble created within the 4 staggered bases 
when the G-segment DNA is bound to gyrase could create the environment suitable 
for quinolone binding 149,151.  Numerous other quinolone models have been proposed 
151 based on experimental data although they all lack solid support from other studies.  
Quinolone binding might also involve Mg2+ 152 as both crystallographic tests and NMR 
show the quinolone drug to form complex with Mg2+ ion in a 1:1 or 2:1 ratio in 
physiological conditions 153-154.  The dynamic nature of the breakage-reunion region 
155 and the complex multi-component interaction required for quinolone binding has 
made it extremely difficult to determine the molecular detail of quinolone binding 
without crystallographic data. 
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1.6.1.6 Recent quinolone structures  
Recently, two x-ray crystal structures of S. pneumoniae topo IV including the ParC-
NTD and a fragmented ParE-CTD have been solved in complex with a 19 bp of dsDNA 
and two quinolone drugs, clinafloxacin and moxifloxacin (PDB code: 3FOF and 3FOE) 
69.  Structure of the moxifloxacin bound topo IV-DNA complex is shown in fig. 1.15 
(Left and Right)69.  The two crystal structures solved at 4.00Å show an electron 
density between the +1 and -1 nucleotide bases respective to the cleavage position.  
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Figure 1.16. (Left & Right) Pictures of a 3D model built based on 4.0 Å 
crystal structure of moxifloxacin-DNA-S. pneumoniae Topo IV complex at 
different angles (PDB:3FOF) .  Position of the G-segment DNA (cyan) and 
moxifloxacin (purple), QRDR resistant residues (D83 (red) & S79 (yellow) of ParC) 
are represented as sticks 69.  Figure on the left: the C-3 group of moxifloxacin is 
positioned near S79.  Figure on the right: the fluorine attached ring of 
moxifloxacin stacked between the +1 and -1 nucleotides.  
The additional electron density was speculated to be contributed by the quinolone 
drug.  In the drug coordinates modelled into the electron density by the authors, the 
fluorine attached ring of both moxifloxacin (figure 1.15) and clinafloxacin stacks 
between the +1 and -1 nucleotides while the C-7 group protrudes out into the minor 
groove, possibly making contact with the B-subunits.  Interestingly, this model 
coincides with the previous suggestion made about the drug binding position on the 
DNA 66 and partly agrees with the quinolone-DNA-protein co-operative binding 
mechanism.  The C-3 oxygen of the modelled drug is in proximity to form a hydrogen 
bond to Ser79 (equivalent to Ser83 in E. coli gyrase) which is in agreement with the 
increased resistance associated with the quinolone resistance conferred by the 
mutation in this residue. 
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The poor resolution of the structure of the protein and the drug render it difficult to 
identify the exact conformation of the drug and the exact nature of the protein-drug 
contacts, which weakens the reliability of the model 69.  The model fails to explain the 
chiral nature of the inhibition displayed in ofloxacin enantiomers, the importance of 
the C-4 oxygen to the drug potency and the role of the mutation of Asp87 of E. coli 
gyrase in quinolone resistance.  In summary, the structure gives a rough hint of the 
positioning of quinolone binding, however it is does not have enough details to 
provide the conclusive answer about the binding mechanism of quinolone. 
 
1.6.2 Aminocoumarins 
2-Aminocoumarins are secondary metabolites produced by Streptomyces species, 
which inhibit gyrase and topo IV (fig.1.16).  2-aminocoumarins share a core coumarin 
moiety and inhibit gyrase and topo IV by targeting the ATPase domain of the B 
subunits of gyrase/topo IV.  Structural studies have shown that 2-aminocoumarins 
binds to the entrance to the ATP-binding site, thereby abolishing the catalytic ability 
of the enzyme.  Novobiocin was the only 2-aminocoumarin used in the clinic as an 
antibacterial.  Despite proving its clinical efficacy 156, strong albumin binding 157 and 
serious side effects such as hepatic impairment and skin eruption 157 has led to its 
withdrawal from the market.     Although novobiocin has failed to enter the clinic, it 
has offered hope that ATPase-targeting bacterial topo II inhibitors with improved 
ADMET properties could have the potential to become successful drug candidates.  
Following the identification of biosynthetic gene clusters for novobiocin 158, Flatman 
et al. had attempted to produce novobiocin analogs with varying side groups by 
manipulating these metabolic gene clusters 159.   Disappointingly, the analogous 
inhibitors generated through this approach displayed no improved potencies against 
bacterial topo II compared to the original compound 159.  The study had nevertheless 
provided additional insight on the structural-activity-relationship of aminocoumarins.   
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Figure 1.17. Chemical structures of various 2-aminocoumarin gyrase 
inhibitors. 
 
1.6.3 Other Agents 
1.6.3.1 Proteinaceous inhibitors 
Numerous proteinaceous inhibitors of DNA gyrase such as CcdB 160 and microcin B17 
161, penta-peptide repeat proteins 162 and monoclonal antibodies 163 have been 
discovered over the years.  However, developments of protein-based therapeutics 
tend to be difficult due to various reasons such as poor bioavailability, poor bacterial 
penetration, and instability and they are in general difficult to formulate.  Although 
the potential for converting these proteinaceous inhibitors into clinical drugs is low, 
their mode of interaction with gyrase could provide insight into the development of 
novel small molecule gyrase inhibitors.  It is observed in the structural studies of 
CcdB 164 and penta-repeat peptide gyrase complex 162, these protein-protein 
interaction interfaces are likely to be flat and involve large surface contact.  
Unfortunately, these relatively flat regions of the protein are generally inappropriate 
for binding small molecule inhibitors.  Microcin B17, a plasmid maintenance toxin is 
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considered to be one of the most promising candidates as it can promote gyrase-
induced DNA cleavage 165 similar to quinolones by inhibiting the breakage-reunion 
reaction.  Understanding the interaction between microcin B17 and gyrase could 
yield important insights for novel inhibitor development.  
1.6.3.2 Simocyclinones 
In recent years, a novel coumarin gyrase inhibitor, simocyclinone, produced in 
Streptomyces antibioticus Tü 6040 has been identified (fig. 1.17 Top) 166.  Although 
simocyclinone shares a coumarin structure with aminocoumarins, instead of 
targeting the GyrB subunit of gyrase it was found to be an inhibitor of the GyrA 
subunit 167.   Further investigation suggested 2 simocyclinone molecules to bind to a 
GyrA dimer at low drug concentration while at high concentration, simocyclinone was 
suggested to induce the formation of a GyrA tetramer binding 4 simocyclinone 
molecules 168.   
 
Figure 1.18. Chemical structure of Simocyclinone D8/D4 (top) and 
Cyclothialidine (bottom). 
1.6.3.3 Cyclothialidine 
Cyclothialidine is a natural gyrase ATPase inhibitor produced in Streptomyces 
filipinesis (fig. 1.17 bottom) 169.    It was found to display a two-fold higher gyrase 
binding affinity than novobiocin and has little activity against eukaryotic 
topoisomerases 169.  Unfortunately it has a weak antibacterial property due to poor 
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penetration 159.    To improve the antibacterial activity of cyclothialidine, several 
analogs were made with increased enzyme inhibition and in vitro antibacterial 
potency 170, although they failed to display sufficient potency in in vivo animal models. 
1.6.3.4 Plant natural products – Flavonoids and Naphthoquinones 
Plants are capable of producing thousands of different secondary metabolites as 
signalling molecules and provide defence mechanisms towards herbivores and 
competing micro-organisms such as fungi and bacteria.  Flavonoids and 
naphthoquinones are a series of natural products with similar chemical scaffolds.  
Both are present in plants and plant-derived food products (e.g., honey).  Many 
flavonoids have been proven to be good gyrase/topo IV inhibitors and were found to 
be potent against pathogenic organisms 171-181.  Several studies found these 
compounds to target the ATPase domain of DNA gyrase and topo IV 181 by inhibiting 
ATP hydrolysis 182-183.  Surprisingly some flavonoids were able to induce gyrase/topo 
IV-mediated DNA cleavage 181 , a feature absent in other gyrase/topo IV ATPase 
inhibitors such as novobiocin.  Naphthoquinones, another class of secondary 
metabolites with a chemical scaffold similar to flavonoids were found to be a defence 
compound against bacterial infection.  They were found to interact with topo II and 
induce DNA cleavage 184 by a mechanism possibly involving DNA binding.  Despite the 
potency of these compounds against bacteria, they also interact with various kinases 
185-186 in eukaryotic cells.  This leads to cytotoxicity and other undesirable side-effects, 
which prevented their development into potential antibacterials.  The availability of 
other GHKL (Gyrase, Hsp90, Histidine Kinase, MutL family) ATPase structures has 
provided hope that allosteric binding site could be exploited to develop enzyme-
specific inhibitors 58.   
1.7. Staphylococcus aureus  
Staphylococcus aureus is a gram positive, facultative anaerobe.  It produces arrays of 
endotoxins and is able to induce fatal conditions such as toxin shock syndrome.  As a 
result of stress, S. aureus can form chemoresistant endospores, which enable it to 
evade chemical attacks and transmit itself through the air current.  Its ability to 
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produce Beta-lactamase and the presence of NorA efflux pump 187 as well as its 
effectiveness in obtaining resistant genes through horizontal gene transfer 188 has 
offered intrinsic resistance mechanisms to Beta-lactam antibiotics and many other 
classes of antibacterials such as macrolides, aminoglycosides, lincosamides, 
sulfonamides, tetracyclines, aminocoumarins and quinolones.    Its prevalence in the 
human body in the nasal passage 189, hair 190 and human skin 191 means it could 
inhabit a healthy individual and cause opportunistic infection, or it can be easily 
transmitted to other hosts through skin-to-skin contact.   
 
1.7.1 Halotolerance and S. aureus induced food poisoning  
Staphylococci are notoriously halotolerant organisms and some strains have even 
been found to grow in salt concentrations as high as 3 - 4.5 M NaCl 192-193.  S. aureus is 
one of the most halotolerant pathogens and therefore high salt conditions (1.28  M 
NaCl) is commonly used for its isolation 194-195.  This halotolerant ability of S. aureus is 
considered as a pathogenic factor by allowing it to colonise in high salt environments, 
such as the human skin 196, thereby increasing the chances of opportunistic 
subcutaneous infection and transmission through direct skin contact.  Some clinically 
isolated strains of MRSA displayed strong halotolerance, although no correlation was 
found between antibiotic resistance and halotolerance 197.   
S. aureus-induced food poisoning has been an important issue in the food industry.  
Usually food products are prepared at a low water activity or high osmolarity to 
prevent the growth of microorganisms.  Distinct from other food poisoning bacteria, S. 
aureus is able to grow in extremely salty conditions (table 1.1) and is therefore often 
the source of processed food spoilage. 
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Organism Minimum Aw for growth 
Caulobacter 1.00 
Spirillum 1.00 
Pseudomonas .91 
Salmonella/E. coli .91 
Lactobacillus .90 
Bacillus .90 
Staphylococcus .85 
Halococcus .75 
Table 1.1 Limiting water activities (Aw) for growth of prokaryotes.  
Organisms with lower Minimum Aw can withstand saltier environments 198. 
 
1.7.2 In vitro properties of S. aureus gyrase and topo IV 
Intriguingly, the supercoiling activity of S. aureus gyrase is highly tolerant to salt in 
vitro.  While  E. coli gyrase negatively-supercoils DNA optimally in the presence of 
100-200 mM potassium glutamate (KGlu) and is inhibited at high salt condition, S. 
aureus gyrase can achieve optimal supercoiling activity similar to E. coli DNA gyrase 
in the presence of >800 mM of KGlu 199.  A similar study from Blanche et al. had 
reported similar results that describe a 500-fold increase in supercoiling activity of S. 
aureus gyrase with the increase of KGlu concentration from 0 to 750 mM 200.  At KGlu 
concentrations of 0-200 mM, S. aureus gyrase could not supercoil DNA but instead 
decatenates catenated DNA in the presence of ATP and relaxes negatively supercoiled 
plasmid DNA in the absence of ATP 199.   In contrast, S. aureus topo IV is less salt 
sensitive and requires 100-200 mM KGlu for optimal DNA relaxation and 
decatenation activity. 
A follow up experiment found that high salt is required for S. aureus gyrase DNA 
wrapping, which could explain the salt requirement for its supercoiling activity 199.    
The authors suggested this particular feature to be due to the relatively high acidicity 
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of S. aureus GyrA C-terminal domain (SaGyrA-CTD) in comparison to E. coli gyrase.  
Using homology modelling, the CTD of SaGyrA was found to have a much lower 
basicity on the circumference of the beta-propeller fold in comparison with E. coli.  
Similarly, gyrase from Streptococcus pneumoniae (Sp) was reported to require a 
moderate level of salt for its supercoiling activity 201 and has reduced basicity in the 
DNA binding region of the beta-propeller fold.  
Despite the strong similarity in surface electrostatic potential in homology models of 
the Sa and Sp gyrase CTD, Sa gyrase CTD is ~2 to 3-fold more salt-sensitive than Sp 
gyrase CTD in vitro.  Further sequence alignment analysis has found a >40 amino acid 
addition at the C-terminal end of GyrA-CTD of Sa gyrase.  Surprisingly, this addition is 
extremely acidic (~38% Asp/Glu) and in silico protein foldability prediction 
(foldindex) suggests this region to be unfolded and highly disordered.  In addition, 
BLAST analysis of this region has yielded the same unique homologous addition in 
gyrases of all staphylococci organisms sequenced to date.  If the acidic addition is indeed contributing to the enzyme’s salt-sensitivity, it might be possible that this 
addition could contribute to the unique halotolerance character of staphylococci 
bacteria. 
In addition, the requirement of KGlu could be due to a difference in co-factor required 
for ATPase activity as monovalent ions such as potassium and sodium were suggested 
to bind to the ATPase region and catalyse ATP hydrolysis 61.  It would be interesting 
to investigate if ATPase activity was affected by the KGlu concentration and whether 
monovalent ions indeed facilitate ATPase reaction of S. aureus gyrase. 
Conversely, S. aureus topo IV has a less distinct salt sensitivity than gyrase and 
requires moderate salt concentration (100-200 mM KGlu) for its decatenation and 
relaxation activity 199. 
 
1.7.3 Quinolone target preference in S. aureus 
Whilst most in vitro inhibitory studies of quinolones were carried out using E. coli 
gyrase and topo IV, relatively little work has been done on the gyrase and topo IV of 
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gram-positive bacteria.  It is established that in E. coli, DNA gyrase is the preferred 
target of norfloxacin and topo IV is 18-fold less sensitive in inducing DNA cleavage in 
vitro 112.   Conversely, S. aureus topo IV is 2.5-fold more sensitive to norfloxacin than 
gyrase 112.  This trend of target preference in gram-positive and gram-negative 
bacteria is also observed in vivo 202-203.  The reason behind such preference is 
currently unknown.  It could be dependent on multiple factors including the changes 
in the conformation of the quinolone-binding site on the enzyme as well as the 
difference in the in vivo activity of the enzyme and physiological state of the cell 
(ATP/ADP ratio, osmolarity, pH etc.)    
Hiasa et al. carried out nascent chain elongation experiments to study the cleavage 
induced by collision between quinolone induced enzyme-DNA complexes and the 
replication fork 199.  The experiment showed that ciprofloxacin induced S. aureus 
gyrase-DNA ternary complex was unable to arrest replication fork progression in low 
salt conditions.  In contrast, E. coli gyrase and topo IV, and S. aureus topo IV were all 
able to arrest replication.  This indicates that DNA fork arrests require gyrase-DNA 
wrapping 109,204 and the inability of S. aureus gyrase to wrap to DNA in the absence of 
salt could be the reason behind S. aureus gyrase quinolone insensitivity.  Moreover, 
while Sa gyrase is capable of DNA wrapping in high salt, quinolone-induced cleavage 
was found to be inhibited in similar salt conditions 199.  It is reasonable to assume 
quinolone binding to involve in electrostatic interaction, it could be greatly impaired 
in high concentrations of counter ions.  It is yet to be proven whether quinolone 
binding is affected in high salt.   
Considering the salt sensitivity of S. aureus gyrase, it is possible for the change in 
osmolarity of the bacterial habitat to affect the activity of gyrase as well as the 
potency of quinolones and other gyrase inhibitors.  This hypothesis could be 
supported by the evidence that S. aureus DNA is more negatively supercoiled in the 
presence of 0.5 M NaCl 205, which reflects an increase in in vivo gyrase activity in high 
osmolarity.  Therefore in low salt growth conditions, the in vivo S. aureus gyrase 
activity could be much lower than topo IV and could lead to the apparent in vivo 
quinolone target preference. 
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1.7.4 Possible connection between KGlu sensitivity of S. aureus gyrase 
and its halotolerance 
Based on the data from a 1978 study measuring the amino acid content of S. aureus 
growing exponentially in a low salt medium, it was found that S. aureus has a high 
amount of intracellular dicarboxylic amino acids 206.  Previous investigations on Sa 
gyrase and topo IV were carried out under the assumption that high KGlu is required 
to mimic the intracellular conditions.  Therefore KGlu has since remained an essential 
additive in the in vitro tests of these enzymes.  The authors suggested that the salt 
sensitivity of Sa gyrase could be the result of the enzyme’s adaption to the high 
intracellular KGlu content in S. aureus 199.   However, several recent studies provide 
contradicting observations that suggest a high concentration of betaine and proline as 
compatible solutes instead of glutamate in S. aureus cytoplasm at high osmolarity 
growth condition 207-208.  It was found that during osmotic shock, S. aureus decreases 
its cell volume 209 as a result of osmosis and this is gradually restored by increasing 
its internal betaine 210-212 and proline 213-214 concentration by up-regulation of the 
active transport system.    As both betaine and proline are placed high in the 
kosmotropic end of the hoffmeister ion series, they could provide a strong 
osmoprotective effect to cellular proteins even at high molarity 215.  Similar to betaine 
and proline, the glutamate ion is a kosmotrope.  It is therefore possible that KGlu rich 
conditions used consistently in these in vitro studies of Sa gyrase and topo IV could 
resemble a physiological condition similar to a betaine- and/or proline- rich 
environment.   
While these studies reported the salt-dependency of Sa gyrase, the fact that S. aureus 
is extremely halotolerant was ignored.  S. aureus gyrase, being highly salt-dependent, 
can function in 4-8 times more salt than E. coli gyrase, thus possibly giving the 
organism an advantage whilst growing in a high osmolarity environment.  
Alternatively Sa gyrase could act as an osmosensing gene regulator in S. aureus that 
promotes or represses gene expression by offsetting chromosome hyperhelicity in 
response to osmotic changes.  In fact, Epicatechin gallate, a flavonoid with structure 
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that highly resembles flavonoids that inhibit gyrase 182-183,216 and topo IV 181, was 
found to reduce halotolerance of S. aureus 12.  This further supports the role that 
gyrase has in the halotolerance of S. aureus and it would be interesting to test out 
these hypotheses. 
1.8. Conclusions and future prospects 
The emergence of multi-drug resistant S. aureus and the shortage in the supply chain 
of novel antibacterial discoveries has led to a great urgency in the discoveries of new 
drugs.  DNA gyrase and topo IV are targets of the clinically important quinolone drugs 
and are proven antibacterial targets for a wide spectrum of pathogenic bacteria.  
While the majority of antibacterial targets have more than one class of drug currently 
on the market, DNA gyrase and topo IV are considered to be under-exploited.  Almost 
30 years of in vitro functional, catalytic and structural knowledge of gyrase and topo 
IV is now providing a vital platform for the development of novel inhibitors.  These 
include various GyrB ATPase binding inhibitors and DNA-GyrA binding agents that 
have been developed over the years.  Despite numerous gyrase inhibitors discovered, 
the mode of action and binding site of most of these compounds are largely 
undetermined.  The difficulties in obtaining crystals of these enzyme-drug complexes 
have limited the medicinal improvement of these potential antibacterials.  With the 
tightened drug safety regulations in recent years and the exceptionally high attrition 
rate of antibacterials in comparison to drug in other therapeutic area, the discovery of 
novel antibacterial is harder than ever.  The success of novel gyrase inhibitors will be 
heavily dependent on a collaborative effort between biologists, chemists and 
pharmacologists to identify successful leads in the early stage of the drug 
development process. 
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1.9 Aims of the project 
1.9.1 Mechanistic exploration of S. aureus gyrase and elucidation of the 
origin of KGlu dependent supercoiling 
While E. coli gyrase has been the main subject of interest for bacterial topo II 
investigations, relatively little work has been carried out on gyrases in gram-positive 
organisms.  Evidence from various studies highlighted the unique KGlu-dependence 
and specific supercoiling stimulation displayed by S. aureus gyrase.  Hiasa et al. 199 has 
extended the finding by suggesting the linkage between GyrA-CTD of S. aureus gyrase 
and its KGlu dependency.  However, it is far from conclusive as it does not support the 
role of K+/Glu- in compensating the difference in supercoiling activities between E. 
coli and S. aureus gyrase.  Moreover, it does not explain the specific requirement of 
the presence of K+/Glu- ions for supercoiling stimulation.  By building on evidence 
from previous studies on KGlu dependency supercoiling of S. aureus gyrase, we 
attempt to locate the enzymatic origin of this phenomenon using mechanistic based 
biochemical assays and mutant studies.  
1.9.2 Naphthoquinones as novel gyrase inhibitors  
Evidence from Karkare et al. 2013  suggested a novel mode of inhibition on M. 
tuberculosis gyrase by diospyrin, a naphthoquinone of plant origin.  This novel 
discovery has raised an interesting proposition of developing naphthoquinones as a 
new class of gyrase-targeting antibiotics.  This also suggested the possibility of 
utilising naphthoquinones as anti-staphylococcal agents.  In order to further confirm naphthoquinones’ potential as tial antibacterial/anti-staphylococcal drug leads, we 
aim to further investigate the in vivo potency of a variety of natural naphthoquinones 
against S. aureus.  We also aim to investigate the activity of these natural 
naphthoquinones against S. aureus gyrase and topo IV in vitro.  In addition, we aim to 
identify the mode of inhibition, structure-activity-relationship and binding position 
for these compounds using a variety of techniques (e.g., mechanistic enzyme assays 
and protein crystallography). 
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Chapter 2 Materials and methods 
2.1 Buffers and Solutions 
Assay Buffers Content 
S. aureus DNA gyrase supercoiling buffer 
/E. coli DNA gyrase supercoiling buffer 
/S. aureus DNA gyrase decatenation buffer 
/S. aureus DNA cleavage buffer 
 
         40 mM HEPES.KOH (pH 7.6) 
         10 mM magnesium acetate 
         10 mM Dithiothreitol 
            2 mM ATP 
     *500 mM potassium glutamate 
0.05 mg/mL Bovine serum albumin 
S. aureus DNA gyrase relaxation buffer 
/E. coli DNA gyrase relaxation buffer 
/thermal shift assay buffer 
         40 mM HEPES.KOH (pH 7.6) 
         10 mM magnesium acetate 
         10 mM Dithiothreitol 
     *500 mM potassium glutamate 
0.05 mg/mL Bovine serum albumin 
S. aureus topo IV relaxation buffer          50 mM Tris.HCl (7.5)  
            5 mM MgCl2 
            5 mM DTT  
         1.5 mM ATP  
       350 mM potassium glutamate  
0.05 mg/mL Bovine serum albumin 
S. aureus gyrase dilution buffer         50 mM Tris.HCl (pH 7.5) 
           1 mM DTT 
           1 mM EDTA 
30 % (w/v) glycerol 
ATPase buffer          40 mM HEPES.KOH (pH 7.6) 
         10 mM magnesium acetate 
         10 mM DTT 
       500 mM potassium glutamate 
0.05 mg/mL Bovine serum albumin 
Electrophoresis buffers  
STEB(x2)       100 mM Tris.HCl (pH 8.0) 
      100 mM EDTA 
40 % (w/v) sucrose 
  0.5 mg/mL bromophenol blue 
TAE          40 mM Tris.acetate (pH 8.0) 
            1 mM EDTA 
SAB        125 mM Tris.HCl (pH 6.8) 
    4% (w/v) SDS 
 20 % (w/v) glycerol 
 10 % (w/v) Ⱦ-methcaptoethanol 
   0.5 mg/mL bromophenol blue 
Table 2.1 Buffers and solutions used in this study 
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2.2 Bacterial strains 
Bacterial strains Genotype 
Escherichia coli RosettaTM 2 pLysS  F-ompT hsdSB(rB- mB-) gal dcm pRARE2 
pLysS  (CamR)  
 
Escherichia coli BL21 (DE3) pLysS  F-ompT hsdSB(rB- mB-) gal 
dcm (DE3) pLysS (CamR) 
 
Escherichia coli TOP10 (invitrogen) F– mcrA Δȋmrr-hsdRMS-mcrBCȌ ΦͺͲlacZΔMͳͷ ΔlacX74 recA1 araDͳ͵ͻ Δȋara leu) 
7697 galU galK rpsL (StrR) endA1 nupG 
 Staphylococcus aureus ATCC 29213  No specific genotype. 
Table 2.2 Strains of bacteria used in this study 
 
2.3 Media 
Luria-Bertani medium was used for the selection and cultivation of both E. coli and S. 
aureus in solution. 
Luria –Bertani medium: 
Tryptone      1% (w/v) 
Yeast extract   0.5% (w/v) 
Sodium Chloride     1% (w/v) 
Terrific Broth is the preferred medium used for high density bacterial growth of up to 
OD600 ~8.  It was used for the large scale production of pBR322 plasmids, where high 
quantities of bacteria were required to provide maximum DNA production. 
Terrific Broth: 
Tryptone      1.2% (w/v) 
Yeast extract         2.4% (w/v) 
K2HPO4      9.4% (w/v) 
KH2PO4      2.2% (w/v) 
Glycerol            4% (v/v) 
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All of the media described above were sterilised before use by autoclaving.  Unused 
liquid media were stored at RT and remained sterile until use. 
Solid Luria-Berth agar media was used for colony isolation and cultivation of newly 
transformed competent E. coli. 
Luria –Bertani agarose solid medium: 
Tryptone       1% (w/v) 
Yeast extract   0.5% (w/v) 
Sodium Chloride      1% (w/v) 
Agarose  1.5% (w/v) 
The solid medium was produced by first autoclaving the mixed ingredients listed.  
The autoclaved mixture was then stored until later use.  Once ready for use, the 
autoclaved mixture was reheated in the microwave until all solid agarose was 
thoroughly melted.  The molten LB agar solution was then left to cool to ~40-50°C, at 
which point the desired antibiotics were added and mixed.  The agar was then 
immediately poured into Sterilin® Petri dishes and left to cool in a sterile 
environment until it solidified.  The LB agar plates can be stored at 4°C in a dark 
environment for later use. 
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2.4 Antibiotics 
Antibiotics were frequently included in bacterial media for the isolation and 
cultivation of E. coli with the desired transformed plasmids.  The type of antibiotics 
and the concentration used in this study are described in Table 2.3 
Antibiotics Stock concentration Working concentration 
Ampillicin 100 mg/mL ͳͲͲ μg/mL 
Chloramphenicol 30 mg/mL ͵Ͳ μg/mL 
 
Table 2.3 Types of antibiotics and their concentrations used for bacterial cultures 
in this study. 
  
2.5 Bacterial Methods 
2.5.1 Preparation of chemically competent cells (BL21(DE3), Rosetta II 
(pLysS))  
Glycerol stocks containing the desired E. coli cells were streaked onto fresh LB agar 
plates and grown overnight at 37°C.  A single colony was then isolated and inoculated 
into 5 mL of LB containing the respective antibiotic, and incubated overnight.  1 mL of 
the overnight culture was then used to further inoculate a fresh 100mL LB.  The cell 
culture was grown at 37°C until OD600= 0.4-0.6 was reached. 
The culture was then cooled on ice for 10 mins before the cells were harvested via 
centrifugation at 3,500x g.  Pelleted cells were carefully resuspended in 20 mL of cold 
100 mM CaCl and incubated on ice for a further 20 mins.  Cells were pelleted again by 
gentle centrifugation at 3,500 x g and subsequently resuspended in 2.4 mL of 100 mM 
CaCl, 20% (v/v) glycerol.  Finally, the resuspended cells were aliquoted into ͷͲ μL 
portions and flash frozen using liquid nitrogen.  The cell aliquots were stored at -80°C 
until later use.  
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2.5.2 Plasmid DNA transformation of chemically competent cells 
Aliquots of chemically competent cells were removed from -80°C and allowed to thaw 
in ice for ~15-20mins.  Once thawed, ~0.5-2ul of plasmid DNA (2-ʹͷ μg/mlȌ was 
gently injected into the cell aliquots.  The resulting cell aliquots were incubated in ice 
for a further 20 mins in order to allow for the diffusion and uptake of the injected 
plasmids by the competent cells.  To initiate plasmid transformation, the cell/DNA 
mixtures were then heat shocked at 42°C for 30-45s using the heating blocks.  The 
cells were immediately transferred back to ice for one minute before ʹͲͲ μL of LB 
media medium was added.  The cells were incubated at 37°C for a further 1 hr (in 
shaking incubators), then were plated onto LB agar containing the relevant antibiotic 
and were subsequently incubated overnight at 37°C   for colony selection. 
 
2.6 DNA methods 
2.6.1. Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used for the separation and identification 
of DNA by their molecular weight or their topology.  Firstly, an agarose gel was 
prepared by melting and dissolving 1% (w/v) agarose into buffer TAE.  The hot 
agarose was then poured into gel casks with well spacers positioned accordingly and 
then allowed to cool at RT for 20-30 mins until the agarose had fully set; once set, the 
1% (w/v) agarose gel is ready for use.  To initiate electrophoresis, the 1% (w/v) 
agarose gel is submerged into an electrophoresis gel tank filled buffer TAE.  An 
adequate quantity of TAE is added to ensure that the gel is covered with ~1 cm depth 
of buffer in order to prevent dehydration.  DNA samples containing loading buffer 
(STEB) were then injected and allowed to settle into preformed wells.  The loaded gel 
was then subjected to an electric current of ~80 V to allow separation of the DNA 
molecules until the dye front had reached ~2/3 the way of the full length of the gel.  The gel was then stained in TAE buffer containing ʹ μg/mL ethidium bromide for ͳͲ-
20 mins.  The gel was visualised under an ultraviolet transilluminator and 
photographed using the Syngene Bio-imaging system.  
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2.6.2. DNA gel-extraction 
The DNA products of desired molecular weight that were separated by agarose gel 
electrophoresis could be extracted using QIA quick gel extraction kit and by following the manufacturer’s recommended protocol. 
 
2.6.3. DNA precipitation 
DNA precipitation was occasionally carried out for the purification, concentration and 
storage of DNA samples.  Ethanol or isopropanol were used interchangeably; to the 
DNA sample were added 1/10 the volume of sodium acetate (3 M, pH 5.2) and either 
ethanol (2.5-3.0x vol) or isopropanol (1x vol).  The resulting mixture was incubated 
on ice for 15 mins to >8 hours (depending on the quantity of the DNA in the sample) 
to allow precipitation.  The sample was then centrifuged at 4°C at >14,000 x g for 30 
mins to pellet the DNA.  The supernatant was removed and the DNA pellet was 
washed with 70% (v/v) ethanol to remove any remaining sodium acetate.  The 
sample was again centrifuged at >14,000 x g for a further 15 mins.  The supernatant 
was then removed and the DNA pellet was redissolved into the desired solvent.  
Alternatively, the DNA pellet was dried in a vacuum dessicator and then stored at RT. 
 
2.6.4. Small scale plasmid DNA production and purification 
Plasmid DNA was transformed into chemically competent E. coli top10 (invitrogen) 
cells according to 2.5.2.  It was then used for inoculating 5 mL of LB medium and was 
grown overnight to reach stationary growth.  The bacteria were then harvested, lysed 
and the DNA was extracted using the appropriate Qiaprep spin miniprep kit (Qiagen) and by following the manufacturer’s recommended protocol. 
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2.6.5. DNA sequencing 
DNA sequencing was carried out using BigDye® v3.1 kit (Applied Biosciences).  A 
typical sequencing reaction (10 µl) consisted of: 
Reaction buffer      1.5 µl 
BigBye v3.1 mix         1 µl 
Sequencing primer (2 µM)        1 µl 
Template DNA   100 ng 
Total volume        10 µl    
 
The following sequencing oligonuleotides were used for sequencing of S. aureus GyrA 
mutants: 
Name Primer sequences (5′ -3′ ) 
SaA1 5′ -GGTATGGCAACGAATATTCC-3′  
 
SaA2 5′ -GGTGTGAATATGATTGCAC-3′  
SaA3 5′ -GGTATGAATACATTGGAAG-3′  
SaA4 5′ -GGTTATGGTAAACGTACGCC-3′  
 
Table 2.4 Sequences of the sequencing primers using for validation of 
mutants produced via site directed mutagenesis 
The reaction was prepared according to the above recipe with the correct sequencing 
primer is then subjected to the thermocycler program describe in table 2.5 to carry 
out the sequencing reaction. 
 
 
 
 
 
 
 
Chapter 2   Material and Methods 
 
53 
 
 
Step Temperature (°C) Time (min:sec) Description 
1 95 1:00 Denaturation of dsDNA 
2 95 0:30 Denaturation of dsDNA 
3 45 0:15 Primer annealing 
4 60 4:00 DNA elongation 
5 - - Loop to step 2 (29 times) 
6 72 10 Ensure completion of DNA elongation 
7 4 N/A End of program 
 
Table 2.5 Thermocycler program used for DNA sequencing reaction.  Reactions 
were carried out using a PCT-200 thermal cycler. 
The products of the sequencing reactions were submitted to the John Innes Genome 
Laboratory for analysis.  Sequences were aligned with the expected sequences to 
confirm the fidelity of the DNA samples and to examine the occurrence of any 
unexpected mutation. 
2.6.6 DNA concentration determination 
DNA concentration was determined using a BioPhotometer (Eppendorf) by 
measuring A260 of a DNA sample diluted in milli-Q-water. 
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2.6.7 Mutagenesis 
2.6.7.1 Oligonucleotides 
Construct Name Direction Primer sequences (5′  -3′  ) 
S. aureus GyrA 
NTD (∆489-
888) 
) 
SaA59QCfor Forward  5′ -ACCGAAATTCAGTAGGGTGGTTTTGAA-3′   
SaA59QCrev Reverse 5′ -TTCAAAACCACCCTACTGAATTTCGGT-3′   
SaGyrA ∆Cterm-
tail(∆811-888) SaAtrunQCfor Forward  5′ -GCCAAAGTTAAATAAGATGCCGAGGAC-3′   SaAtrunQCrev Reverse 5′ -GTCCTCGGCATCTTATTTAACTTTGGC-3′   
SaANTD(1-
489)-EcACTD 
(523-875) 
chimeric GyrA 
  
T7 forward Forward 5′ -ACCGAAATTCAGTAGGGTGGTTTTGAA-3′   
SaANTDrevDS Reverse 5′ -GTCTGCGCTGTTGGCTTGAATTTCTGTACG-
3′   EcACTDforDS Forward 5′ -CGTACAGAAATTCAAGCCAACAGCGCAGAC-
3′   EcACTDrev Reverse 5′ -ATATATATGGATCCTTATTCTTCTTCTGG-3′   
Table 2.6 DNA primers used for the PCR based site directed mutagenesis. 
 
2.6.7.2 QuikChange® plasmid Site-directed mutagenesis (SaGyrA-NTD / SaGyrA 
∆Cterm-tail plasmid construction) 
QuikChange® site-directed mutagenesis developed by Qiagen was used to introduce 
point mutations (e.g., premature termination codons) into plasmid DNA sequences 
for the production of mutant proteins (SaGyrA-NTD/SaA54, SaGyrA ∆Cterm-tail).  The 
plasmid DNA template consisted of coding sequence of a full length wt SaGyrA 
inserted between NdeI and BamHI of the multiple cloning site.  Site-directed 
mutagenesis was performed via polymerase chain reaction (PCR), whereby the a stop 
codon was introduced after the desired termination amino acid using DNA primers 
with the designed stop codon (SaA59QCfor/SaA59QCrev and SaAtrunQCfor/ 
SaAtrunQCrev).  A typical 50 µl PCR reaction contained: 
Template DNA 100 ng 
dNTPs ʹͲͲ μM 
Phusion DNA polymerase (NEB) 1 unit 
DNA primers Ͳ.ͷ μM 
Phusion HF buffer Added to 1x 
 
The DNA primers used are listed in table 2.6.  Table 2.7 Shows a typical thermocycler 
program used. 
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Step Temperature (°C) Time (min:sec) Description 
1 95 1:00 Denaturation of dsDNA 
2 95 1:00 Denaturation of dsDNA 
3 50-68  0:15 Primer annealing 
4 72 1:00 – 8:00 DNA elongation (time = 30s/1kb) 
5 - - Loop to step 2 (15 times) 
6 72 10 Ensure completion of DNA elongation 
7 4 N/A End of program 
Table 2.7 Thermocycler program used for the Quickchange® site-directed 
mutagenesis reaction.  Reactions were carried out using a PCT-200 thermal 
cycler.  Annealing temperature and time for DNA elongation step are determined 
by the Tm of primers used and the length of the template DNA. 
Following the amplification of the mutant, 10-20 units of DpnI, a restriction enzyme, 
is added to the reaction.  The mixture was incubated at 37°C for one hour.  The 
mutated DNA product was then transformed into E. coli top10 cells (invitrogen) and 
grown in LB agar plates containing the required antibiotics.  The plasmid DNA was 
then isolated from the colonies and the introduction of the mutation was confirmed 
by DNA sequencing (2.6.5). 
2.6.7.3 Chimeric SaNTD-EcCTD GyrA construct production 
Production of the expression construct for the chimeric SaNTD-EcCTD GyrA (SaANTD 
(1-489) - EcACTD (523-875)) mutant was achieved by carrying out two separate PCR 
reactions of the SaNTD and EcCTD sequence.  The SaNTD PCR reaction uses 
T7forward and SaANTDrevDS (table 2.6) as primers.  The EcCTD PCR reaction uses 
EcACTDforDS and EcACTDrev as primers (table 2.6) as primers.  This produces two 
DNAs with 30 nt of sequence compatible overhangs for the 2nd step PCR.  The 2nd step 
PCR used the two PCR products from the 1st step PCR as templates.  The forward 
primer of the SaANTD PCR reaction (T7 forward) and reverse primer of EcCTD PCR 
reaction (EcACTDrev) to produce a final PCR product with DNA sequence encoding 
the SaNTD-EcCTD GyrA protein.  Sticky-ends were then introduced to the construct 
using restriction enzymes (NdeI and BamHI), following the recommended standard 
protocol.  The DNA product was subsequently ligated into an empty pET22b plasmid 
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(with the compatible NdeI/BamHI ends) overnight using T4 DNA ligase (Invitrogen) in accordance to the manufacturer’s instructions.  The ligated plasmid was then 
transformed into E. coli top10 cells (invitrogen) and grown in LB agar plate 
containing the required antibiotics.  The plasmid DNA was then isolated from the 
colonies and the introduction of the mutation was confirm by DNA sequencing (2.6.5). 
2.7 Protein Methods 
2.7.1 Basic protocol 
2.7.1.1 Dialysis 
The dialysis procedure was usually required for removal of salt and solute from the 
protein samples.  The process involved the submergence of the dialysis apparatus 
containing the protein samples into desired buffers of 200x the volume of the sample.  
Various dialysis equipments were used depending on the volume of the sample: 
10-ͷͲͲ μL    Slide-A-Lyzer MINI Dialysis Units, 10K MWCO (Thermo 
Scientific) ͷͲͲ μL – 3 mL Slide-A-Lyzer Dialysis Cassettes, 10K MWCO (Thermo Scientific) 
>3 mL   SnakeSkin Dialysis Tubing, 10K MWCO (Thermo Scientific) 
 
2.7.1.2 Protein concentration 
Concentration of protein solution was typically carried out by ultrafiltration using 
Amicon® filter spin concentrators.  
 
2.7.1.3 Protein concentration determination 
The Bradford Method 217 was used throughout this study for the determination of 
protein concentration in protein samples.  Bradford reagents were acquired from 
Sigma.  ͷ μL of protein solution were diluted into ͳͲͲ μL of ͷͲ mM Tris.(Cl ȋp( 7.5).  The diluted protein sample was then mixed with ͻͲͲ μL of Bradford reagent.  
Samples were allowed to incubate at RT for 5 mins and their absorbance at 595 nm 
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was subsequently measured using a spectrophotometer.  The recorded value 
corresponded to the background value subtracted by the value recorded from a blank sample consisting of ͳͲͲ μL of ͷͲ mM Tris.(Cl ȋp(͹.ͷȌ mixed in ͻͲͲ μL of Bradford 
reagents.  The protein concentration was then derived by a calibration curve obtained 
from measurements generated from identically treated BSA standards.  
 
2.7.1.4 SDS PAGE 
Analysis of protein samples were carried out by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE).  Samples were heated in a boiling 
water bath for ~1 min in 1x SAB buffer (125 mM Tris.HCL, 4% (w/v) SDS, 20% (w/v) glycerol, ͳͲ% ȋv/vȌ Ⱦ-mercaptoethanol, 0.002% (w/v) bromophenol blue).  The 
boiled samples were next loaded onto and run on discontinuous polyacrylamide gels 
(12.5%, 4% stacking gel) mounted in a Bio Rad Miniprotein-III setup for ~1.5 hrs at 
200 V until the dye front had reached the end of the gel.  Samples were run together 
with LMW marker (GE healthcare) protein standards used as molecular weight 
references.  Gels were then stained with a Coomassie stain (15% (v/v) acetic acid, 
10% (v/v) methanol and 0.1% (w/v) Coomassie stain).  The gels were subsequently 
destained in Milli-Q water and photographed using a Syngene GeneGenius Bio-
Imaging system. 
 
2.7.2 Recombinant protein expression  
Expression plasmids with corresponding constructs listed in table 2.8 were 
transformed into expressing E. coli strains according to 2.5.2.  The E. coli strain 
carrying the desired expression plasmid was then inoculated into 5 ml of  LB broth 
containing the appropriate antibiotic and then grown overnight (~12-16 hrs) with constant shaking at ͵͹°C.  ͷͲͲ μL of the grown saturated E. coli were used to 
inoculate a 50 ml subculture with fresh LB broth containing antibiotic.  This 
subculture was then grown overnight at 37°C under constant shaking for~12-16 hrs.  
10 ml of the grown subculture were then used to inoculate 1 L LB expression culture 
containing the relevant antibiotic.  The expression culture was grown at 37°C in 
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shaking incubator until the log phase growth level was reached (OD600 ~0.4-0.6).  
The expression culture was subsequently induced by addition of IPTG to a final 
concentration of 0.5 mM.  The induced culture was then incubated in 25°C for a 
further (~12-16 hrs) to allow total expression of the protein.  To harvest the 
generated cells, the culture was subjected to centrifugation at 9,900 x g for 10 mins at 
4°C.  The resulted supernatant was discarded and the cell pellet was resuspended 
using TGED buffer (50 mM Tris.HCl pH 7.5, 1 mM DTT, 1 mM EDTA, 10% (v/v) 
Glycerol).  The resuspended cells were then flash frozen using liquid nitrogen and 
were stored at -80°C until further use. 
 
 
Protein 
expressed 
Expression plasmid Expression E. coli 
strain 
Antibiotics used Protein 
affinity tag 
S. aureus GyrA pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
S. aureus GyrB pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
S. aureus ParC pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
S. aureus ParE pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
S. aureus GyrA 
NTD 
pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
E. coli GyrBNTD pAJ1 Escherichia coli 
BL21 (DE3) pLysS 
Ampicillin, 
chloramphenicol 
N/A 
SaGyrA ∆Cterm-
tail 
pET11a Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
N/A 
SaNTD-EcCTD 
GyrA 
pET22b Escherichia coli 
RosettaTM 2 pLysS 
Ampicillin, 
chloramphenicol 
C-terminal 
His-tag 
Table 2.8 Expression systems used for the expression of recombinant proteins. 
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2.7.3 Cell lysis and protein extraction  
The frozen cells referred to in 2.7.2 were thawed and incubated at RT for 30 mins to 
allow lysozyme-induced cell lysis.  The cell lysate was then centrifuged at 48,000 x g 
for 1 hr at 4°C to remove the cell debris.  The resulting supernatant containing the 
expressed protein was then subjected to SDS-PAGE analysis to assess the expression 
level of the protein. 
2.7.4 Protein purification protocol 
2.7.3.1 Purification of S. aureus GyrA and SaGyrA mutants (SaGyrA NTD and 
SaGyrA ∆Cterm-tail) 
S. aureus GyrA and the SaGyrA ∆Cterm-tail mutant were both purified by applying 
three FPLC protein affinity column steps.  Firstly, powdered ammonium sulphate was 
gradually added into the cell lysate containing the expressed protein, to a final 
concentration of 1.5 M.  The lysate was loaded onto a Phenyl sepharose 20 ml column 
pre-equilibrated with 3 column volumes of 1.0 M ammonium sulphate TGED (50 mM 
Tris. HCl pH 7.5, 1 mM DTT, 1 mM EDTA, 10% (v/v) Glycerol) buffer.  The column was 
then washed with one column volume of 1.5 M ammonium sulphate TGED buffer.  
Any bound proteins were eluted using a gentle gradient of 1 M - 0 M ammonium 
sulphate TGED buffer.  Eluted fractions containing the desired protein were dialysed 
against TGED buffer overnight.  The dialysed sample was passed through a 5 ml Q 
sepharose column pre-equilibrated with TGED buffer.  The column was washed with 
excess TGED buffer and any bound proteins were eluted with 0-1 M NaCl TGED buffer 
salt gradient.  The eluted protein fraction containing the desire protein was then 
dialysed against excess TGED buffer overnight.  Finally, the dialysed protein fraction 
was loaded onto a 20 ml MonoQ column pre-equilibrated with TGED buffer.  The 
column was washed with excess TGED buffer and the bound proteins were eluted 
with 0-1 M NaCl TGED salt buffer gradient.  Eluted fractions containing the desired 
protein were dialysed against excess TGED (30% (v/v) Glycerol) buffer overnight.  
The dialysed protein was then aliquoted, flash-frozen with liquid nitrogen and finally 
stored at -80°C.  The sample of the purified protein was then digested by trypsin by 
the proteomics service in John Innes Centre. The mw of digested fragement was  
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examined by MALDI-ToF mass spectrometry (in-house).  The mass spectrum 
generated was then searched against the SPtrEMBL database using the MASCOT 
search tool to confirm the identity of the protein. 
. 
2.7.3.2 Purification of S. aureus GyrB 
S. aureus GyrB was purified using protein affinity chromatography over two steps.  
Firstly, cell lysate with expressed S. aureus GyrB protein was passed through a 5 ml 
Heparin sepharose column pre-equilibrated with TGED buffer.  The column was then 
washed with excess TGED buffer and any bound proteins were eluted with 0-1 M 
NaCl TGED salt buffer gradient.  The eluted protein fraction containing desired 
protein was then dialysed against excess TGED buffer overnight.  The dialysed protein 
fraction was then loaded onto a Q sepharose 5 ml column pre-equilibrated with TGED 
buffer.  The column was washed with excess TGED buffer and bound proteins were 
eluted with 0-1 M NaCl TGED salt buffer gradient.  Eluted fractions containing the 
desired protein were dialysed against excess TGED (30% (v/v) Glycerol) buffer 
overnight.  Dialysed protein was then aliquoted, flash-frozen with liquid nitrogen and 
stored at -80°C.  The identity of the purified protein was then examined by MALDI-
ToF fingerprint. 
2.7.3.3 Purification of S. aureus ParC 
S. aureus ParC was purified using protein affinity chromatography over two affinity 
column steps.  Firstly, cell lysate with the expressed S. aureus ParC protein was 
passed through a 2x5 ml Heparin sepharose column pre-equilibrated with TGED 
buffer.  The column was then washed with excess TGED buffer and bound proteins 
were eluted with 0-1 M NaCl TGED salt buffer gradient.  The eluted protein fraction 
with the desired protein was then gradually mixed with powdered ammonium 
sulphate until a final concentration of 1.5 M ammonium sulphate was reached.  The 
protein fraction was loaded onto a 20 ml Phenyl sepharose column pre-equilibrated 
with 3 column volumes of 1.0 M ammonium sulphate TGED (50 mM Tris. HCl pH 7.5, 
1 mM DTT, 1 mM EDTA, 10% (v/v) Glycerol) buffer.  The column was next washed 
with one column volume of 1.5 M ammonium sulphate TGED buffer.  Any bound 
proteins were eluted by application of a gentle gradient consisting 1 M - 0 M 
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ammonium sulphate TGED buffer.  Eluted fractions containing the desired protein 
were dialysed against excess TGED (30% (v/v) Glycerol) buffer overnight.  The 
dialysed protein was then aliquoted, flash-frozen with liquid nitrogen and stored at -
80°C.   
2.7.3.4 Purification of S. aureus ParE 
S. aureus ParE was purified using protein affinity chromatography over two affinity 
column steps.  Firstly, cell lysate with the expressed S. aureus ParE protein was 
passed through a 5 ml Heparin sepharose column pre-equilibrated with TGED buffer.  
The column was washed with excess TGED buffer and bound proteins were eluted 
with 0-1 M NaCl TGED salt buffer gradient.  The eluted protein fraction containing the 
desired protein was then dialysed against an excess of TGED buffer overnight.  The 
dialysed protein fraction was then loaded onto a 20 ml MonoQ column pre-
equilibrated with TGED buffer.  The column was washed with excess TGED buffer and 
bound proteins were eluted with 0-1 M NaCl TGED salt buffer gradient.  Eluted 
fractions containing the desired protein were dialysed against excess TGED (30% 
(v/v) Glycerol) buffer overnight.  The dialysed protein was then aliquoted, flash-
frozen with liquid nitrogen and stored at -80°C.  The identity of the purified protein 
was then examined by by MALDI-ToF fingerprint. 
2.7.3.5 Purification of E. coli GyrBNTD 
E. coli GyrBNTD was purified using protein affinity chromatography over two affinity 
column steps.  Firstly, cell lysate with the expressed E. coli GyrBNTD protein was 
passed through a 2x5 ml Q sepharose column pre-equilibrated with TGED buffer.  The 
column was washed with excess TGED buffer and bound proteins were eluted with 0-
1 M NaCl TGED salt buffer gradient.  The eluted protein fraction containing the 
desired protein was then gradually mixed with powdered ammonium sulphate until a 
final concentration of 1.5 M ammonium sulphate was reached.  The protein fraction 
was then loaded onto a 1 ml Phenyl sepharose column pre-equilibrated with 3 
column volumes of 1.0 M ammonium sulphate TGED (50 mM Tris. HCl pH 7.5, 1 mM 
DTT, 1 mM EDTA, 10% (v/v) Glycerol) buffer.  The column was then washed with one 
column volume of 1.5 M ammonium sulphate TGED buffer.  Any bound proteins were 
next eluted by applying a gentle gradient of 1 M - 0 M ammonium sulphate TGED 
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buffer.  Eluted fractions containing the desired protein were dialysed against excess 
TGED (30% (v/v) Glycerol) buffer overnight.  The dialysed protein was then 
aliquoted, flash-frozen with liquid nitrogen and stored at -80°C.  The identity of the 
protein purified was then examined by by MALDI-ToF fingerprint.  Part of the 
EcGyrBNTD protein used in this study was gifted by Lesley Mitchenall. 
2.7.3.6 Purification of SaNTD-EcCTD GyrA chimeric mutant 
Purification of SaNTD-EcCTD GyrA involved a one-step nickel affinity 
chromatography step.  The Hi-trap column used was discharged by passing 3 column 
volumes of 50 mM EDTA buffer through it.  It was then recharged by passing 1 ml of 
100 mM NiCl2 and washed with 3 column volumes of water.  The cell lysate with the 
expressed protein was then passed through a 2x 5 ml pre-charged Hi-Trap column 
pre-equilibrated with buffer A (50 mM Tris.HCl, 0.5 M NaCl, 5 mM imidazole, pH 7.5).  
The column was washed with excess buffer A to remove non-specifically bound 
protein.  The bound proteins were finally eluted using a 0-100% buffer B gradient (50 
mM Tris.HCl, 0.5 M NaCl, 500 mM imidazole, pH 7.5).  Eluted fractions containing the 
desired protein were dialysed against excess TGED (30% (v/v) glycerol) buffer 
overnight.  The dialysed protein was then aliquoted, flash-frozen with liquid nitrogen 
and subsequently stored at -80°C.  The Identity of the protein purified was then 
examined by by MALDI-ToF fingerprint.   
2.8. Biochemical and bacterial Assays 
2.8.1. DNA supercoiling/relaxation assays 
DNA supercoiling and relaxation assays were used throughout the study to assess the 
enzymatic ability to supercoil and relax circular DNA.  Using pBR322 closed circular 
plasmid DNA as a substrate, DNA supercoiling activity of the enzyme could be 
assessed semi-quantitatively by determining the quantity and the supercoiling state 
of the DNA substrate at the end of the reaction.  Both of these assays were typically carried out in ͵Ͳ μL.   
2.8.1.1 DNA supercoiling assays 
For the DNA supercoiling assay reactions, the supercoiling assay buffers described in table ʹ.ͳ, as well as Ͳ.ͷ μg of relaxed DNA plasmid and ͳ U of DNA gyrase ȋ~64 nM 
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concentration for S. aureus / 1-40 nM of E. coli) were utilised.  1 U of DNA gyrase is defined as the quantity of enzyme required to fully supercoil Ͳ.ͷ μg of relaxed DNA 
plasmid at 37°C in 30 mins in a typical reaction.  The reactions were carried out by 
incubating the samples at 37°C in a temperature controlled water bath for 30 mins.  To terminate the reaction, equal volumes ȋ͵Ͳ μLȌ of ʹx STEB buffer and chloroform 
were added into the reaction mixture and were subsequently thoroughly mixed by 
vortexing.  The samples were then briefly centrifidged (15,700 x g, 1 min) to separate 
the aqueous and the organic phase.  The aqueous (upper) phase of the mixture, 
containing the DNA substrate, was then analysed via agarose gel electrophoresis (80 
V, three hours).  
 
2.8.1.2 DNA relaxation assays 
The DNA relaxation assays were carried out using an almost identical protocol to the 
DNA supercoiling assays; the only exception was that fully negatively supercoiled 
DNA was used instead of relaxed plasmid DNA.  Additionally, DNA relaxation buffer, 
which lacks ATP, was used instead of the DNA supercoiling buffer (table 2.1) as DNA 
gyrase only relaxes DNA in the absence of ATP. 
 
2.8.1.3. DNA decatenation assays 
Decatenation assays were used for assessing enzymatic activity of the enzymes to 
unlink catenated circular DNA.  The format of the assay is highly similar to that of the 
supercoiling and relaxation assays.  The reaction contained decatenation assay buffer, 
which was identical to that of the DNA supercoiling assay.  The DNA substrate used in 
this case was kinetoplast DNA (kDNA) extracted from Crithidia fasciculata.  kDNA is a 
network of catenated circular DNA consisting of maxi DNA circles of 20 and 40kb and 
mini circles of 0.5 and 1kb.  In the presence of enzyme exhibiting decatenation 
activity, DNA circles were released from their DNA networks (fig. 2.1) and were 
subsequently separated and visualised by gel electrophoresis.  To prepare the 
decatenation reaction, 200 ng of kDNA, in conjunction with 1 unit of gyrase and decatenation buffer were added to a volume of ͵Ͳ μL and mixed.  The reaction 
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mixture was immediately incubated for 30 mins at 37°C.  It was then terminated by 
addition of equal volumes of 2x STEB buffer and chloroform, followed by vigorous 
vortexing and finally by centrifugation at 15,700 x g for 1 min.  DNA from the upper 
aqueous phase was then analysed by agarose gel electrophoresis. 
 
 
Figure 2.1. DNA products generated from decatenation of Kinetoplast DNA 
2.8.1.4 DNA cleavage assays 
DNA cleavage assays were used for the detection of the formation of cleavage 
complex formation caused by interruption of DNA gyrase strand passage.  In the usual 
strand passage reactions of DNA gyrase, DNA cleavage only occurs transiently, and is 
subsequently rapidly resealed to ensure the integrity of the DNA substrate.  In the 
event that the strand passage, between the cleavage and resealing steps, is 
interrupted by external factors, DNA gyrase could be stalled, resulting in a DNA-DNA 
gyrase covalent complex and a permanent double-stranded DNA cut.  The DNA 
cleavage reaction is typically carried out by incubation of supercoiled pBR322 
together with 1 U of DNA gyrase and DNA relaxation assay buffer in a ͵Ͳ μL reaction 
in 37°C for 30 mins.  To terminate the reaction, 0.2 % SDS and 0.1 mg/ml of 
proteinase K were added and incubated at 37°C for a further 1 hr to denature and 
digest the DNA gyrase.  Equal volumes of 2xSTEB buffer and 
chloroform:isoamylalcohol (24:1) were then added to the samples, mixed thoroughly 
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using a vortex shaker, and centrifuged (15,700 x g, 1 min) briefly to separate the 
proteinaceous material from the DNA substrate.  The DNA substrate (upper aqueous 
phase) was then directly loaded onto a 1% (w/v)  agarose gel for electrophoresis 
analysis. 
 
2.8.2. PK/LDH ATPase assay 
The PK/LDH enzyme coupled ATPase assay was deployed for the analysis of the rate 
of ATP hydrolysis of GyrB over a time period of 30-60 mins.  The assay was prepared 
by mixing ~0.6 µM of enzyme with ATPase buffer, 20 mM NADH, 80 mM PEP and . 
The ATPase reaction was initiated by the addition of 2 mM final concentration of ATP.  
The changes in OD340 were monitored using SPECTRAmax GEMINI microplate reader 
(25°C temperature control) and the data was collected at 1min time intervals, with at 
least 20 continuous time intervals (20 mins).  As it was an enzyme coupled assay in 
the presence of excess of NADH and PEP, ADP was constantly converted to ATP 
during the reaction.  At a theoretically fixed substrate concentration, linear kinetics is 
expected during the reaction. 
 
  
Figure 2.3 Schematic diagram showing components of PK/LDH coupled 
enzyme ATPase assay.  
 
To ensure that the data collected is statistically significant, the coefficient of 
determination (R2) of the sets of data points collected from each experiment  were 
assessed to examined how well the data sets fitted the linear regression model.  Sets 
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of data with their R2 value below 0.98 are omitted to ensure accuracy of the rate 
recorded and the entire experiment was repeated until R2 value of above 0.98 is 
achieved.  As ATP is consumed, ADP is then regenerated by pyruvate kinase; through 
the enzyme coupled system, this would result in an equal molar conversion of NADH 
to NAD+.  As the maximum absorbance at 340 nm of NADH is not shared by NAD+, the 
reduction in OD at 340 nm over time can be used to directly calculate the ATP 
consumed using Beer-Lambert law: A = ε.l.c  
A = absorbance ε = extinction coefficient 
c = concentration 
 
With the extinction coefficient ȋε Ȍ of NADH being 6.22 mM-1.cm-1 and the path length 
(l) being 0.67 cm , concentration (c) of NADH or ATP decrease over time can be 
calculated using absorbance data (A) of NADH at OD430 using the Beer-Lambert law. 
2.8.3. S. aureus susceptibility drug test 
A broth microdilution procedure was used to determine the MIC of reagents against S. 
aureus ATCC 29213.  A 50 mL Mueller-Hinton broth inoculated with S. aureus was grown overnight at ͵ͷ°C whilst shaking was maintained.  ͷͲ μL of the overnight 
culture was then used to inoculate 25 mL of fresh Mueller-Hinton broth and the 
resulting inoculum was incubated at 35°C with shaking until OD600 ~0.4 was reached.  
The culture was then diluted to OD600 ~0.13 with fresh Mueller-Hinton broth and 
then further diluted 150x.  The S. aureus culture was then diluted 2x by mixing with final concentrations of ͸Ͷ, ͵ʹ, ͳ͸, ͺ, Ͷ, ʹ, ͳ, Ͳ.ͷ, Ͳ.ʹͷ μM of the desired drug and ͷ% 
(v/v) DMSO with the total volume being ʹͲͲ μL.  The drug containing S. aureus 
cultures were then incubated at 35°C for 18 hrs.  OD600 of the cultures were then 
recorded with the Gemini Spectramax microplate reader, with baseline absorbance 
subtracted against uninoculated cultures. 
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2.8.4. Thermal-shift assays ʹͷ μL reactions containing Ͳ.ͷ mg/mL of protein ȋSaGyrA/SaGyrB/EcGyrA/EcGyrBȌ, 
1x SYPRO orange dye, 1x thermal shift buffer (table 2.1) and KGlu at final 
concentrations of 0, 150, 300, 450, 600, 750 and 900 mM were heated from 20 to 95 
°C in 0.2°C steps using MJ research Opticon2 qPCR system.  Each temperature step 
was held for 12 s.  Fluorescent intensity was measured over time at 
excitation/emission wavelengths of 490/575nm.  
2.8.5. DNA densitometry 
After the DNA sample(s) is ran and separated in size on 1% agarose gel, it is left to 
stain in in TAE buffer containing ʹ μg/mL ethidium bromide for ͳͲ-20 mins.  The gel 
was visualised under an ultraviolet transilluminator and photographed using the 
Syngene Bio-imaging system.  Imagine taken was then analysed using GeneTools 
(Syngne) software package, were intensity of all DNA bands in each lane on the gel 
image were quantified. 
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2.9.1 Protein crystallography: protein crystallisation 
2.9.1.1 Crystallisation trials of EcB-NTD (EcB 43) in the presence of diospyrin 
and 7-methyjuglone (7MJ) and S. aureus GyrB-NTD (SaGyrB49) 
Crystallisation trials with a combination of EcB43 +/-ADPNP +/- diospyin +/- 7-
methyljuglone and S. aureus GyrB-NTD (SaGyrB49) were tested with in-house 
commercial crystallisation screens (table 2.9): JSCG-plus (Molecular Dimension), The 
PEGs suite (Qiagen) and Structure Screen (Molecular Dimension).  The vapour 
diffusion crystallisation screens were set up in a sitting drop format using 96-well 
MRD plates (Molecular Dimensions) with 50 μL of crystallisation well solutions.  The 
sitting drops were prepared by mixing 0.6 μL of 10 mg/ml of EcGyrBNTD with equal 
volumes of well solution. The crystallisation screens were then sealed and stored at 
20°C in a dark environment. 
 
Crystallisation trials JSCG-plus The PEGs suite Structure 
Screen 
EcB43 Yes Yes N/A 
EcB43 + 1.6 mM diospyrin Yes Yes N/A 
EcB43 + 0.5 mM 7MJ Yes Yes N/A 
EcBͶ͵ + Ͷ0 μM ADPNP + 
1.6 mM diospyrin 
Yes Yes Yes 
EcBͶ͵ + Ͷ0 μM ADPNP + 
0.5 mM 7MJ 
Yes Yes Yes 
Table 2.9 Crystallisation screening using commerical crystallisation 
screens with various different combinations of proteins and ligands. 
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2.9.1.2 Production of E. coli GyrBNTD-ADPNP crystals in the presence of 
K+/Na+/K+ and Na+ 
E. coli GyrBNTD-ADPNP crystals in various M+ were grown by mixing of the 
EcGyrBNTD containing solution (~10 mg/ml in TGED buffer (50 mM Tris. HCl pH 7.5, 
1 mM DTT, 1 mM EDTA, 10% (v/v)  Glycerol)) with equal volumes of well solution 
(typically 0.6 µl : 0.6 µl) at a range of refined crystallisation conditions (described in 
table 2.10) adapted  from conditions described in Jackson et al 218.  The drops were 
then prepared in a vapour diffusion, sitting format using 96-well MRD plates 
(Molecular Dimensions) with 50 μL of crystallisation well solution.  All crystallisation 
trials were performed in a dark, constant temperature room at 20°C.  Observable 
sizes of crystals typically appeared within 1 hr-1 day after the crystallisation trials 
were initiated.  Crystals of >0.8 µm3 in size were consistently produced.  Crystals 
were successfully obtained in both sitting drop and hanging drop crystallisation 
settings.  
 
M+ used Crystallisation conditions Cryprotectants 
No salt 100 mM Tris.HCl pH 8.0, 15-25% 
(v/v)  PEG3350, 2 mM MgCl2 
100 mM Tris.HCl pH 8.0, 15-25% (v/v)  
PEG3350, 10% (v/v)  Glycerol 
K+ 100 mM Tris.HCl pH 8.0, 15-25% 
(v/v)  PEG3350, 200 mM KCl, 2 
mM MgCl2 
100 mM Tris.HCl pH 8.0, 15-25% (v/v)  
PEG3350, 200 mM KCl, 10% (v/v)  
Glycerol 
Na+ 100 mM Tris.HCl pH 8.0, 15-25% 
(v/v)  PEG3350, 200 mM NaCl, 2 
mM MgCl2 
100 mM Tris.HCl pH 8.0, 15-25% (v/v)  
PEG3350, 200 mM NaCl, 10% (v/v)  
Glycerol 
K+/Na+ 100 mM Tris.HCl pH 8.0, 15-25% 
(v/v)  PEG3350, 100 mM KCl, 100 
mM NaCl, 2 mM MgCl2 
100 mM Tris.HCl pH 8.0, 15-25% (v/v)  
PEG3350, 100 mM KCl, 100 mM NaCl, 
10% (v/v)  Glycerol 
 
Table 2.10 Crystallisation conditions of EcGyrBNTD-ADPNP co-crystals 
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2.9.2 Protein Crystallography: Data collection and structure 
determination 
2.9.2.1 X-ray data collection 
Protein crystals were mounted using CryoLoops (Hampton Research) with 
cryprotection by soaking the crystals in cryoprotectants (described in table 2.10) for 
5-10 s.  X-ray data were collected at a synchrotron radiation facility (Diamond Light 
Source, Oxford).  Cryoprotected protein crystals were flashed-cooled by submerging 
them into liquid nitrogen (<-196°C).  The protein crystals were stored in liquid 
nitrogen in a vacuum flask for transport to the synchrotron facility.  Remotely 
controlled robotic arms were then used to mount the crystals on the goniostat.  The 
temperature of the crystal containing loop was maintained at 100 K with a nitrogen 
cryosteam.  The wavelengths of the X-ray source used for diffraction for each of the 
crystals examined are listed in table 2.10).  Grid diffraction scans were performed to 
identify highly diffracting regions of the crystals.  Once a strongly diffracting portion 
of the crystal was located, diffraction images were taken at 0° and 90° to assess the 
estimate resolution of the diffraction.  These images were also used for indexing 
purposes in order to identify the crystal symmetry and cell parameters using 
MOSFILM219.  The optimal starting angle and the total number of degrees required for 
completion of the dataset collection were then calculated. 
2.9.2.1 Processing of diffraction data 
Diffraction data collected was processed by MOSFILM 219 and SCALA 220.    Molecular 
replacement was performed using PHASER221.  Refmac5 software was used to 
perform auto-refinement of the model.  The auto-refined model was then manually 
refined using Coot 222.  The Phenix software package was used for the modelling of the 
water molecules 223. 
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Chapter 3 Origin of Staphylococcus aureus DNA gyrase 
supercoiling activity dependency on potassium glutamate 
(KGlu) 
3.1 Introduction 
In a previous in vitro enzyme study 224, S. aureus DNA gyrase was found to behave 
differently from other gyrases studied.  Initially, Blanche et al. established that the 
ability of S. aureus gyrase to negatively supercoil DNA substrate was strictly 
dependent on high concentrations of KGlu (700 mM), unlike the well-studied E. coli 
gyrase 224.  In addition, this stimulation is also shown to be salt specific as Blanche et 
al. were unable to activate Sa gyrase supercoiling by substituting KGlu with 
tris(hydroxymethyl aminomethane) or sodium glutamate.  Furthermore, substitution 
of KGlu with various amino acids (e.g., Ala, Arg, Gly, Lys, Pro, Ser) and metabolites of 
similar properties (4-aminobutyrate, glutarate, succinate, trans-glutaconate, γ-
glutamyl-glutamate) were unable to activate supercoiling.  Also, KCl of up to 800 mM 
was unable to support Sa gyrase.  Surprisingly, despite the failure to activate Sa 
gyrase with various different supplements, the potassium salts of D-Glu, Asp, 2-
methylglutamate (fig 3.1) were all able to stimulate Sa gyrase supercoiling. 
L-Asp
D-Glu
L-Glu
2-methylglutamate
 
Figure 3.1 Glutamate-compatible anion: L-Glu, L-Asp, D-Glu, 2-
methylglutamate.  
Overall, the study suggested K+ to be strictly essential for the supercoiling activation 
of Sa gyrase.  The anion requirement for supercoiling stimulation was possibly less 
specific than the cation salt component, as anions with similar physiochemical 
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properties to glutamate were also able to stimulate Sa gyrase.  This intriguing 
phenomenon subsequently led Hiasa et al 199 to attempt to elucidate the enzymatic 
origin of the KGlu dependency of Sa gyrase and also to examine the reason behind the 
differential behaviour between S. aureus and E. coli gyrase. 
Again, Hiasa et al 199discovered Sa DNA gyrase to only display DNA supercoiling 
activity in the presence of high concentrations of KGlu (400-800 mM), while the E. coli 
counterpart showed optimal supercoiling activity at a much lower KGlu concentration 
(100-200 mM) and was mildly inhibited at high KGlu concentration (800 mM).  
Interestingly, both the DNA relaxation and decatenation activities of S. aureus gyrase 
were found to require little KGlu, which suggested that this KGlu dependency 
originates from a mechanistic aspect of the enzyme related to DNA supercoiling.  
Further evidence suggested the salt-dependent supercoiling activity is the result of 
the salt-dependent GyrA-CTD-DNA wrapping in S. aureus gyrase 199. 
Current evidence suggests that the high KGlu requirement for Sa gyrase supercoiling 
activity is distinct from any gyrases studied so far.  However, apart from one 
experiment suggesting the CTD of Sa GyrA to be responsible for the KGlu-dependency, 
evidence for its origin is limited.  In particular, we currently have no understanding of 
the salt-specificity requirements observed in Sa gyrase supercoiling stimulation. 
The biological implications of this enzymatic effect in vivo are currently unknown.  It 
is interesting to note that Staphylococcus is halotolerant and well known for its ability 
to grow at a wide range of salt 225.  This implies that Staphylococcus organisms could 
adjust their cytoplasm to a wide range of ionic strengths to counteract their 
surrounding environment to relieve tension on the cell envelope generated by the 
osmotic pressure.  In vivo, gyrase will be expected to subject to fluctuations in salt 
concentration intracellularly, affecting its activity and thereby influencing the 
supercoiling state of the bacterial chromosome.  Gyrase could potentially act as an 
osmotic sensor that regulates the topology of the bacterial chromosome and could 
trigger gene expression and repression as a response to osmotic changes.  As the 
potency of DNA gyrase inhibitors such as fluoroquinolones are influenced by the in 
vivo activity of gyrase, the osmotic pressure of the habitat of S. aureus (e.g., nose 
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versus skin) can potentially affect the frequencies of mutant emergence against these 
antibiotics. 
In relation to the potential biological and therapeutic significance, it is therefore 
important to gain further understanding the origin of salt effect on Sa gyrase.  In this 
study, it was decided to deploy a series of in-depth experiments to probe the origin of 
the salt dependency and specificity demonstrated in Sa gyrase, hopefully discovering 
the mechanistic difference between the two enzymes. 
3.2 Sa gyrase supercoiling is dependent on high concentration of 
KGlu 
To confirm and extend the findings of Hiasa et al 199, we conducted a range of 
electrophoresis assays to assess Sa gyrase supercoiling activity in a broader range of 
KGlu concentration with finer intervals.  We chose to perform the experiments in 7 
different concentrations of KGlu in the range of 0-900 mM at 150 mM concentration 
intervals.  As a direct comparison, we have also tested E. coli gyrase in the same sets 
of reaction conditions.  
As shown in figure 3.2, a typical supercoiling gel assay involves the incubation of 1 U 
of gyrase (A and B subunits) with 0.5 µg of relaxed pBR322 plasmid as DNA substrate 
at 37°C, as describe in chapter 2.8.1.1.  The reaction was then terminated after 30 
mins by thorough mixing with chloroform:isoamyl alcohol to deactivate gyrase 
activity.  The treated mixture was then subjected to gel electrophoresis to separate 
the supercoiled and relaxed plasmid DNA.  As supercoiled DNA topoisomers tend to 
have a more compact conformation, they travel faster and further than the relaxed 
topoisomers with the more open conformations. 
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Figure 3.2 S. aureus gyrase DNA supercoiling at a range of KGlu 
concentrations.  0.5 ng of relaxed pBR322 was supercoiled with 1U S. aureus 
gyrase in various concentrations (0 – 900 mM) of KGlu (lane 2-8) in conditions 
described in chapter 2.8.1.1.  As relaxed DNA become supercoiled, it becomes 
more compact and thus travels further than its relaxed topoisomers.  Note: as 
DNA becomes more supercoiled they are less easily separated using gel 
electrophoresis.  Therefore supercoiled DNA appeared as a single band on the gel 
even if in fact a range of supercoiled topoisomers is present.  Figure lables: Rel 
control (lane 1) – no enzyme is added.  Sc control (lane 9) – 1 U of S. aureus 
added at 500 mM KGlu. 
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Figure 3.3 E. coli gyrase DNA supercoiling at a range of KGlu 
concentrations.  0.5 ng of relaxed pBR322 was supercoiled using 1 U S. aureus 
gyrase in various concentrations (0 – 900 mM) of KGlu (lane 1-7) in conditions 
described in chapter 2.8.1.1.  The noticeable smearing in lane 6-7 is caused by the 
high salt concentration in the loaded DNA sample, thereby affecting the 
migration speed of the DNA sample.  Figure labels: –enz (lane 8) - no enzyme was 
added; Rel pBR322 – relaxed pBR322 plasmid; Sc pBR322 – supercoiled pBR322 
plasmid. 
As expected, Sa gyrase is unable to supercoil DNA in the absence of KGlu (fig. 3.2, lane 
1).  In the presence of moderate concentrations of KGlu (150-450 mM) (fig. 3.2, lane 
3-5) we were able to observe a clear increase in supercoiling activity with Sa gyrase.  
While little apparent increase in activity was observed between 600-900 mM KGlu 
(fig. 3.2, lane 6-9), it is difficult to quantify their differences in activity as most DNA 
substrates in the reactions are already saturated with negative supercoils.  In contrast, 
Ec gyrase was able to demonstrate noticeable supercoiling activity in the absence of 
KGlu (figure 3.3, lane 1), while at 150 mM KGlu full supercoiling activity was observed 
(figure 3.3, lane 2).  Therefore although Ec gyrase does not require KGlu to supercoil 
DNA, inclusion of low concentrations of KGlu dramatically enhanced its activity. 
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3.3 Quantitative assessment of Sa gyrase supercoiling activity 
versus KGlu 
In order to produce a quantitative understanding of Sa gyrase supercoiling activity 
versus KGlu concentration using the gel assay (a semi-quantitative method), time-
trial supercoiling experiments with multiple incubation end points was deployed.  
Supercoiling reactions were setup as described in chapter 2.8.1.1.  One-hour 
incubations with 5 minute time-points were run in the same range of KGlu and KCl 
concentration (0, 150, 300, 450, 600, 750, 900 mM) as used in previous experiments.  
The individual Sc reactions were terminated at 5 min intervals and the assay samples 
were subsequently run on 1% (w/v) agarose gels to separate the supercoiled and 
relaxed DNA substrates.  The intensity of the Sc band for each time point was then 
quantified using DNA densitometry (Syngene GeneTools).  Background signal at 0 
time point is used as a reference to reset the baseline for the signals measure at the 
rest of the time points.  The signal reading with the baseline subtracted, the relative 
intensity of the supercoiled band, was then used as a quantitative measurement of the 
supercoiling activity.  The values generated were then plotted against reaction times 
and the initial rates of reactions from the plot were then included in a secondary plot 
against KGlu concentration.  As a result, further information about the quantitative 
differences between the supercoiling activities of Sa gyrase in different KGlu 
concentrations can then be deduced. 
As shown in fig. 3.4 & 3.6, a gradual increase in supercoiling activity was observed as 
KGlu concentration was increased from 150 mM to 600 mM.  Supercoiling stimulation 
then stabilised at ~750-900 mM KGlu, with no apparent increase in activity observed.  
Again the results confirmed that Sa gyrase is inactive in supercoiling in the absence of 
KGlu and requires high KGlu concentrations (~600 mM) to reach its optimal activity. 
In a parallel experiment performed in the presence of KCl, Sa gyrase supercoiling 
activity was limited in almost the entire range of concentrations tested (figure 3.5 & 
3.7).  Only at 150 mM and 300 mM KCl the enzyme is able to show minimal activity.  It 
is also interesting to note that at 150 mM KCl, small amount of supercoiled DNA was 
observed at the 5th minute of the incubation; however the quantity of the supercoiled 
DNA did not increase further as time progressed.  This could suggest that Sa gyrase 
Chapter 3   S. aureus DNA gyrase KGlu dependency 
 
77 
 
achieve high level of supercoiling and that the supercoiling set point* was 
significantly reduce by the replacement of Glu- by Cl-.  As DNA wrapping is known as 
an important mechanism that determines supercoiling setpoint* of the gyrase 226, Glu-
/Cl- replacement could have reduced the ability for gyrase to wrap DNA.  
*supercoiling set point – DNA gyrase supercoiling is gradually slowed and eventually stopped 
by the torsion created in the highly-supercoiled DNA during supercoiling.  Supercoiling set point is the 
highest supercoiling state achievable by gyrase in the specific condition, during which the rate of DNA 
supercoiling and ATP-independent DNA relaxation are at equilibrium.  The higher the supercoiling set 
point, the more negative supercoils can be introduced into the same DNA substrate.  Recent studies 226 
found that the supercoiling set point of gyrase can be changed by modification of the DNA wrapping 
CTD of the GyrA subunit, hinting at a relationship between DNA wrapping process and the limit of 
supercoil achievable by gyrase. 
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Figure 3.4 Gel image of time-trial of S. aureus DNA gyrase supercoiling assays 
performed in 0, 150, 300, 450, 600, 750 and 900 mM KGlu.  0.5 ng of DNA is 
incubated with 1 U of S. aureus DNA gyrase in the conditions described in chapter 2.8.1.1.  
Reactions prepared and performed simultaneously in a 96 well plate.  Reactions are 
terminated at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 mins by addition of terminating 
solution. Note: discrepancy of the results exist in the reaction with 750 mM at 10 mins 
could be been caused by the lack of mixed of the enzyme and the DNA solutions. 
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Figure 3.5 Gel image of time-trial of S. aureus DNA gyrase supercoiling assay performed 
in 0, 150, 300, 450, 600, 750 and 900 mM of KGlu.  0.5 ng of DNA is incubated with 1 U of S. 
aureus DNA gyrase in the conditions described in chapter 2.8.1.1.  Reactions prepared and 
performed simultaneously in a 96 well plate.  Reactions are terminated at 5, 10, 15, 20, 25, 30, 
35, 40, 45, 50, 55, 60 mins by addition of terminating solution. Note: Discrepancy in the 55th 
mins of the experiments with 450 mM, 600 mM, 750 mM and 900 mM KCl could havecaused by 
mishandling of the multi-channel pipette resulting in the transfer of salt across a single 
colum/row within the well. 
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Figure 3.6 Relative quantity of supercoiled DNA substrate between 
reactions measured by DNA densitometry against the reaction time in 
various KGlu concentrations.  Supercoiled and relaxed DNA species are 
separated by gel electrophoresis and visualised by ethidium bromide staining 
(figure 3.5). The quantities of DNA species within each reaction are quantified by 
DNA densitometry (describe in chapter 2.8.5).  The relative intensity of the 
supercoiled DNA band was calculated by dividing the intensity of the fully 
supercoiled DNA band with the intensity of both relaxed and supercoiling DNA 
bands presence on the same gel column/ in the same supercoiling reaction. 
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Figure 3.7 Relative quantity of supercoiled DNA substrate between 
reactions measured by DNA densitometry against the reaction time in 
various KCl concentrations.  Supercoiled and relaxed DNA species are 
separated by gel electrophoresis and visualised by ethidium bromide staining 
(figure 3.5). The quantities of DNA species within each reaction are quantified by 
DNA densitometry (describe in chapter 2.8.5).  The relative intensity of the 
supercoiled DNA band was calculated by dividing the intensity of the fully 
supercoiled DNA band with the intensity of both relaxed and supercoiling DNA 
bands presence on the same gel column/ in the same supercoiling reaction. 
 
3.4 Sa gyrase and Ec gyrase folding stability versus KGlu 
As experiments have confirmed that Sa gyrase activity is dependent on high 
concentrations of KGlu, it is crucial to confirm that the salt-dependent supercoiling 
phenomenon is not the results of salt-dependent protein folding.  Traditional means 
of protein folding stability assessments such as circular dichroism and FTIR, however, 
are inoperable under the concentration of KGlu of interest.  To circumvent the 
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problem, we have decided to use a thermal-shift fluorophore assay to detect protein 
melting temperature, which involves the use of a environment-sensitive fluorescent 
dye (SYPRO-orange) that fluoresces strongly in the region of low dielectric constant 
such as the hydrophobic patches exposed in unfolded proteins (fig. 3.8) .  In this 
experiment, melting temperatures (Tm) of S. aureus GyrA and GyrB, and E. coli GyrA 
and GyrB were tested in the presence of 0-900 mM KGlu to examine the influence of 
KGlu concentration on the folding stabilities of these proteins.  The protein samples 
were subjected to a temperature gradient over time and the fluorescence intensity of 
the dye was monitored. 
 
Figure 3.8 Thermal-shift fluorophore assay: general melting profile of protein 
depicted as the changes in fluorescence signal versus temperature of the 
reaction.  Reproduced from www.bio.anl.gov 227.  
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Figure 3.9 Thermal-shift assay melting profile of SaGyrB.  Note that high 
fluorescence observed between 20-30°C was artefact as a result of high non-
specific binding at low temperature. 
 
Figure 3.10 Thermal-shift assay melting profile of of EcGyrB.  
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Figure 3.11 Thermal-shift assay melting profile of melting profile of 
SaGyrA.  
 
 
Figure 3.12 Thermal-shift assay melting profile of melting profile of EcGyrA.  
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In general, the increase of KGlu concentration raised the folding Tm of the proteins 
assayed (fig. 3.9, 3.10, 3.11, 3.12).  No dramatic changes in melting temperature were 
observed, indicating that the concentration of KGlu does not have great influence on 
the folding of the proteins tested.  The results overall suggested that salt dependency 
of Sa gyrase supercoiling is not related to the folding stability of protein in different 
KGlu concentration. 
 
It is important to note that the melting temperature of SaGyrA is potentially incorrect, 
as the results suggested that the protein is melting below the temperature of 
incubation (37°C) for the supercoiling enzyme assay.  This outlying result is possibly 
caused by the low signal to background ratio, contributed by the lack of hydrophobic 
patches of SaGyrA for dye binding.   
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3.5 Relaxation by S. aureus gyrase is not dependent on high KGlu 
concentration 
Previously Sa gyrase was shown to depend on high concentrations of KGlu to 
supercoil DNA optimally.  Relaxation activity of the gyrase utilises a different T-
segment capturing mechanism and does not require the closure of the N-gate (as 
GyrB ∆NTD alone can support strand passage), ATP hydrolysis and GyrA-CTD-DNA 
wrapping.  Therefore we decided to test relaxation activity of Sa gyrase in the 
presence of 0-900 mM KGlu for a direct comparison with the supercoiling results (fig. 
3.13). 
 
Figure 3.13. Relaxation activity of wt Sa gyrase in different KGlu concentrations 
showing the optimal relaxation activity between 150-450 mM KGlu.   
Figure labels: 
Sc/Rel Markers – Relaxed and supercoiled DNA markers 
Lane 3-9 - 8 U of Sa Gyrase relaxation reaction with 0.5 ng of supcoiled pBR322 at various KGlu 
concentrations for 60 mins. 
Lane 10 – Positive control (0.5 ng Sc pBR322 / 8 U of Sa Gyrase / 500 mM KGlu) 
Lane 11-13 – Negative control with no Sa GyrB (-B), no Sa GyrA (-A) and no Sa GyrA and GyrB (-
A-B). 
As shown in 3.14, Sa gyrase was found to relax optimally between 150-450 mM KGlu.  
Relaxation activity was minimal from >600 mM KGlu onwards.  This result confirmed 
that Sa gyrase only required low concentrations of KGlu (150-300 mM) to achieve 
optimal relaxation while high concentrations of KGlu (>600 mM) inhibit relaxation 
completely.   
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3.6 Decatenation of S. aureus gyrase is not dependent on high KGlu 
In addition, we decided to test KGlu dependency of decatenation in Sa gyrase, a strand 
passage process that involves unlinking catenated DNA circles.  As GyrA-CTD is not 
required for the decatenation reaction, we also decided to use the SaGyrA ∆CTD 
mutant gyrase to perform the experiment to eliminate the influence of the GyrA-CTD 
on the reaction.   
 
Figure 3.14 Decatenation assay of SaGyrA ∆CTD reconstituted gyrase in various 
concentrations of KGlu.  Decatenation assays were performed according to chapter 
2.8.1.3, where any released DNA minicircles from the kinetoplast DNA (kDNA) are 
detected by gel-electrophoresis.  Control reactions were run in lane 1, 9 and 10 where no 
enzyme (-A-B), A subunit only (-B) and B subunit only (-A) were included in the 
reactions respectively.  A series of KGlu concentrations were used from lane 2 to lane 8 
to assess decatenation activity of SaGyrA ∆CTD gyrase versus [KGlu].  Between 0-300 
mM KGlu (lane 2-4) it was able to decatenate kDNA.  It is apparent that SaGyrA ∆CTD 
gyrase decatenates optimally in the 0-150 mM KGlu range.  In the 300 mM KGlu reaction, 
gyrase showing intermediate activity demonstrated by the presence of multimer 
circular DNA indicating incomplete decatenation. 
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The detail methods of the decatenation reaction performed is describe in chapter 
2.8.1.3.  As shown in figure 3.14, Sa gyrase displayed decatenation activity and 
released mini DNA circles from the ketoplast DNA substrate between 0-300 mM KGlu 
in the presence of ATP (Figure 3.14 lane 2-4).  At and above 450 mM negligible 
activity was observed.  This KGlu concentration versus activity profile is fairly similar 
to the relaxation KGlu optimal profile (150-300 mM).  It is not surprising given that 
the current model suggested that relaxation and decatenation reaction cycle of DNA 
gyrase both has similar mechanisms that only involves the passage of dsDNA within a 
DNA juxtaposition and no DNA wrapping .  However, one mechanistic feature that 
decatenation shared with supercoiling yet different from relaxation is the 
requirement of ATP, as ATP hydrolysis greatly stimulates decatenation and is 
required for supercoiling but not relaxation.  The ability for Sa gyrase to display high 
level of decatenation activity at low KGlu concentration therefore suggested that 
processes such as ATP binding, hydrolysis, and the subsequent strand passage 
induced are just as functional at low KGlu as well as at high KGlu. 
This provided indirect evidence that ATP hydrolysis, which is crucial for both 
decatenation and supercoiling activity of gyrase, is not the origin of KGlu dependency. 
Together, the lack of KGlu dependency demonstrated in Sa gyrase relaxation and 
decatenation leads to the conclusion that G-segment binding to the NTD of GyrA, 
which is required for any gyrase-strand passage including relaxation and supercoiling, 
is present across a wide range of KGlu (0-900 mM).  While in most cases high salt 
concentration prevents DNA-protein binding, this combined results rules out the 
possibility of KGlu interfering with G-segment DNA binding and contributing to salt 
dependency. 
Moreover, crucial mechanistic processes required for any gyrase-strand passage 
events (e.g., relaxation, decatenation and supercoiling), such as G-segment DNA 
binding, DNA cleavage and resealing, DNA gate and C-gate opening, are shown to be 
functional at across the whole range of KGlu tested (0-900 mM).  Therefore the 
possibility of these processes being the cause of KGlu dependency is excluded.  As 
strand passage, the primary function of Sa gyrase is perfectly functional at low KGlu 
as demonstrated in decatenation assay, it also confirms that Sa gyrase is able to adopt 
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a functional fold in a wide range of KGlu concentration, dismissing the notion that salt 
dependent supercoiling are the results of salt dependent folding. 
 
3.7 Sa gyrase supercoiling stimulation is specific to KGlu 
In the preceding experiments it has been established that Sa gyrase supercoiling is 
stimulated by high concentration of KGlu, achieving optimal activity in the 
concentration range of 600-900 mM.  Blanche et al 224 describe that this stimulation is 
specific to limited types of salt, and that replacing either the cation or anion 
component of the salt can completely abrogate the stimulation.  As an example, both 
the replacement of K+ with Na+ (NaGlu), and Glu- with Cl- (KCl) results in the complete 
loss of supercoiling stimulation.  However, as the data and methodology of the 
experiments were not published, we decided to carry out our own detailed 
examination on the claims made.  Supercoiling activity of Sa gyrase was subsequently 
tested in the presence of 150-900 mM NaGlu and KCl together with KGlu as a positive 
control. 
As shown in Fig 3.16, Sa gyrase showed optimal supercoiling activity between 600-
900 mM KGlu as expected.  When K+ was replaced with Na+ (NaGlu), supercoiling 
activity was almost completely abolished across the whole range of concentration 
(figure 3.15).  At a closer examination, between 300-750 mM NaGlu weak 
supercoiling activity could be observed.  More intriguingly, linear DNA was observed 
between 150-700 mM, with 450 mM NaGlu generating the most cleaved DNA.  
Similarly when Glu- was replaced with Cl- (KCl), Sa gyrase supercoiling was defective 
across the whole range of concentration tested.  At 150 mM KCl, weak supercoiling 
activity was observable whilst large amount of cleaved DNA was generated at the 
same time.  
Although Sa gyrase requires a high concentration of KGlu to stimulate its DNA 
supercoiling activity, the fact that neither NaGlu nor KCl was able to stimulate Sa 
gyrase suggested that ionic strength of the solution is not the only factor that 
underpins the salt dependent stimulation phenomenon.  This therefore suggested 
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that K+ and Glu- have the unique properties to provide an environment crucial for the 
supercoiling reaction mechanism of Sa gyrase.  This can be elicited in two ways: K+ 
and/or Glu- could influence Sa gyrase in a micro sense, which involve specific binding 
of the ions to a specific site(s) within the Sa gyrase ; in a macro sense K+ and Glu- 
could be involved in non-specific binding towards Sa gyrase and/or the DNA 
substrate.  Some supercoiling activities were observed when Sa gyrase was 
supplemented with 450-600 mM NaGlu or 150 mM KCl (figure 3.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3   S. aureus DNA gyrase KGlu dependency 
 
91 
 
 
  
Fig
u
re 3
.1
5
 S. a
u
reu
s g
yra
se su
p
ercoilin
g
 a
ctivity versu
s 0
-
9
0
0
 m
M
 K
G
lu
 (top
-left), N
a
G
lu
 (b
ottom
-left), K
Cl (top
-rig
h
t).  
Standard supercoiling reaction (Chapter 2.8.2)  w
ere perform
ed 
w
ith S. aureus gyrase under the supplem
entation of varies salts 
containing alkali m
etal cations.  In lane 8 and 9 of each series of 
reactions, –enz represents –ve control w
ith no gyrase added, 
w
hilst 500 m
M
 K
G
lu w
as used for the +ve control reaction  in the 
presence of 1U
 of S. aureus gyrase.  In lane 1-7, 1U
 of Sa gyrase 
w
as supplem
ented w
ith 0-900 m
M
 of K
G
lu (top-left), N
aG
lu 
(bottom
-left) and K
Cl (top-right).  A
s expected Sa gyrase show
ed 
a stim
ulated supercoiling activity in the presence of K
G
lu 
betw
een 450 m
M
 and 900 m
M
.  N
aG
lu and K
Cl w
ere unable to 
stim
ulate supercoiling activity of Sa gyrase.  R
ed arrow
s 
indicated the presence of linear D
N
A
 produced from
 dsD
N
A
 
cleavage. 
 
Chapter 3   S. aureus DNA gyrase KGlu dependency 
 
92 
 
3.8 Ec gyrase supercoiling stimulation is not salt-specific 
Following the evidence that Sa gyrase supercoiling is dependent on KGlu specifically 
and that Ec gyrase is stimulated by low concentration of KGlu, we investigated if E. 
coli gyrase also displays salt specificity similar to S. aureus gyrase.  To do that, we 
subjected Ec gyrase to conditions with different concentrations (0-900 mM) of NaGlu 
and KCl, with KGlu used as a control.   
As shown in fig. 3.16, in the presence of >150 mM KGlu, Ec gyrase supercoiling is 
strongly stimulated as expected.  Surprisingly, NaGlu (150-300 mM) and KCl (150 mM) 
were also able to support Ec gyrase supercoiling fully.  The overall results confirmed 
that both the dependency of high concentration of KGlu and K+/Glu+ specificity are 
absent in E. coli gyrase and is unique to S. aureus gyrase.   
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Figure 3.16.  E. coli gyrase supercoiling activity versus 0-900 mM KGlu (top), 
NaGlu (middle), KCl (bottom).  0.5 ng of relaxed pBR322 is reacted with 1 U of E. coli 
gyrase for 30mins in the conditions describe in chapter 2.8.1.1.  Figure labels: –enz: no 
enzyme control. 
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3.9 Origin of salt dependency – mutant studies 1: Sa GyrA C-terminal 
tail deletion (∆822-887) 
The evidence so far suggested that supercoiling but not relaxation is dependent on 
KGlu, clearly indicating that KGlu plays an important role in the mechanism that sets 
apart supercoiling from the relaxation reaction cycle.  It is understood that the 
majority of the strand-passage mechanism is identical between the supercoiling and 
relaxation reactions.  The two main features in gyrase distinguish a supercoiling 
reaction from a relaxation reaction are: 
1) The ability of the GyrA-C-terminal domains to wrap DNA. 
2) The ability of the GyrB N-terminal domain to utilise energy from hydrolysed 
ATP to compensate for the energy uphill generated from DNA torsional strain 
during DNA supercoiling. 
Hiasa et al. believed that the CTD of Sa GyrA is the origin of salt dependency, as their 
experimental data suggest a possible salt-dependent difference in the DNA wrapping 
between Sa and Ec gyrase 199. 
To expand on that hypothesis we undertook a bioinformatic analysis to explore the 
differences between the S. aureus and E. coli GyrA C-terminal domains.  The protein 
sequences of S. aureus GyrA, GyrB, ParC, ParE were aligned against the sequences of 
gyrases from 9 other bacteria of diverse phyla (Brucella melitensis, Escherichia coli, 
Klebsiella pneumoniae, Helicobacter Pylori, Bacillus subtilis, Streptococcus pneumonia, 
Clostridium difficile, Corynebacterium diptheriae, Mycobacterium tuberculosis) using a 
primary protein sequence alignment program (Invitrogen AlignX).    
Based on the alignment data (fig. 3.18), one of the most striking differences between 
the CTD of S. aureus GyrA and E. coli GyrA is the addition of 38 amino acids on the C-
terminal end of SaGyrA.  Amino acid content analysis found that this addition was 
largely made up of acidic residues (42%).  A BLAST analysis found the addition to be 
present only in Staphylococcus organisms.  In addition, due to the acidic nature of the 
addition, protein folding stability prediction server FoldX predicted it to be largely 
unfolded and hydrated. 
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Figure 3.18 Primary amino acids sequence alignments of GyrA from B. melitensis, E. coli, 
K. Pneumonia, H. Pylori, B. subtilis, S. pneumonia, C. difficile, C. diptheriae, M. 
tuberculosis and S. aureus GyrA C-terminus using AlignX®.  
Based on this analysis, the highly negatively charged C-terminal peptide possessed by 
SaGyrA has the potential to interfere with DNA-protein binding and possibly 
contributes to salt dependency by affecting DNA wrapping of the GyrA-CTD. 
Therefore to investigate the effect of the GyrA C-terminal addition on the salt 
dependency of the Sa gyrase, a SaGyrA mutant with the acidic C-terminal tail 
truncated ∆822-887 (SaGyrA ∆Cterm-tail) was produced for a comparison study with 
the wild-type.  The KGlu dependency of SaGyrA ∆Cterm-tail reconstituted gyrase was 
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subsequently investigated.  
 
Figure 3.19. Supercoiling activity of SaGyrA ∆Cterm-tail reconstituted gyrase 
(0.5U and 5U) in the presence of 0, 150, 300, 450, 600, 750, 900 mM KGlu .  0.5 ng 
of relaxed pBR322 was reacted with the reconstituted mutant gyrase for 30mins at 0-
900 mM KGlu (5U gyrase: lane 3-9, 0.5 gyrase, lane 13-19).  Figure labels: Rel/Sc 
Markers (Lane 1, 2, 11 & 12): relaxed and supercoiled DNA markers; –enz (lane 10 & 
20): no enzyme control. 
 
As shown in figure 3.19 0.5U and 5 U of SaGyrA ∆Cterm-tail reconstituted gyrase was 
titrated against 0-900 mM KGlu.  It is clear that KGlu dependency is still present as the 
mutant was unable to display supercoiling activity in the absence of KGlu while 
showing almost full supercoiling activity ~750-900 mM.  With intermediate activity 
between 150-400 mM, the mutant showed the same trend of KGlu stimulation as the 
wild-type enzyme (fig. 3.20). 
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Figure 3.20 S. aureus gyrase DNA supercoiling at a range of KGlu concentrations.  
0.5 ng of relaxed pBR322 was supercoiled by 1 U S. aureus gyrase in various 
concentrations (0 – 900 mM) of KGlu (lane 2-8) in condition described in chapter 2.8.1.1.  
As relaxed DNA become supercoiled, it becomes more compact and thus travels further 
than its relaxed topoisomers.  Note: as DNA becomes more supersoiled they become less 
separable using gel electrophoresis.  Therefore supercoiled DNA appeared as a single 
band on the gel even in fact a range of supercoiled topoisomers is present.  Figure labels: 
Rel control – no enzyme is added; Sc control – 1 U of S. aureus gyrase added at 500 mM 
KGlu. 
 
This result suggests that the acidic C-terminal addition was not responsible for the 
KGlu dependency of Sa gyrase supercoiling.  Assuming that salt dependency is solely 
originated from GyrA-CTD as Hiasa et al has suggested 199, the salt dependency would 
have to be contributed from the differences in the composition of the core of the 
GyrA-CTD.   
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3.10 Origin of salt dependency – mutant studies 2: SaNTD-EcCTD 
GyrA domain swap mutant (SaANTD (1-489)- EcACTD(523-875)) 
To confirm that salt dependency of Sa gyrase supercoiling is indeed solely 
contributed by the CTD of GyrA, a SaNTD-EcCTD GyrA domain swap protein was 
made to replace the CTD of Sa GyrA completely with its less salt-dependent E. coli 
counterpart (GyrA).  The reconstituted mutant gyrase was tested against various 
KGlu concentrations to verify its KGlu dependency.  
 
Figure 3.21. Supercoiling activity of SaNTD-EcCTD GyrA + Sa GyrB reconstituted 
Gyrase versus various KGlu concentrations (0 – 900 mM).  0.5 ng of DNA is 
supercoiled by 1 U of SaNTD-EcCTD GyrA + Sa GyrB reconstitute gyrase in the 
conditions described in chapter 2.8.1.1 in addition to the presence of 0, 150, 300, 450, 
600, 750, 900 mM for 30 mins at 37°C.  In the absence of KGlu the reconstituted 
mutant gyrase was unable to display supercoiling activity.  The mutant gyrase 
supercoiling activity increases with the increase of KGlu concentration between 150-
450 mM.  It reaches maximal supercoiling activity between 450 mM and 600 mM, and 
diminished at 750-900 mM KGlu.   
As shown in fig. 3.21, no activity was observed in the absence of KGlu.  Surprisingly 
the mutant had optimal supercoiling activity at 450-600 mM KGlu and the 
supercoiling activity of the enzyme at 750-900 mM KGlu concentrations were 
reduced in comparison to wt Sa Gyrase.  In comparison with wt Sa gyrase (fig. 3.20), 
the domain swap mutant gyrase operates optimally in ~300 mM less KGlu.  
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This apparent shift in salt optimal concentration is caused by the swapping of 
SaGyrA-CTD with EcGyrA-CTD and therefore GyrA-CTD must partially contribute to 
KGlu dependency in Sa gyrase.  As a crystal structure of SaGyrA-CTD is not available, 
we have generated a structural model via the Swiss-Model protein structure 
prediction server based on the existing E. coli GyrA-CTD structure (PDB:1ZI0).  The 
model structure predicted no significant structural changes in the no. of blades and 
integrity of the the six-blade cylinder structure in Sa GyrA-CTD in comparison with Ec 
GyrA-CTD.  However a comparison of surface electrostatic map between the Sa and Ec 
gyrase CTD (fig 3.22) showed that SaGyrA-CTD is much less positively charged than 
EcGyrA-CTD, and this includes the DNA-wrapping surfaces. 
 
Figure 3.22 Surface electrostatic potentials of C-terminal domain (CTD) of 
E. coli and S. aureus (swiss model) GyrA subunit generated in Molsoft ICM-
Pro.   Both the E. coli and S. aureus GyrA-CTD have cyrindrical appearance, with 
the its DNA-wrapping outer curved-surface filled with positively charge amino 
acids.  S. aureus GyrA-CTD appeared to have a less electro-negative DNA-
wrapping surface than its E. coli counterpart.  Scale bars = 10 Å. 
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Therefore, one possible explanation of the reduced salt dependency observed in the 
domain swap mutant is that Sa GyrA-CTD has weaker DNA wrapping ability and that 
KGlu supplementation was needed to support sufficient wrapping to sustain the 
supercoiling reaction.  Although it is difficult to reason how increasing KGlu 
concentration could benefit DNA wrapping, previous studies228 suggested how KGlu 
can stimulate activity of other DNA binding enzymes.  It is speculated that while 
chloride salts encourage dissociation of DNA-protein interaction via charge shielding 
228, the Glu- ion is much more hydrated due to its kosmotropic nature and does not 
interfere with DNA-protein interfaces even at high concentration.  In fact, high 
concentration of Glu- ion could strengthen the water network in bulk solvent 
(increasing surface tension) and thereby encourages DNA-protein interaction by 
decreasing the entropic cost of DNA-protein association 228. 
Alternatively, it is also possible that a structural difference between the E. coli and S. 
aureus GyrA-CTD (excluding the acidic tail) can contribute to the salt dependency. 
Nevertheless, the domain swap did not completely reverse KGlu dependency to the 
level observed for E. coli gyrase, indicating that while high KGlu dependency of Sa 
gyrase is partially linked to GyrA-CTD composition, the inability to stimulate Sa GyrA 
supercoiling at lower KGlu (0-150 mM) is possibly contributed by other component(s) 
of Sa gyrase. 
 
3.11 ATP hydrolysis does not contribute to KGlu dependency of Sa 
gyrase 
Previously, we have been able to establish the partial connection between the CTD of 
Sa GyrA and high KGlu dependency.  However it is clear that there is possibly a 
secondary element that is contributing to the KGlu dependency.  Aside from DNA 
wrapping, ATP hydrolysis is also an essential step for gyrase to introduce negative 
supercoils to DNA.  We therefore decided to investigate and compare S. aureus and E. 
coli GyrB ATPase activity in the presence of various concentrations of KGlu, NaGlu 
and KCl to examine the potential contribution of ATP hydrolysis to KGlu dependency. 
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The experiment utilises the PK/LDH coupled enzyme assay to colorimetrically detect 
the release of ADP from GyrB.  As GyrB hydrolyses ATP and produces ADP + Pi, the 
ADP release is converted back to ATP by PK (pyruvate kinase), using PEP 
(phosphoenolpyruvate) as the phosphate donor.  PEP is converted into pyruvate, 
which would be swiftly converted into lactate by LDH (lactate dehydrogenase) using 
NADH as a reducing agent.  NAD+ would be produced as the end product of the 
coupled enzyme assay and NADH/NAD conversion is monitored by measuring the 
decreases of OD at 340 nm.  The assays were run for duration of one hour with OD340 
measured at 1 min intervals.  The decrease in OD340 was plotted against time to 
obtain a relative rate of ATP hydrolysis (fig. 3.23), which is then finally compared 
against the salt concentration used in the experiment.  
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Figure 3.23.  Primary absorbance data from a typical PK/LDH coupled ATPase 
assay.  The ATPase assay is prepared according to chapter 2.8.2.  Absorbance reading at 
340 nm decreases over time as ATP in the reaction is converted into ADP.  Relative OD340 
of each reaction was calculated by subtracting absorbance data by their OD430 reading 
at 0 min.  Figure labels: +ATP: ATP was added; +B: 10 nM of EcGyrB subunit was added; 
+DNA: 0.5 ng of pBR322 was added; +A: 10 nM of EcGyrA was added.  Reaction with ATP 
and EcGyrB subunit added (+ATP +B) showed the intrinsic ATPase activity of EcGyrB.  In 
the presence of DNA (+ATP +GyrB +DNA), EcGyrB ATPase activity is similar to the +ATP 
+B reaction showing a slight stimulation.  In the presence of GyrA (+ATP+A+B), EcGyrB 
display is noticeably stimulated in its ATPase activity, possibly as a result of the presence 
of EcGyrA assisting GyrB dimerisation.  In the presence of EcGyrA and DNA 
(+ATP+A+B+DNA), GyrB displayed the most stimulation in its ATPase activity by 
triggering the DNA-dependent ATPase activity of Gyrase 84. 
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Surprisingly, the stimulation profile of SaGyrB ATP hydrolysis by KGlu (fig. 3.24) was 
similar to that of EcGyrB (fig. 3.25), both enzymes showed low ATPase activity in the 
absence of KGlu.  While the extent of stimulation varies between different salts, both 
enzymes hydrolyse ATP optimally beyond 450 mM.  This was unexpected, as Ec 
gyrase is able to supercoil optimally in the presence of ~150 mM of KGlu/NaGlu/KCl.  
In addition, NaGlu and KCl were able to stimulate SaGyrB ATP hydrolysis to a similar 
extent to KGlu, with optimal activity observed at around ~600-750 mM.  This is 
unexpected as NaGlu and KCl was not able to stimulate Sa gyrase supercoiling activity 
at all. 
The results showed that the optimal salt-stimulation of ATPase activity in both E. coli 
and S. aureus GyrB does not match with its supercoiling activity versus KGlu profile.  
This suggested that although ATPase activity is essential to gyrase supercoiling 
activity, its rate of hydrolysis is only weakly linked to its ability to optimally supercoil 
DNA.  The fact that Ec gyrase was able to fully supercoil the DNA substrate based on 
minimal ATPase activity at 0 mM KGlu also showed that ability for gyrase to supercoil 
DNA to a high negative supercoil saturation set-point is not dependent on ATP 
hydrolysis. 
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Figure 3.24 S. aureus GyrB DNA-independent ATP hydrolysis rate versus 0-
900 mM of KGlu, NaGlu and KCl.  ATP/NADH coupled ATPase assay were 
preformed according to methods in chapter 2.8.2. using ~64 nM S. aureus GyrB 
subunit.  ATPase activity of S. aureus GyrB were tested in triplicate in 0, 150, 300, 
450, 600, 750 and 900 mM concentrations of sodium glutamate (NaGlu), 
potassium glutamate (KGlu) and potassium chloride (KCl).  Linear regression 
models similar to fig. 3.23 were generated from from each reaction using the 
OD340 absorbance of a minimium of 20 consecutive time points with 1 min 
intervals.  Relative ATPase activity of each reaction was calculated from the 
gradient of the regression model (-∆OD340.s-1) of each reactions, as the -∆OD340.s-1 
corresponded to the disappearance of NADH within each reaction, which is 
proportion to the release of ADP from ATP hydrolysis.  Data points on the graph 
showed the average of the relative ATPase activity from the triplicate reactions, 
with the error bars showing the standard deviation values calculated from the 
three sets of data in each concentration. 
This suggests that ATP hydrolysis is not the rate limiting step for the supercoiling 
cycle.  The fact that both enzymes shared similar ATPase activity profile versus KGlu 
concentration suggested that ATPase activity is not the factor differentiating the two 
enzymes in terms of KGlu dependency.  The comparable ATPase stimulation of the 
GyrB subunits of E. coli and S. aureus by KGlu, NaGlu and KCl titration clearly 
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suggested that ATPase activity does not contribute to salt dependency and specificity 
observed in Sa gyrase. 
 
 
Figure 3.25 E. coli GyrB DNA-independent ATP hydrolysis rate versus 0-900 mM of 
KGlu, NaGlu and KCl.  ATP/NADH coupled ATPase assay were preformed according to 
methods in chapter 2.8.2. using ~10 nM concentration of E. coli GyrB subunit.  ATPase 
activity of E. coli GyrB were tested in triplicate in 0, 150, 300, 450, 600, 750 and 900 mM 
concentrations of sodium glutamate (NaGlu), potassium glutamate (KGlu) and 
potassium chloride (KCl).  Linear regression models similar to fig. 3.23 were generated 
from from each reaction using the OD340 absorbance of a minimium of 20 consecutive 
time points with 1 min intervals.  Relative ATPase activity of each reaction was 
calculated from the gradient of the regression model (-∆OD340.s-1) of each reactions, as 
the -∆OD340.s-1 corresponded to the disappearance of NADH within each reaction, which 
is proportion to the release of ADP from ATP hydrolysis.  Data points on the graph 
showed the average of the relative ATPase activity from the triplicate reactions, with 
the error bars showing thestandard deviation values calculated from the three sets of 
data in each concentration. 
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3.12 Discussion and Conclusion  
E. coli gyrase has been the subject of study for the last three decades and continues to 
be a subject of fascination.  Gyrase’s multi-fasit mechanism and the dynamism of its 
supercoiling cycle are intriguing, as it remains unclear how it is able to regulate DNA 
topology through its coordinated double-strand passage mechanism without causing 
permanent DNA damage or breakage.   
In this chapter, we begin our investigation with the aim to identifiy and explain the 
effect of salt concentration on the supercoiling activity of Sa gyrase.  This was carried 
out originally with the intent to understand the underlying differences in KGlu 
dependency between Sa gyrase and its E. coli counterpart.  Although previous studies 
have attempted to identify the cause of this phenomenon 224,229, it was far from 
conclusive, with no clear explanation offered as to why high concentration of 
potassium and glutamate specifically was required to support the DNA supercoiling 
activity of Sa gyrase.  By understanding this unique feature of Sa DNA gyrase, we 
hoped to unlock more unknown mechanistic details of gyrase. 
Through numerous biochemical examinations we were able to gain an improved 
understanding on the origin of the unusual high KGlu dependency displayed in Sa 
gyrase for its DNA supercoiling activity. 
3.12.1 Effect of salt on Sa gyrase supercoiling 
We began the investigation by studying the relative supercoiling activity of Sa gyrase 
in the presence of various concentrations of KGlu.  The E. coli gyrase was also tested 
in identical conditions as a direct comparison.  We established that Sa gyrase indeed 
displayed a strong dependency on KGlu for its supercoiling activity as it requires 300 
mM to begin to supercoil DNA, whereas E. coli gyrase showed some supercoiling 
activity in salt-less condition.  The DNA supercoiling activity of Sa gyrase was 
gradually stimulated as KGlu concentration was increased to upto 750 to 900 mM.  
This confirms the differential KGlu requirement for Sa gyrase but not E. coli gyrase, 
which warranted further investigation.  
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3.12.2 Specificity of salt stimulation of S. aureus gyrase supercoiling  
After we confirmed the presence of the KGlu dependent supercoiling stimulation in Sa 
gyrase, we were curious to investigate further on why KGlu in particular was able to 
support its acitivity.  In an attempt to establish the specific salt requirement for the 
supercoiling activity of Sa gyrase, we tested the supercoiling activity of Sa gyrase in 
the presence of various salts with different ion components, such as NaGlu and KCl.  
We discovered that the supercoiling activity of Sa gyrase could not be stimulated by 
NaGlu as the K+ component of KGlu is replaced by Na+.  This result implies that the 
presence of a K+ ion is crucial to the supercoiling function of Sa gyrase and that Na+ 
can not support it.  Furthermore, Glu- ion also appears to be essential to the function 
of Sa gyrase as KCl could not support its supercoiling activity. 
 
3.12.3 Effect of salt on S. aureus gyrase relaxation and decatenation 
Whilst we were able to establish that Sa gyrase required K+ and Glu- ions specifically 
to stimulate its supercoiling activity, we were intrigued to find out if relaxation and 
decatenation of Sa gyrase is influenced by salt.   
The reaction mechanism responsible for the relaxation of Sa gyrase is intrinsically 
different to that of the supercoiling reaction, as DNA relaxation of gyrase does not 
require the wrapping of DNA around the CTD of GyrA.  Therefore, mechanistically, the 
enzyme can undergo DNA relaxation in the absence of the CTD of GyrA 230.  This is 
evidented in a previous study 230 where a mutant E. coli gyrase without CTD of GyrA 
was able to relax and decatenate DNA but displayed no DNA supercoiling activity.  
Gyrase DNA decatenation mechanism was proposed to be similar to that of the DNA 
relaxation 230, where strand-passage was initiated as soon as the DNA juxtaposition in 
the cross-over between the two dsDNA is recognised by the GyrA and GyrB units.   
Interestingly, both relaxation and decatenation activity of Sa gyrase did not require 
high KGlu activity.  Decatenation activity of Sa gyrase is unaffected by the absence of 
salt and is able to decatenate at a near optimal level at 0 mM KGlu.  On the other hand 
relaxation activity of Sa gyrase required a low concentration of KGlu.  It relaxes 
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optimally at 300 mM KGlu and did not require high concentration of KGlu (>600 mM).   
This implied that the high KGlu requirement for Sa gyrase is confined to its 
supercoiling activity.  The enzyme is able to undergo decatenation in the absence of 
KGlu also indicates that the strand passage mechanism is fully functional without 
KGlu.  It is important to note that unlike decatenation, relaxation activity of Sa gyrase 
required a low concentration of KGlu.  This indicated that subtle differences may lie 
between the relaxation and decatenation mechanism of gyrase, as they displayed 
subtle differences in their activity profile against KGlu concentrations.   
   
3.12.4 Folding stability of gyrase as a function of potassium 
glutamate concentration 
As the changes in salt concentration are likely to have an effect to the folding of 
gyrase, it is necessary to ensure that the KGlu dependency is not the result of salt 
dependent protein folding.  We have tested the thermal stability of A and B unit of 
both Sa and E. coli gyrase in the presence of different concentrations of KGlu using the 
thermal-shift fluorophore assay.  Overall the thermal stability of both A and B units of 
E. coli gyrase and the Sa GyrB remained stable across the entire range of KGlu 
concentrations tested (0-900 mM).  Sa GyrA, however, displayed an surprising 
melting profile with a Tm of ~37°C.  This is not possible as Sa gyrase is functional at 
37°C, as demonstrated repeatedly by the supercoiling assays (37°C reaction 
temperature).  Alternatively, this could have been a false result or the result of the 
presence of other contaminants (such as lipids) remained after the purification 
process.  It remained unconclusive as to whether potassium glutamate influences 
supercoiling activity of the Sa gyrase by altering its folding.   However, the fact that Sa 
gyrase is able to complete DNA strand-passage in the absence of KGlu may suggest 
that it is able to retain its structural intergrity without the presence of KGlu. 
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3.12.5 The salt dependency of S. aureus gyrase is not dependent on 
the GyrA C-terminal tail. 
Hiasa et al. 229 previously proposed that the CTD of GyrA of Sa gyrase, responsible for 
the wrapping of the DNA substrate, is different to that of the E. coli gyrase and that 
this difference contributes to the salt-dependent supercoiling behaviour in Sa gyrase.  
Here, we attempted to identify the key difference between the CTD of SaGyrA and 
EcGyrA and locate the potential origin of salt dependency.  By bioinformatics analysis, 
we were able to identify a ͶͲ amino acid ǲtailǳ, consisting of largely negatively 
charged amino acids, towards the C-terminus of Sa GyrA unique to staphylococcus 
organism.  Due to its acidic nature, we initially proposed that it may interfere with the 
wrapping of DNA. 
Subsequently, we have produced a mutant Sa gyrase (SaGyrA ∆Cterm-tail) with a 
truncated C-terminal tail to investigate the function of the acidic tail.  Suprisingly, the 
C-terminal tail truncation did not produce any notable changes on the supercoiling 
activity nor the salt-dependency of the enzyme.  It is therefore apparent that the 
origin of KGlu dependency lies in other parts of the Sa Gyrase. 
3.12.6 The salt dependency of S. aureus gyrase is only partially 
attributed to the CTD region of the GyrA subunit  
In order to examine whether the CTD of Sa GyrA indeed contributes to the salt-
dependent behaviour of Sa gyrase, we have produced a domain-swap GyrA mutant 
which constitutes a NTD from Sa GyrA and a CTD from E. coli GyrA.  The reconstituted 
domain swap mutant Sa gyrase displayed a reduced salt-dependent activity profile 
when compared with wt Sa GyrA.  Although we were unable to revert the KGlu 
dependency of Sa gyrase to that of a wt E. coli gyrase by the GyrA-CTD domain swap, 
we were able to deduce that the high KGlu dependent supercoiling activity displayed 
by Sa gyrase is partially attributed to the SaGyrA-CTD.  This is a contradicting result 
to Hiasa et al. 229 as they proposed that salt-dependency is entirely attributed by the 
CTD of Sa gyrase.  As the CTD of GyrA is solely responsible for the wrapping of the T-
segment DNA, we proposed that the presence of a high concentration of KGlu assisted 
the wrapping of DNA through an unknown mechanism.   
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3.12.7 The salt dependency of S. aureus gyrase is not dependent on 
the ATPase reaction 
Whilst we were able to confirm that CTD of Sa gyrase only partially contributed to its 
salt-dependent supercoiling characteristics, it was unclear as to what contributed to 
the remaining salt-dependent supercoiling behaviour of the enzyme.   As the 
hydrolysis of ATP is essential to the supercoiling but not relaxation or decatenation 
activities of DNA gyrase, we decided to investigate the potential link between salt 
concentration and the hydrolysis of ATP by gyrase.  Intriguigingly, both Ec and Sa 
GyrB were able to hydrolyse ATP in the absence of KGlu/KCl/NaClu.  Moreover, both 
ATP hydrolysis of Ec and Sa gyrase were stimulated as salt concentration was 
increased.  As Ec and Sa GyrB hydrolyse ATP at a similar rate when exposed to 
different concentrations of various salts, it is apparent that ATPase hydrolysis does 
not contribute to high KGlu-dependent and KGlu-specific supercoiling.  This was 
further confirmed as the ATPase activity of Sa GyrB was decreased by a third between 
750 mM and 900 mM KGlu (figure 3.24), whilst there were no observable differences 
in the supercoiling activity of Sa gyrase between 750 mM and 900 mM KGlu (figure 
3.2 & 3.6).  Although ATPase activity is crucial to the supercoiling activity of Sa gyrase, 
it only requires a certain rate of ATP hydrolysis to support the rate of supercoiling.  
Any additional stimulation in ATP hydrolysis beyond a certain threshold does not 
appear to increase the rate of DNA supercoiling.  Thus it can be concluded that ATP 
hydrolysis is not the rate-limiting step of DNA supercoiling at medium (300 mM) to 
high (900 mM) salt concentration.  
Nevertheless, this is the first time that gyrase ATP hydrolysis was reported to be 
stimulated by the presence of a monovalent ion-containing salt.  In the light of our 
findings in chapter 5 where two novel monovalent metal ions (M+) binding sites were 
identified in close proximity to the ATP binding pocket, it can be argued that the 
increase of Na+ and K+ concentration could potentially stimulate the hydrolysis of ATP 
by specific binding to the M+ binding sites.  Future investigations could be conducted 
to further establish if the stimulation of ATP hydrolysis is indeed specific to M+ 
containing salts by testing it against other monovalent non-metal ions containing salt, 
such as ammonium (NH4) salt. 
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3.12.7 New lights on the mechanistic understanding of high KGlu-
dependent supercoiling in S. aureus gyrase  
With the new evidence emerged with the current studies, Sa gyrase was found to be 
stimulated by the presence of KGlu in a concentration-dependent manner.  
Nonetheless, we were unable to deduce the kinetics behind the stimulation without 
further quantitative evidence.  It can be concluded that GyrA CTD of Sa gyrase 
contributed to the KGlu dependent supercoiling.  We were, however, unable to revert 
the KGlu dependency of Sa gyrase to that of a wt Ec gyrase by domain-swapping the 
CTD of SaGyrA.  Therefore, it can be argued that high-KGlu dependent is not solely 
contributed by the CTD of GyrA and that a secondary mechanism is present, which 
prevents the progression of the supercoiling reaction cycle of the S. aureus gyrase at 
low KGlu.   
Using the experimental evidence gathered in the various investigations carried out, 
we were able to eliminate the following events as the contributing factor(s) to the 
salt-dependent supercoiling of Sa gyrase: 
1. ATPase hydrolysis 
2. Protein folding  
3. G-segment DNA binding 
4. DNA cleavage and resealing  
5. DNA gate operation  
6. C-gate operation  
While we are unable to fully elucidate the origin of KGlu dependency, by examining 
the processes essential and unique to the supercoiling mechanism of DNA gyrase, we 
were able to narrow down to two possible causes that could contribute to the 
secondary origin of KGlu dependency: 
1. T-segment DNA capture 
2. N-gate operation 
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The operation of the N-gate has been difficult to study due to its dynamic nature and 
the lack of structural information for full length GyrB.  Recently several SM-FRET 
studies carried out by Klostermeier et al. 231 were able to give further insight into the 
intricately co-ordinated processes involved in N-gate operation.  Narrowing and 
closure of the N-gate, T-segment capture and ATP binding are considered to be a 
series of closely co-ordinated processes that initiate the gyrase strand-passage 
reaction.  In addition, recent studies from the Klostermeier group found that B. 
subtilis gyrase supercoiling activity is dependent on the presence of K+ 231.  
Surprisingly, similar to Sa gyrase, Na+ was unable to stimulate B. subtilis gyrase 
supercoiling.  Subsequent SM-FRET further revealed that K+ is essential to the 
complete closure of the N-gate.  Gubaev et al. 231 speculated that K+ binding at a 
monovalent metal cation (M+) binding site conserved in GHKL ATPase assisted 
closure of the N-gate.  This site was predicted to be an octahedrally-coordinated 
binding site located around residues Ile94, Val97, A100, G117, S121 and the Ƚ-
phosphate of the ATP substrate.  However, in previous crystal structures, only 
electron density equivalent to a water molecule was ever observed in the site 
predicted.  Our attempt to co-crystallise E. coli GyrB-NTD with sodium and potassium 
has yielded the discovery of two M+ binding sites with different ion preferences.  This 
discovery which could potentially explain the missing link in Sa gyrase KGlu 
dependency and B. subtilis gyrase K+ dependency, will be described in chapter 5.  
Further implications of the discovery of the two M+ binding sites on KGlu dependency 
of Sa gyrase and K+ dependency of B. subtilis gyrase will be discussed further in 
chapter 5. 
3.12.8 The mistery of KGlu-specific S. aureus gyrase supercoiling 
stimulation  
The specific requirement of K+ and Glu- to support Sa gyrase supercoiling remained 
unclear.  E. coli gyrase not only displayed no dependency on high salt, it also showed 
no salt specificity, as it is able to supercoil in the presence of K+/Na+ and Glu-/Cl-.  
Therefore, the strigent requirement of a K+ and Glu- ion for DNA supercoiling in S. 
aureus gyrase appears to be unique to the enzyme. 
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As we established from the model generated for the CTD of S. aureus GyrA, it has less 
positively charged amino acid residue and therefore is likely to display a weaker 
ability to wrap DNA in comparison to E. coli gyrase.  Previous studies on the ǲglutamate effectǳ on other DNA interacting enzymes suggested that the kosmotropic 
nature of Glu- ion could lead to entropy reduction in DNA-protein association 228.  It is 
therefore possible that the presence of Glu- could have assisted the weak DNA 
wrapping ability of S. aureus gyrase and enables it to undergo its supercoiling 
reaction cycle.  Replacing Glu- with Cl- could therefore upset the entropy reduction 
effect of Glu- , which in turn affects the DNA wrapping ability of S. aureus gyrase.  On 
the other hand, the increases in concentrations of monovalent ions such as K+ in 
DNA-protein interaction systems are often found to be detrimental.  Studies 
suggested that the K+ would bind onto the negative charge of the DNA backbone and 
compete with the DNA-protein surface binding and weakens the DNA-protein 
interaction.    
 
Additionally, as a secondary origin of KGlu dependency is envisaged, it can be 
hypothesised that K+ is directly linked with this secondary factor while Glu- is 
associated with the primary-factor, i.e., DNA wrapping.  The evidence that K+ supports 
supercoiling by ensuring N-gate closure  in B. subtilis gyrase, and the discovery of the 
two novel M+ binding sites on Ec GyrB-NTD (Chapter 5) suggests that such an ion 
binding mechanism can potentially be the secondary origin of Sa gyrase supercoiling.  
The potential K+/Na+ preference in the two M+ binding sites may also provide the K+-
specific stimulation seen in S. aureus gyrase and B. subtilis gyrase but not E. coli 
gyrase.  Further implications of the two GyrB-NTD M+ binding sites on Sa gyrase K+ 
dependency and specificity will be discussed in detail in chapter 5. 
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Chapter 4 - S. aureus DNA gyrase as antibacterial target 
4.1 Introduction 
Ever since the introduction of the fluoroquinolones, the only class of clinically 
successful gyrase inhibitors, DNA gyrase has been regarded as one of the most 
effective antibacterial targets.  However, as traditional fluoroquinolones were more 
effective against gram-negative bacteria, DNA gyrase has been relatively neglected as 
an antibacterial target for the gram-positive pathogens.  While the pressure to 
develop new anti-S. aureus treatments are increasing, DNA gyrase could be the ǲAchilles heelǳ of MRSA and provides the low-hanging fruits for antibacterial 
discovery. 
4.2 Naphthoquinones  
The Naphthoquinones are a class of chemicals widely produced across Streptomyces 
232-233, plant and fungi 234.  They are found to display a diverse range of bioactivity, 
including antibacterial 235-237, anti-fungal, antiviral 238, anti-malarial 239, 
antitrypanosomal and anti-cancer activity 240.  Naphthoquinones in plants often 
contain the 1,4-Naphthoquinone core (fig 4.1).   
 
Figure 4.1.  Chemical structure of basic naphthoquinones 
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Naturally occurring naphthoquinones e.g., 7-Methyljuglone (fig. 4.3), diospyrin, 
Neodiospyrin and Isodiospyrin were first documented in 1972 241.  They were 
obtained from the root extract of Diospyros kaki, also known as Japanese Persimmon.  
It was later revealed that these phyto-naphthoquinones are present in other exotic 
plants used in folk medicines, including Euclea Natalensis (fig. 4.2), naturally found in 
the east coast of South Africa 242, and Diospyros montana Roxb. from India 243.  Various 
structurally analogs of naphthoquinones and bisnaphthoquinones are also found in 
the extract of Euclea Natalensis (fig. 4.3, 4.4) 244. 
 
Figure 4.2 Euclea Natalensis, producer of diospyrin, a widely used 
medicinal plant distributed in the southern to eastern coast of Africa.  
Reproduced from http://www.worldbotanical.com/Euclea-natalensis-pl.jpg 245. 
Diospyrin (fig. 4.4) is a natural covalent dimer of 7-methyljuglone (7MJ) (fig.4.5).  It 
has particularly caught the attention of scientists as it was known to possess good 
antitumour activity 246-247.  Over the years many synthetic analogues of diospyrin 
have been produced experimentally to study their anticancer 248, antifungal 249 and 
antibacterial 250 properties.  However all of these studies have only produced 
preliminary experimental results and have not attracted genuine interest to further 
develop them into drug leads. 
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Figure 4.3 Structures of naphthoquinones extracted from Euclea 
Natalensis  
 
Figure 4.4. Structures of bisnaphthoquinones, covalent dimers of 7-
methyljuglone: diospyrin (1,6-linkage), isodidospyrin (6,8-linkage), 
neodiospyrin (1,8-linkage) extracted from Euclea Natalensis 
 
4.3 Natural naphthoquinones as DNA gyrase inhibitors 
Diospyrin and 7-methyljuglone (7MJ) have in the past displayed strong antimicrobial 
properties, inhibiting topoisomerase I in Leishmania donovani 251 and targeting 
mycothiol disulfide reductase in M. tuberculosis 252.  They have been the drugs of 
interest in Lall’s research group 243.  They are phytochemicals that were originally 
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extracted from Euclea natalensis in Lall’s research group and were discovered to 
inhibit growth of M. tuberculosis 243.   
Intriguingly, S. Karkare discovered that both diospyrin and 7MJ were able to inhibit M. 
tuberculosis DNA gyrase supercoiling at 10 µM 253.  Both diospyrin and 7MJ inhibit 
relaxation activity of the enzyme with lower potency.  E. coli gyrase DNA supercoiling 
is inhibited by diospyrin and 7MJ with similar potency, implying that their binding 
pocket is likely to involve a conserved region of the enzyme.  Some experimental 
evidence has suggested the binding site of diospyrin to be within the N-terminal 
domain of the B-subunit, which includes the N-terminal ATPase domain and the 
transducer domain 253.  Existing inhibitors that binds to the NTD of GyrB 243 include 
the aminocoumarins, e.g., novobiocin and clorobiocin, which bind to the ATP pocket, 
directly competing with ATP binding and inhibiting ATP hydrolysis 254-256.  ATP 
competition experiments from S. Karkare suggested that diospyrin does not compete 
with ATP binding 253.  In addition diospyrin was able to inhibit the growth of an E. coli 
lab strain at ʹͳ μM 253.  This further demonstrates their potential as an antibacterial 
lead. 
Since both diospyrin and 7MJ has demonstrated their activity against DNA gyrase and 
showed bioactivity against both gram-negative and mycobacterium, this indicates 
that these natural naphthoquinones has the capacity to be developed into broad 
spectrum antibacterials. 
 
4.4 Natural naphthoquinones inhibit S. aureus growth in liquid 
medium 
To further explore the antibacterial spectrum of natural naphthoquinones beyond 
gram-negative bacteria (E. coli) and mycobacteria, we decided to test their bioactivity 
against S. aureus as a model bacterium of the gram-positive spectrum. 
Due to the lack of commercial availability of these compounds, we decided to deploy 
micro-titre plates (100 µl per well) for the study to reduce material consumption.  
Liquid media was chosen over solid media for the ease of preparation, reducing the 
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possibility degradation of heat-sensitive compounds in hot agar and improved 
diffusion of the drugs. 
A series of concentrations of each naphthoquinone was added to the S. aureus- ATCC 
29213 inoculated-liquid culture and grown overnight.  The cultures were incubated in 
the shaking incubator at 37°C.  OD600 of the S. aureus cultures were measured at the 
end of the 16 hrs incubation. 
As shown in fig. 4.5 all 6 naphthoquinones tested completely inhibited the growth of S. 
aureus at 200 µM.  Isodiospyrin and Shinalone moderately inhibited the growth of S. 
aureus in the assay condition with MICs of >64 µM.  Neodiospyrin, diospyrin and 
menadione were more potent, with MIC values between 16-32 µM. 
The most obvious and important criteria of the success of an antibiotic is its ability to 
penetrate the bacteria cell envelop and to subsequently inhibit bacterial growth.  
Many reagents developed by a target-based approach, which displays strong in vitro 
inhibition could fail to inhibit bacterial growth simply due to their inability to 
penetrate the bacterial envelope.  The ability of these compounds to inhibit the 
growth S. aureus as well as E. coli and M. tuberculosis means that they can effectively 
penetrate cell envelopes of various types of bacteria.  Assuming that these 
compounds share the same single specific cellular target, it is possible that the target 
of inhibition is conserved among these bacteria.  All this evidence suggested the 
potential of naphthoquinones to become wide-spectrum antibiotics. 
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Figure 4.5.  Inhibition of S. aureus growth by natural naphthoquinones and existing gyrase 
inhibitors:  A) ciprofloxacin, B) novobiocin, C) menadione, D) shinalone, E) neodiospyrin, F) 
isodiospyrin, G) 7-methyljuglone, H) diospyrin.  S. aureus ATCC 29213 was inoculated in 100 µl of 
compounds containing LB media (10% DMSO) and grew for 16 hrs at 37°C with constant shaking.  
The OD600 of the media was then recorded using a SPECTRAmax GEMINI microplate reader at the 
end of the incubation.  As shown in the control ciprofloxacin (A) and novobiocin (B) infused assays, 
OD600 decreases as concentration of the compounds increases, indicating the inhibition of growth.
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4.5 Natural naphthoquinones inhibit S. aureus gyrase 
Since all the natural naphthoquinones tested on S. aureus inhibit its growth to a 
various degree, and that they share similar chemical structure, there is likely to be a 
common cellular target.  The fact that some of them are inhibitors of E. coli and M. 
tuberculosis gyrase has led us to test them in the supercoiling assay of S. aureus 
gyrase.  As well as the six natural naphthoquinones, we have decided to include a few 
other known bacterial topo II inhibitors including simocyclinone D8, Quercetin, Rutin, 
etc. 
As one of the most widely used fluoroquinones, ciprofloxacin has an IC50 of ~30 µM, 
we have decided to assay the compounds at a fixed concentration of 50 µM to identify 
genuine inhibitors of S. aureus gyrase (fig. 4.6).  As expected, ciprofloxacin, 
novobiocin and simocyclinone D8 effectively inhibit S. aureus gyrase.  All 
naphthoquinones tested inhibited S. aureus gyrase supercoiling to a certain extent, 
with neodiospyrin and diospyrin being the most potent inhibitors.  As menadione was 
one of the most potent naphthoquinones acting against S. aureus, it is surprising to 
find that it has an IC50 exceeding 50 µM.  One possible explanation is that mendione 
inhibits an alternative cellular target and this inhibition is more potent than that of 
DNA gyrase.  However there are no existing studies of mendione inhibition on other 
bacterial targets. 
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Figure 4.6. S. aureus gyrase supercoiling inhibition at 50 µM by various gyrase 
inhibitors and naphthoquinones.  0.5 ng of DNA is supercoiled by 1 U of 
reconstituted gyrase in supercoiling assay conditions (10% DMSO) described in 
method chapter 2.8.1.1.   Lanes with red asterisks highlights supercoiling assay 
reactions inhibited by the sampled drugs, with a reduced quantity of the supercoiled 
circular DNA presence.  Figure labels: –Gyr – supercoiling assay without gyrase; 
DMSO control – supercoiling assay with gyrase in 5% (v/v) DMSO.   
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Figure 4.7. S. aureus gyrase DNA supercoiling inhibition by natural 
naphthoquinones: 7-methyljuglone (top-left), diospyrin (top-right), 
neodiospyrin (bottom-left) and isodiospyrin (bottom-right).  0.5 ng of DNA 
is supercoiled by 1 U of reconstituted gyrase in the supercoiling assay conditions 
(10% DMSO) described in method chapter 2.8.1.1.   Lanes with red arrows 
highlights the intermediate inhibition concentration of the sampled drug, 
indicating approximate IC50  (50% inhibition concentration) of the particular 
drug against S. aureus gyrase.  Figure labels: Relaxed/Supercoiled – 
relaxed/supercoiled pBR322; –ve: no enzyme control (10% DMSO); +ve: gyrase 
only control (10% DMSO).
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To further define the inhibitory activity of naphthoquinones, all of the 
bisnaphthoquinones, together with their chemical progenitor 7-methyljuglone were 
assayed in detail (fig. 4.7).  Diospyrin, which is the most potent inhibitor against M. 
tuberculosis gyrase out of the three bisnaphthoquinones, inhibits S. aureus gyrase 
supercoiling with an IC50 of ~8 µM.  This figure is comparable to its IC50s against E. 
coli (4 µM) and M. tuberculosis gyrases (15 µM) 253.  Both isodiospyrin and 
neodiospyrin are relatively less active with IC50s values of ~16 µM and ~32 µM, 
respectively.  Surprisingly, while the IC50s of 7MJ and diospyrin for M. tuberculosis 
gyrase were fairly similar, against S. aureus gyrase 7MJ (IC50~64 µM) is significantly 
less potent (8 times) than its dimer analogue diospyrin (IC50~8 µM).  These data are 
summarised in Table 4.1. (page 126) 
It is interesting to find that neodiospyrin was superior to both diospyrin and 
isodiospyrin in the S. aureus growth inhibition assay, while neodiospyrin is the least 
potent of the three in the gyrase assay.  Assuming gyrase is the only cellular target of 
these compounds, it is possible that neodiospyrin possesses structural and/or 
physicochemical difference that favours cellular accumulation, which in turn makes it 
more potent than diospyrin.  An alternative explanation would be that neodiospyrin 
has a second cellular target, which gives it an extra dimension of inhibition and thus 
the extra potency. 
 
4.6 Natural Naphthoquinones inhibit S. aureus topo IV 
Topo IV is crucial to the survival of most bacteria and is the secondary target of most 
DNA gyrase inhibitors (including ciprofloxacin and novobiocin) due to its homology 
with DNA gyase.  While most bacterial topo II inhibitors known to date have 
preferential potency against gyrase over topo IV in gram-negative bacteria 257, some 
display stronger activity against topo IV than gyrase in S. aureus 116,201.  The target 
preferences have huge implications on the MIC and mutant prevention 
concentratrion (MPC) of the compound, which directly affects the probabilities of 
mutant emergence258. 
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Figure 4.8 S. aureus topo IV DNA relaxation inhibition by natural 
naphthoquinones by various gyrase inhibitors and naphthoquinones. 0.5 
ng of DNA is supercoiled by 1 U of reconstituted gyrase in the supercoiling assay 
conditions (10% DMSO) described in method chapter 2.8.1.1.  Lanes with red 
asterisks highlights relaxation assay reactions inhibited by the sampled drugs at 
50 µM, with an increase quantity of the remaining supercoiled circular DNA.  
Figure labels: –TopoIV – relaxation assay with topo IV; DMSO control – 
supercoiling assay with Sa topo IV in 5% (v/v) DMSO.  
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Figure 4.9 Sa topo IV DNA relaxation inhibition by natural 
naphthoquinones: 7-methyljuglone (top-left), diospyrin (top-right), 
neodiospyrin (bottom-left) and isodiospyrin (bottom-right).  0.5 ng of DNA 
is supercoiled by 1 U of reconstitute gyrase in the supercoiling assay conditions 
(10% DMSO) described in method chapter 2.8.1.1.   Lanes with red arrows 
highlights intermediate inhibition displayed by the stated concentration of the 
sampled drug corresponding to the lane, indicating approximate IC50  (50% 
inhibition concentration) of the particular drug against S. aureus Topo IV.  
Figure labels: Relaxed/Supercoiled – relaxed/supercoiled pBR322; –ve: no 
enzyme control (10% DMSO); +ve: gyrase only control (10% DMSO). 
To investigate the target preference of the naphthoquinones, we have tested the four 
gyrase-inhibiting naphthoquinones against topo IV in a relaxation assay (fig. 4.8 & 
4.9).  All four naphthoquinones have inferior potency towards topo IV when 
compared with DNA gyrase.  The bisnaphthoquinones (diospyrin, isodiospyrin and 
neodiospyrin) all have IC50s between 32 to 64 µM.  7MJ has the least activity, with 
only minor inhibition observed at 64 µM.  diospyrin and isodiospyrin are slightly 
more potent than neodiospyrin and showed observable inhibition from 16 µM and 
upwards.  These data are summarised in Table. 4.1. 
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4.7 Natural naphthoquinones as inhibitors of bacterial 
topoisomerase II 
In summary, natural naphthoquinones displayed good anti-S. aureus activity and 
inhibit both S. aureus gyrase and topo IV, with S. aureus gyrase as the preferential 
target.  One of the major concerns with in vitro drug screening is that many promising 
positive hits can in fact be false positives and inhibit the target of interest via non-
specific inhibition (detergent effect, aggregation etc.).  The fact that diospyrin and 
other naphthoquinone analogs are able to inhibit gyrase from a wide range of 
organisms and the differential IC50 between S. aureus gyrase and topo IV provides a 
strong indication that naphthoquinones do inhibit gyrase and topo IV via specific 
binding. 
One of the major problems with the development of an antibacterial agent is that it is 
difficult to develop an antibacterial that is potent and yet does not show bio-activity 
towards humans.  Human bioactivity is undesired as it induces unwanted side-effects, 
cytotoxicity and greatly impairs usability of an antibacterial drug.  Occasionally, an 
antibacterial lead has the ability to inhibit a secondary target in humans and thereby 
displays human bioactivity.  For example, novobiocin binds to the ATPase portion of 
GyrB and was found to inhibit Hsp90259-260 and other GHKL class ATPases 260.  Such 
undesirable secondary inhibition is proposed to be the reason for its undesirable side 
effects 261.  Novobiocin was later abandoned in the clinic. 
 
 
Table 4.1 Bioactivities of natural naphthoquinones against S. aureus in vivo (MIC), 
and Sa Gyrase and Sa Topo IV in vitro (IC50), derived from data in figure 4.5. 
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Table 4.2 Order of potency for natural naphthoquinones against S. aureus 
in vivo (MIC), and Sa Gyrase and Sa Topo IV in vitro (IC50) 
In previous studies, Diospyrin was shown to possess anti-cancer characteristics 262-263.  
It is therefore likely that it has a secondary target in human cells and could have 
undesirable side effects when administered in human.  In order to reduce side effects 
and enhance efficacy of an antibacterial, it is vital to maximise the specificity of the 
drug to its target.  It is therefore important to understand molecular details of the 
inhibition to obtain positional details of the binding pocket.  This would provide 
valuable insight into future chemical modifications to improve affinity and specificity 
of the inhibitors.  By understanding if the compound binds to an evolutionary 
conserved portion of the enzyme, it enables the prediction of secondary target 
binding.   
 
4.8 Diospyrin binds the NTD of GyrB – solution evidence 
Previous in vacuo evidence from electro-Nano spray MS showed that diospyrin to 
able to bind to the NTD of E. coli GyrB.  This suggested that the binding site of 
diospyrin is located on the GyrB NTD253.  However, we have yet to produce solution 
evidence of diospyrin-GyrB binding to date.  Therefore, we designed an experiment 
involving titration of EcGyrB-NTD into an S. aureus DNA gyrase supercoiling assay at 
an inhibitory concentration of diospyrin.  As the NTD of EcGyrB does not have 
supercoiling activity, any apparent recovery of supercoiling activity with increasing 
concentration of EcGyrBNTD would be a result of it binding to inhibitors, reducing the 
bulk inhibitor concentration and thereby relieving inhibition on S. aureus gyrase. 
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Figure 4.10 Diospyrin-Sa gyrase supercoiling inhibition is relieved by EcB-NTD 
titration.  The standard DNA supercoiling assay with 0.5 U (~64 nM) of S. aureus gyrase 
was titrated with a x0, x0.5, x1, x2, x4, x6 molar excess of EcB-NTD in the presence of 30 
µM Ciprofloxacin (bottom left), 300 nM Novobiocin (top right) and 12 µM Diospyrin 
(bottom right) and no drug control (top left).  Figure labels: Relaxed/Supercoiled – 
relaxed/supercoiled pBR322; –Gyr: no enzyme control. 
 
As shown in fig. 4.10, increasing the EcBNTD concentration does not affect the 
supercoiling activity of S. aureus gyrase (fig. 4.10 top left).  A parallel experiment in 
the presence of 300 nM of novobiocin, which is known to bind to the NTD of GyrB 
showed that inhibition of S. aureus gyrase is gradually reduced by the EcB-NTD 
titration (fig. 4.10 Top right).  Not surprisingly, EcB-NTD titration did not reduce 
ciprofloxacin inhibition (fig. 4.10 bottom left).  Finally, in the presence of diospyrin 
(fig 4.10 bottom right), EcBNTD titration did reduce inhibition in manner similar to 
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the novobiocin experiment.  Therefore, it is concluded that diospyrin binds to the 
NTD of GyrB in solution. 
 
4.9 Diospyrin inhibits ciprofloxacin-induced cleavage 
Since diospyrin is able to inhibit both the supercoiling and relaxation activities of 
DNA gyrase, we investigated its ability to inhibit DNA cleavage.  Ciprofloxacin is able 
to induce double-strand DNA cleavage via gyrase by inhibiting the DNA religation 
step within the gyrase strand-passage reaction cycle264.  By testing ability of diospyrin 
to inhibit ciprofloxacin-induced DNA cleavage, we hope to gain further understanding 
on the diospyrin inhibition mechanism. 
 
Figure 4.11. Diospyrin but not novobiocin inhibits Ciprofloxacin induced 
double-strand cleavage by gyrase.  0.3 µg of upercoiled pBR322 plasmid is 
cleaved by incubating with 10 nM S. aureus induced by the presence of 100 µM 
ciprofloxacin in a standard supercoiling assay condition (10% DMSO).  Lane 3 
shows the appearance of an additional band (ds break) demonstrating the 
cleavage activity, comparing to the no enzyme reaction in lane 1.  The increased 
concentration of diospyrin (lane 8-12) inhibited the ciprofloxacin induced 
cleavage while the control reaction with Novobiocin (lane 3-7) did not.  Figure 
labels: Relaxed - relaxed pBR322; Supercoiled – supercoiled pBR322; ds break – 
double-stranded DNA break or linear pBR322;  -Gyr – no gyrase added; - Cipro – 
no ciprofloxacin added; +Novo – 0.1 nM novobiocin added; +Dio – 40 µM 
diospyrin added. 
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As demonstrated in fig. 4.11, increasing concentrations of novobiocin were unable to 
inhibit ciprofloxacin-induced DNA cleavage.  The fact that relaxation does not require 
the NTD of GyrB 265 and that Cipro alone was able to inhibit relaxation activity of 
gyrase indicated that N-gate closure was not required for Cipro-induced DNA 
cleavage.  As indicated in fig. 4.11 Cipro-induced DNA cleavage was gradually 
inhibited when diopsyrin concentration was increased.  This suggested that diospyrin 
was inhibiting the gyrase reaction subsequent to N-gate closure and prior to the 
initial DNA cleavage reaction step. 
4.10 Naphthoquinone partially inhibits the ATPase reaction of S. 
aureus GyrB 
Cumulative evidence from mechanistic studies of diospyrin-gyrase inhibition 
suggested that diospyrin does not compete with ATP binding and binds to the NTD of 
GyrB.  As shown in fig. 4.14 the crystal structure of E. coli GyrB-NTD has a compact 
structure and does not have many apparent pockets available for ligand binding.  
According to ligand pocket prediction by the Molsoft ICM-Pro software package, a 
pocket between the ATPase domain and the transducer domain is most likely to be 
the binding pocket of diospyrin (fig. 4.14). 
GyrB possesses intrinsic ATPase activity and is able to hydrolyse ATP in the absence 
of GyrA and a DNA substrate266.  This ATP hydrolysing activity is dependent on GyrB 
dimerisation and it would be affected by disruption in the dimerisation interface .  
The transducer region is linked to ATPase activity as the absence of transducer 
domain completely disables ATP hydrolysis267.  Therefore given the prediction that 
naphthoquinones bind close to the ATPase portion of GyrB, we would expect its 
presence to affect ATP hydrolysis.  In this experiment, we aimed to investigate this by 
assessing the rate of ATP hydrolysis in increasing concentrations of diospyrin. 
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Figure 4.12 ATPase activities of S. aureus GyrB in the presence of Diospyrin 
and Novobiocin.  The ability for S. aureus GyrB subunit (~64 nM) to hydrolyse 
ATP in the presence of a series of concentration of Novobiocin and Diospyrin was 
examined using standard  ATP/NADH coupled assay describe in chapter 2.8.2.  
Using the changes in absorbance at 340 nm, which corresponds to the 
absorbance peak of NADH, the concentration decrease of NADH and ATP over 
time interval of 20x 1 minute was calculated using Beer-Lambert law.  ATP/s 
representing the number of ATP hydrolysed by each molecule of GyrB per second 
is calculated.  Novobiocin, a known GyrB ATPase inhibitor was able to completely 
abolish ATPase activity of GyrB at concentrations of 300 – 500 µM.  Diospyrin 
also displayed inhibition towards GyrB ATPase activity from 2 µM concentration 
and above but only partially inhibit GyrB at saturating concentrations. 
Fig. 4.12 showed the effect of Diospyrin and novobiocin on the ATPase activity of S. 
aureus GyrB in ATP/NADH coupled assays.  Novobiocin  causes near complete-
inhibition of the ATPase activity of S. aureus GyrB at saturating concentration.  This 
inhibition profile reflects the known fact that novobiocin binds to the ATP binding 
pocket and competitively inhibits ATPase activity 255.  Diospyrin titration decreased 
Chapter 4   S. aureus DNA gyrase as antibacterial target 
 
132 
 
ATPase activity in the concentration range between 0-20 µM.  As the diospyrin 
concentration was increased further, ATPase inhibition was reduced and stabilised at 
~40 µM.  This suggested that at ~40 µM all diospyrin binding sites are saturated.  
Surprisingly diospyrin at saturating concentrations only partially inhibits S. aureus 
GyrB ATPase, with only 1/3 of the intrinsic ATPase activity inhibited, in contrast to 
the full inhibition seen with novobiocin.  This suggests that diospyrin is inhibiting the 
ATPase of SaGyrB allosterically and does not compete with ATP binding.  To confirm 
the authenticity of these findings, a parallel ATPase experiment was carried out with 
7MJ as the inhibitor.  
As shown in fig. 4.13 7-methyljuglone titration inhibits ATP hydrolysis of SaGyrB 
between 0-20 µM, with over 1/3 of the activity inhibited at 20 µM.  Similar to 
diospyrin, 7-methyljuglone ATPase inhibition plateau at ~40 µM and does not further 
inhibit ATPase activity at 60-80 µM.  This result confirms the fact that 
naphthoquinones do not compete with ATP binding and affects ATPase activity 
allosterically.  The similarities between the inhibition profile of diospyrin and 7MJ 
suggests that naphthoquinones share the same mode of action and same binding site 
in gyrase. 
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Figure 4.13 7-methyljuglone partially inhibits ATPase activity of SaGyrB 
ATP/NADH coupled ATPase assay were preformed according to methods in 
chapter 2.8.2 using ~64 nM of S. aureus GyrB subunit.  ATPase activity of S. 
aureus GyrB were tested in triplicate in the presence of 0, 10, 20, 40, 60 and 80 
mM concentrations of 7-methyljuglone (7-MJ) and 25 µM of Novobiocin.  Linear 
regression models similar to fig. 3.22 were generated from from each reaction 
using the OD340 absorbance of a minimium of 20 consecutive time points with 1 
min intervals.  Relative ATPase activity of each reaction was calculated from the 
gradient of the regression model (-∆OD340.s-1) of each reactions, as the -∆OD340.s-1 
corresponded to the disappearance of NADH within each reaction, which is 
proportion to the release of ADP from ATP hydrolysis.  Data points on the graph 
showed the average of the relative ATPase activity from the triplicate reactions.    
The error bars represents the standard deviation values calculated from the 
three sets of data in each concentration. 
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4.11 Possible binding pocket for diospyrin 
 
Figure 4.14. Available ligand-binding pockets on E. coli GyrB predicted by Molsoft 
ICM Pro, ICM pocket finder.  A van der Walls grid map was produce using a carbon 
atom probe based on algorithm published in An et al. 268 designed for the identification 
of ligand binding sites.  Cavities on the grid map produced were then ranked based on 
their sizes.  Three biggest cravities found are visualised in space relative to the protein 
structure.  
 
With the availability of the crystal structure of E. coli GyrB-NTD fragment (43 kDa), 
we were able to generate a prediction of available pockets for ligand binding using 
the Molsoft ICM Pro package.  Assuming that the drug-bound protein conformation is 
the same as the crystal structure, there are three potentially available ligand-binding 
pockets.  Pocket 1 is the ATP-binding pocket, which is also the binding pocket for 
novobiocin.  However as it was established that diospyrin does not compete with ATP 
binding and that ATP binding completely occupies pocket 1, diospyrin binding to 
pocket 1 is not anticipated.  Both pocket 2 and pocket 3 sit at the boundary between 
the ATPase domain and the transducer domain.  Pocket 2 is about 103 Å3 in volume 
and therefore predicted to be too small for diospyrin binding.  Therefore pocket 3 is 
predicted to be the most likely binding site of diospyrin. 
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4.12 Model of diospyrin inhibition 
The binding of diospyrin does not abolish the ATP hydrolysis activity of SaGyrB.  
However, it appears to bind to the NTD of GyrB, which consists of the ATPase domain 
and the transducer domain.  This suggests that diospyrin may bind to the transducer 
region of GyrB.  However, it is surprising that the NTD of GyrB is not needed for the 
relaxation activity of gyrase, yet diospyrin was able to influence relaxation activity via 
binding to transducer domain.  This could indicate that perhaps diospyrin binding to 
the transducer domain of the GyrB causes it to adopt a conformation that restricts 
DNA strand passage.  Similarly, diospyrin could inhibit relaxation by simply 
restricting transducer domain to translate the conformational change needed for DNA 
cleavage. 
Ciprofloxacin is able to induce dsDNA cleavage by preventing religation step of DNA 
gyrase and is not dependent on the presence of T-segment DNA264.  The evidence that 
diospyrin inhibits ciprofloxacin-induced dsDNA cleavage implies that diospyrin 
inhibits DNA cleavage and possibly prevents steps prior to DNA cleavage.   
4.13 Synthetic naphthoquinones 
4.13.1 Synthetic naphthoquinones (set I) 
While it has been established that natural naphthoquinone such as 7-methyljuglone 
and diospyrin inhibit DNA gyrase of S. aureus, E. coli and M. tuberculosis, little is 
known about their structure-activity relationships (SARs).  To explore this, we have 
acquired a range of structurally similar synthetic naphthoquinones from Prof. Vishnu 
Tandon, Lucknow University, India (Table 4.3).  A total of 16 naphthoquinones and 
related compounds at a concentration of 300 µM were assayed against S. aureus 
gyrase supercoiling to eliminate inactive candidates.  Out of the 16 compounds, 7 
were shown to display IC50s of <300 µM (fig. 4.14).  These were further assayed to 
establish their detailed IC50 values.  As shown in fig. 4.15, compounds that had shown 
inhibition were further assayed at 100 µM.  3 out of the 9 assayed have sub-100 µM 
IC50s and were later found to have IC50s of ~25 µM (fig. 4.16). 
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The results of this screen further confirm potential of naphthoquinone as a gyrase 
inhibitor with 3 candidates that showing equivalent IC50s (25 µM) to ciprofloxacin 
(~30 µM) prior target specific medicinal chemistry modifications.  It is disappointing 
that none of them demonstrate superior IC50s to diospyrin and that this has not 
generated significant knowledge on the SAR of naphthoquinones.  
 
 
 
 
Figure 4.15. Synthetic naphthoquinones (set I) inhibits S. aureus gyrase 
supercoiling at 300 µM.  0.5 ng of DNA is supercoiled by 1U of reconstitute 
gyrase in the supercoiling assay conditions (10% DMSO) described in method 
chapter 2.8.1.1.  16 synthetic analogs of naphthoquinones were tested against S. 
aureus gyrase.  The identity of the naphthoquinones can be identified in table 
4.3a and 4.3b.  Red boxes highlighted the naphthoquinone samples inhibiting S. 
aureus gyrase supercoiling at 300 µM.  Figure labels: Rel/Sc Markers - 
relaxed/supercoiled pBR322 markers; Rel/Sc pBR322 – relaxed/supercoiled 
pBR322; Cipro – gyrase plus 20 µM ciprofloxacin (10%DMSO); –ve con – gyrase 
only control (10% DMSO). 
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Figure 4.16 Synthetic naphthoquinones (set I) inhibits S. aureus gyrase 
supercoiling at 100 µM.  0.5 ng of DNA is supercoiled by 1 U of reconstitute gyrase in 
the supercoiling assay conditions (3% DMSO) described in method chapter 2.8.1.1.  9 
naphthoquinones with S. aureus gyrase inhibiting activity at 300 µM were tested at 100 
µM to eliminate weak or non-specific inhibitors.  Naphthoquinones showing inhibition 
to S. aureus gyrase at 100 µM were labelled with red asterisk (*).  Note:  lack of intensity 
in lane 14 is the result of a photographic artefact at the edge of a photo after the 
contrast of the image was altered to enchance visibility. 
Figure labels: Lane 1-2 - Relaxed (Rel) and supercoiled (Sc) pBR322 markers 
 Lane 3-11 – S. aureus gyrase supercoiling assay in the presence of various napthoquinones 
 Lane 12-14 –Control supercoiling reactions in the presence of 20 µM ciprofloxacin, DMSO only 
(DMSO) and without gyrase (-Gyr). 
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Figure 4.17.  Synthetic naphthoquinones: HT-4A, HT-4B, HVK-124 inhibits 
Sa DNA gyrase.  0.5 ng of DNA is supercoiled by 1 U of reconstitute gyrase in the 
supercoiling assay conditions (3% DMSO) described in method chapter 
2.8.1.1.   Three naphthoquinones with S. aureus gyrase inhibiting activity at 100 
µM were tested at 6.25, 12.5, 25, 50, 100 µM to identify their individual IC50 
values.  Concentrations of the naphthoquinones showing IC50 level of inhibition 
on S. aureus gyrase were labelled with red arrows.   
Figure labels: (lane 1 & 2) Rel/Sc Markers - relaxed/supercoiled pBR322 markers; 
control supercoiling reactions (lane 18 &19): DMSO only (DMSO) and without gyrase (-
Gyr). 
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Table 4.3a. IC50s of Synthetic naphthoquinones (set I) against S. aureus 
gyrase 
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Table 4.3b. IC50s of Synthetic naphthoquinones (Tandon) against S. aureus 
gyrase 
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4.13 Synthetic naphthoquinones (set II) 
In addition, we have acquired an additional set of naphthoquinone related 
compounds from Dr. David Kinston (Virginia Tech.).  This set of compounds consisted 
of a range of fragmented versions of 7-methyljuglone as well as a few anthraquinones 
(Table 4.4).  As expected, all of the smaller naphthoquinone fragments failed to inhibit 
Sa gyrase at the concentration of 100 µM.  Juglone and 5,8-dihydroxyl-1,4-
naphthoquinone, both close chemical relatives of diospyrin, were able to inhibit at 
~50 µM.
 
Figure 4.18 Synthetic naphthoquinones (set II) inhibits Sa DNA gyrase at a final 
concentration of 100 µM, 3% DMSO.  Red asterisks at lane 5, 7 and 9 represents 
gyrase inhibition displayed by the corresponding naphthoquinone compound.   
Figure labels: (lane 1) Sc - supercoiled pBR322 markers; control supercoiling reactions 
(lane 12, 13 & 14): Gyrase added plus 1 µM Novobiocin (Novobiocin), DMSO only (DMSO) 
and without gyrase (-Gyr). 
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Table 4.4. IC50s of synthetic naphthoquinones (set II) against Sa gyrase 
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Figure 4.19. Detailed IC50 determination of SC-201-140-7c, juglone and 5,8-
dihydroxyl-1,4-naphthoquinone against Sa gyrase. 0.5 ng of DNA is 
supercoiled by 1 U of reconstitute gyrase in the supercoiling assay conditions 
(10% DMSO) described in method chapter 2.8.1.1.  Figure labels: Rel/Sc - 
relaxed/supercoiled pBR322 markers. 
 
In summary 32 different analogs of naphthoquinones were screened against S. aureus 
gyrase, with 1, 1, 4 and 6 naphthoquinone at found to have a IC50 values of below 10 
µM, between 10-20 µM IC50, between 20-50 µM and between 50-100 µM.  While none 
of the synthetic naphthoquinones screened exceeds the IC50s achieved by diospyrin, 
valuable information was obtained with regard to structural-activity-relationship 
using pharmacophore modelling (see pharmacophore modelling at chapter 4.14) 
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4.14 Naphthoquinones Pharmacophore Modelling – LigandScout 3.0 
A pharmacophore is the core structure of an inhibitor that makes important contacts 
with its target.  With the number of naphthoquinones screened, there are sufficient 
IC50 data to predict and construct a pharmacophore model by associating the 
structure of the ligand to its in vitro activity.  The subsequent model generated could 
further our understanding on the properties of the naphthoquinone binding site and 
its structural-activity relationship. 
Initially, the most potent inhibitors in vitro, diospyrin and isodiospyrin are used as 
the model training ligands (training-set) to provide initial template for the 
pharmacophore model.  Once the training-set was aligned, other sub-100 µM ligands 
were then included as a test-set to align with the predicted preliminary 
pharmacophore.  At the end of the alignment analysis several pharmacophore models 
would be generated and the one with pharmacophore-fits scores that matches closest 
with the real IC50s were chosen as the most accurate model. 
 
 
Figure 4.20. 3D 
Pharmacophore model of 
Naphthoquinone gyrase 
inhibitor: 
Yellow sticks -> Diospyrin 
Blue sticks -> Isodiospyrin 
Yellow sphere: Hydrophobic 
interaction. 
Red sphere: Hydrogen bond 
acceptor. 
Red and green: Both hydrogen 
bond acceptor and donor. 
Shadowed sphere: weak 
pharmacophore fit 
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From the pharmacophore model generated (fig. 4.19 & 4.20), it was predicted that 
both diospyrin and Isodiospyrin shared the main core of the pharmacophore with 
their position-6 alkylated naphthoquinone moiety.  Most of the ligand interactions 
occur around the core naphthoquinone, this include the two carbonyl group acting as 
hydrogen bond donors, aromatic interaction in ring 2, hydrophobic interaction with 
the 7-methyl-group as well as the additional hydrogen bond with the group five 
hydroxyl.  In addition, carbonyl and hydroxyl groups from the second half of 
naphthoquinone are predicted contribute to minor hydrogen bonding interactions.  
Whilst there is currently no crystal structure of naphthoquinone-bound DNA gyrase 
available, it is possible that this naphthoquinone pharmacophore model could be 
used to guide the development of more potent gyrase inhibiting naphthoquinones in 
the future.
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4.15 Discussion 
In attempt to address the current needs to develop new classes of antibacterial agents 
to combat the rises in antibiotics-resistance in S. aureus, we explored the targeting of 
S. aureus gyrase as an antibacterial target in this study.  In particular, we have focused 
on examining the potential of natural and synthetic naphthoquinones as a novel class 
of DNA gyrase inhibitor.  Several natural naphthoquinones, including diospyrin, has 
previously been shown to display in vivo activity against M. tuberculosis 243.  
Naphthoquinone such as diospyrin and 7-methyljuglone were also shown to be 
inhibitors of M. tuberculosis gyrase, with a novel mode of action.  As the potential of 
developing natural naphthoquinones such as diospyrin and 7-methyljugalone as a 
novel class of gyrase inhibitor hold much promises, their activity against S. aureus in 
vivo as well as S. aureus gyrase in vitro were chosen as a starting point for the 
investigation.   
4.15.1 Inhibition of S. aureus growth in liquid culture 
Target-based antibiotics discovery are often hindered by the ability for the reagents 
to effectively penetrate the cell wall and/or cell membrane of the target bacteria.   We 
therefore decided to begin assessing the potential of naphthoquinones agent against S. 
aureus by monitoring the ability for the compounds to suppress growth or kill the 
bacteria in liquid culture.   All of the six naturally obtained naphthoquinones tested 
were able to demonstrate dose-dependent growth inhibition against S. aureus, of 
which diospyrin (MIC ~32 µM), neodiospyrin (MIC ~16-32 µM) and menadione (MIC 
~32 µM) displayed the strongest responses.  Whilst these naphthoquinones do not 
provide the ideal potency as an immediate candidate for antibiotics, their cell ability 
to penetrate bacterial are promising given that most drug leads undergo extensive 
medicinal modifications to improve cell penetration properties before a desireable 
potency can be reached.  Since these natural naphthoquinones represent a good 
developmental starting point for more potent drugs. 
4.15.2 Inhibition of S. aureus gyrase and topo IV by natural naphthoquinones 
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Gyrase and Topo IV are proven, efficacious antibacterial targets, owing to their 
important roles in both bacterial growth and survival.  Due to their shared genetic 
origin, Gyrase and topo IV are also highly structurally similar.  Therefore, much of 
known gyrase inhibitors also inhibit topo IV.  The dual-targeting action properties of 
these reagents provide additional potency as well as prevention against resistant-
development.  Previous studies Shantanu et al. 269 discovered that several natural 
naphthoquinones, such as diospyrin and 7-methyljuglone were able to inhibit gyrases 
of M. tuberculosis and E. coli.  Whilst we were able to demonstrate the activity of 
several natural naphthoquinones in vivo, we have decided to investigate the 
inhibition of these compounds against their potential cellular targets: S. aureus gyrase 
and topo IV.  Whilst most gyrase inhibitors displayed fairly comparable activities 
against topo IV, naphthoquinones showed considerable selectivity against gyrase 
over topo IV.  The dual-targeting feature of naphthoquinones also makes it an 
attractive agent from the developmental viewpoint.  Given the structural similarity of 
the two enzymes, the dual targeting characteristic of naphthoquinones against gyrase 
and topo IV also reveal a potentially similar mode of drug binding shared between the 
two enzymes. 
Out of all the naphthoquinones tested, Diospyrin was found to be the most potent 
naphthoquinone against S. aureus gyrase activity, with an IC50 value of ~ͺ μM.  This is 
comparable to the IC50 value of ciprofloxacin ȋ~͵Ͳ μMȌ, one of the most widely used 
gyrase-inhibiting antibiotics in the clinics.  Other natural naphthoquinones which 
inhibits both gyrase and topo IV includes isodiospyrin (Gyrase IC50 ~16 μM), 
neodiospyrin (Gyrase IC50 ~32 μM) and 7-methyljuglone (Gyrase IC50 ~64 μM).  
Isodiospyrin, neodiospyrin and diospyrin all displayed promising activity against 
gyrase.  Diospyrin in particular was able to display sub-10 μM IC50 value without 
medicinal modification.  The activity of these naphthoquinone compounds against 
gyrase, and to a lesser extent against topo IV, suggested promising developmental 
potential towards more potent naphthoquinone variants. 
Bisnaphthoquinones, dimeric analogs of the simple naphthoquinones, are found to be 
more potent than mono-naphthoquinones in vitro and in vivo.   Interestingly, 
coumermycin A1, another dimeric gyrase inhibitor was also a more potent inhibitor 
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than its monomeric analog, novobiocin.  Novobiocin binds to the NTD portion of GyrB, 
whilst its dimer, Coumermycin A1, was found to induce GyrB dimerisation by binding 
to identical pockets in two individual GyrB monomers270.  It remain interesting to discover whether both of the monomer naphthoquinone ǲheadsǳ binds to the same 
GyrB monomer or if it is able to induce dimerisation by binding to two individual 
GyrB monomer simultaneuously. 
4.15.3 Inhibition of S. aureus gyrase by synthetic naphthoquinones 
As we discovered that natural naphthoquinones were capable of inhibiting S. aureus 
DNA gyrase and topo IV, we were intrigued to find out if synthetically produced 
naphthoquinones can reach similar, if not improved potency in vitro.  Thanks to the 
generosity of our collaborators, we were able to obtain 25 synthetic naphthoquinone 
analogs for assays against S. aureus gyrase.  Although some of the naphthoquinones 
were found to inhibit gyrase with below 100 μM IC50 values, only one candidate 
(juglone) displayed near 50 μM )C50 value against S. aureus gyrase.  Given the limited 
chemical diversity in the group of 25 napthquinone analogs tested, it was anticipated 
that the chances of finding a more potent compound would be slim.  If possible, it 
would be ideal to build a chemical library using the chemical structure of 
bisnaphthoquinones such as diospyrin as a chemical template in order to increase the 
chance of developing a compound more potent than natural nathoquinones e.g., 
diospyrin. 
 
4.15.4 Investigation of the site and mode of action of naphthoquinones against 
DNA gyrase 
In order to further develop naphthoquinones as gyrase inhibitors, it is crucial that its 
inhibition profile and mechanism are investigated to assess its mode of binding and 
suitability of modification.  However, previous knowledge of naphthoquinones-gyrase 
inhibition mechanism has been limited.  Shantanu et al. 269 was able to deduce that 
diospyrin is likely to bind the NTD portion of GyrB in vacuo using electro-Nano spray 
MS.  Unlike other GyrB NTD binding inhibitors such as novobiocin, diospyrin does not 
appear to compete with ATP binding of GyrB 253.  To further explore the unique 
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inhibitory mechanism of diospyrin, we studied the GyrB-diospyrin interaction in 
solution and found that the excess of NTD-GyrB was able reduce diospyrin-induced 
gyrase inhibition.  This confirms the previous evidence that napthoquinone inhibits 
gyrase by binding to the NTD portion of GyrB subunit.  Furthermore, we were able to 
establish that naphthoquinone i.e., 7-methyljuglone and diospyrin were able to 
partially inhibit (~1/3) ATPase activity of GyrB at saturating ligand concentrations ȋͺͲ μMȌ.  This inhibition profile is distinct from other known GyrB-NTD targeting 
gyrase inhibitors e.g., novobiocin, which occupies the ATP pocket and inhibits ATPase 
activity in a competitive fashion.  Furthermore, diospyrin was found to display 
inhibitory action against Cipro-induced DNA cleavage activity of DNA gyrase.  The 
novel inhibition mechanism displayed by diospyrin showed it to be a truly unique 
class of inhibitor of DNA gyrase.  Through further investigative on the naphthoquinones’ precise mode of binding and inhibition, there is hope that this 
novel inhibitory mechanim can be exploited to design novel anti-gyrase antibacterial 
agents.  In chapter 5, we describe the attempt to examine and define the mode of 
binding of naphthoquinones against GyrB using protein crystallography. 
4.15.4 Pharmcophore modelling of gyrase inhibiting naphthoquinone 
Without the structural information of the drug binding site on the target, one of the 
most used strategies in drug discovery industry is to produce a pharmacophore 
model.  This involves linking the inhibition data of numerous compounds tested and 
their spatial and chemical characteristic to predict which of these features 
contributed to improved potency or affinity.  This pharmacophore could in turn 
provide valuable insights to for future ligand designs without the structural 
knowledge of the target.  The range of natural and synthetic naphthoquinones 
analogues tested against the S. aureus gyrase provided a mass of data sufficient for 
the construction of the pharmacaphore model.  The model clearly illustrates positions 
of potentially important ligand contact, which could be used as a guide in the future 
for the design of gyrase inhibiting naphthoquinones. 
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Chapter 5 Protein x-ray crystallography  
5.1 Introduction  
We have identified two aspects of this current study that have the potential to benefit 
from structural information from protein crystallography: the binding of diospyrin, 
and the proposed monovalent metal cation (M+) binding site of DNA gyrase.  Based on 
extensive evidence from previous experiments (Chapter 4) (e.g., diospyrin affects 
ATPase hydrolysis and addition of EcB43 to gyrase reduces supercoiling inhibition by 
diospyrin), there were strong indications that diospyrin reside in the N-terminal 
domain of GyrB.  In addition, there are also suggestions of the putative M+-ion binding 
located in GyrB-NTD 231.  Although the putative M+ ion binding site has not been 
observed in the previous structures of the EcGyrB-NTD-ADPNP complex 68,271, it is 
important to note that these data might not have been of sufficient resolution to 
distinguish a water molecule from a Na+ ion due to their similarity in electron density.  
In addition, previous crystallography studies did not include Na+ and K+ in the 
crystallisation conditions thus reducing the chance of observing M+-binding.  We 
therefore decided to re-examine the possibility of M+-binding sites by pursuing higher 
resolution structures of the E. coli GyrB-NTD-ADPNP dimer complex in the presence 
of K+ and Na+ ions. 
5.2 Production of EcGyrBNTD-ADPNP complex crystals 
As there is no existing evidence proving crystallisability of S. aureus GyrBNTD, we 
have decided to utilise established crystallisation condition218  to produce protein 
crystals of E. coli GyrBNTD-ADPNP complex for ligands soaking and co-crystallisation 
experiments with diospyrin and 7MJ.  E. coli GyrB-NTD fragment is expressed and 
purified according to chapter 2.7.3.5 (figure 5.1).  Diffracting protein crystals were 
successfully produced (fig. 5.2) using the method and conditions described in 2.9.1.2, 
resulting with a diffraction resolution of ~1.8 - 2.1 Å. 
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Figure 5.1. SDS PAGE of purified recombinant E. coli GyrB-NTD (43 kDa) 
 
 
 
5.3 Crystallisation attempts for 7-methyljuglone (7MJ)- and 
diospyrin-complexed EcGyrBNTD 
As diospyrin and 7MJ were found not to compete with binding of ADPNP, we 
proposed that its might be possible to generate 7MJ/diospyrin-EcGyrBNTD-ADPNP 
crystals.  As EcGyrBNTD is a proven crystallisable construct, we have chosen this 
construct for the generation of 7-methyljuglone and diospyrin-bound EcGyrBNTD 
crystals.  To achieve this, we decided to use two strategies: crystal-ligand soaking and 
co-crystallisation. 
Figure 5.2. Crystals of 
EcBNTD-ATP obtained in 
100 mM Tris.HCl pH 8.0, 
15-25% PEG3350, 2 mM 
MgCl2 (No salt). 
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5.3.1 Diospyrin and 7-methyljuglone ligand soaking 
Although production of the EcGyrBNTD-ADPNP crystal was successful, soaking of the 
crystals in saturating concentrations of 7MJ and diospyrin for up to 24 hrs failed to 
produce drug-complexed crystals, as no additional electron density consistent with 
7MJ and diospyrin was observed.  The solvent content of the crystals was predicted to 
be ~60% 272.  Therefore, sufficient solvent channels should have been available 
within the crystal to allow drug diffusion.  It is possible that the binding pocket was 
concealed by tight crystal packing, thereby blocking the access of 7MJ/diospyrin.  As 
diospyrin and 7MJ binding affects ATP hydrolysis, we suspected that 7MJ/diospyrin 
binding might require conformational changes in the GyrBNTD.  Therefore, diospyrin 
binding might not be permitted with the restricted protein conformation allowed 
within the rigid crystal packing of EcGyrB-ADPNP crystals.  
 
In order for the ligand soaking approach to succeed, we proposed that generation of 
new crystal forms with alternative protein conformations that allow diospyrin 
binding, would be necessary.  However, attempts to generate alternative crystal 
forms for the EcGyrBNTD-ADPNP complex were unsuccessful, since only crystals with 
morphologies resembling P2221 GyrB-ADPNP crystal were found in the range of 
crystallisation conditions tested. 
 
From these observations, it can be argued that EcB43 highly favours the formation of 
protein crystals in the P2221 space group in the presence of ADPNP.  As the presence 
of ADPNP drives the formation of the GyrB dimer, 273 we attempted to explore 
alternative crystal forms by crystallising EcGyrB-NTD plus or minus diospyrin in the 
absence of ADPNP using preset commercial crystallisation screens.  Disappointingly, 
we were unable to establish any observable crystals from this approach.  This is not 
entirely surprising, particularly since production of crystals of apo GyrB-NTD has not 
been reported to date.  
5.3.2 Diospyrin and 7-methyljuglone EcGyrBNTD co-crystallisations 
Attempts to generate crystals with the EcGyrBNTD-ADPNP-drug complex and the 
EcB43-drug complex in co-crystallisation trials (table 2.9) were also unsuccessful.  As 
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the solubility of 7MJ and diospyrin in crystallisation conditions were low, we 
attempted to increase the DMSO concentration of the ligand soak solution to 20-40% 
(v/v)  in order to increase their saturation concentrations.  Disappointingly, this 
strategy generated either crystals with no drug bound, or crystals with crystal 
packing disrupted by the high DMSO concentration and that did not subsequently 
diffract.  We also generated protein crystals in the presence of 30% (v/v) DMSO in the 
hope of withstanding soaking of drug at up to 30% (v/v)  DMSO.  Despite the success 
in generating protein crystals with 30% (v/v)  DMSO, we were unable to generate 
coloured crystals through soaking.  As both 7MJ and diospyrin were strongly 
orange/brown in colour, this indicated that the attempts directed to generating 7MJ 
or diospyrin bound crystals were unsuccessful.   
 
Overall, it can be concluded that alternative crystallisation constructs might be 
required for generating diospyrin co-crystals of diffraction quality. 
 
5.4 Data collection for Na+/K+-complex EcGyrBNTD-ADPNP crystals 
Crystals for which diffraction data were collected were grown in conditions described 
in table 2.10.  The crystals were also cryoprotected by immersing them in the 
cryoprotectant described in table 2.10.  The diffraction datasets for the H2O, K+, Na+, 
and K+ and Na+ co-crystal of EcB43-ADPNP were collected to 1.95 Å, 1.87 Å, 1.96 Å 
and 2.04 Å, respectively, (table 5.2) at a synchrotron radiation facility (Diamond Light 
Source, Oxford, (K+ and Na+: I24) (IO4-1, K+ plus Na+).  In addition, anomalous 
scattering experiments with the K+ co-crystal of EcB43-ADPNP were collected to 2.92 
Å.  The data collection strategies used for each crystal are listed in table 5.1.  A typical 
image of the diffraction collected is shown in fig. 5.3 
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#Salt Station 
no. 
Wavelength 
(Å) 
No. of images 
taken 
Starting 
angle (°) 
Oscillation 
(°) 
Exposure 
No salt I04-1 0.979 200 79 1.00 1.00 sec 
K+ I24 1.033 1500 39 0.15 0.20 sec 
Na+ I24 1.033 1500 160 0.15 0.20 sec 
K+ * 
anomalous 
I24 1.908 2400 0 0.15 0.07 sec 
K+ plus Na+ I04 0.979 200 21 1.00 1.00 sec 
 
Table 5.1 X-ray data collection strategies for various GyrB-ADPNP co-crystals 
# Salt used during co-crystallisation. 
*Anomalous data collection. 
 
 
Figure 5.3 Typical image collected from the X-ray diffraction of GyrBNTD-
ADPNP crystal grown in the absence of K+/Na+.  Images were collected to 
~2Å. 
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5.5 Data processing  
The diffraction data collected was processed by MOSFILM 219and SCALA 220. 
Subsequent detailed data analysis was carried out using software packages in the 
CCP4 suite 274.  Statistics of processing from the data collected are summarised in 
table 5.2. 
 
Table 5.2. Summary of X-ray data collected for GyrBNTD-ADPNP complexes grown 
in the presence of various salts.  The figures in brackets indicate the values for 
outer resolution shell. 
 No salt K+ Na+ K+/Na+ Anomalous 
K+ 
Space group 
 
P2221 P2221 P2221 P2221 P2221 
Multiplicity 4.1 6.1 8.1 7.8 12.3 
Cell parameters 
(Å) 
 
a = 87.79, 
b = 141.47, 
c = 88.29 
a = 87.86, 
b = 141.07, 
c = 79.55 
a = 87.98, 
b = 140.90, 
c = 79.450 
a = 87.50, 
b = 140.93, 
c = 79.86 
a = 87.98, 
b = 140.90, 
c = 79.450 
Resolution 
range (Å) 
 
54.65-1.95 
(2.00-1.95) 
28.70-1.87 
(6.21-1.87) 
27.20-1.96 
(8.77-1.96) 
74.34-2.04 
(6.12-2.04) 
43.85-2.92 
(13.06-2.92) 
Unique 
reflections  
 
36777 (2671) 35811 (2633) 35811 (2633) 31829 (5102) 1173 (808) 
Completeness 
 
99.3% (100%) 99.9% (100%) 99.8% (99.9%) 99.9% (100%) 99.7% (99.7%) 
Rmerge 0.102 
(0.638) 
0.118 
(0.688) 
0.064 
(0.763) 
0.122 
(0.699) 
0.120 
(0.883) <)>/<σ)> 
 
14.7 (3.3) 7.2 (2.9) 18.7 (3.7) 10.7 (3.6) 12.6 (4.0)  
Wilson B value 
 
41.6 25.69 33.77 27.24 82.76 
Solvent content 57.98% 57.46% 57.08% 57.7% 58.18% 
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5.6 Molecular replacement  
Coordinates of the previously solved 2.5 Å resolution crystal structure of the 
GyrBNTD ADPNP dimer complex 271 were used as the search model for molecular 
replacement after removal of solvent molecules.  Molecular replacement was 
performed using PHASER221 with the P2221 space group.  Preliminary examination of 
the model with Coot 222 suggested two independent molecules with strong 
resemblance to the EcGyrBNTD dimer to form the asymmetric unit.  Solvent content 
of the crystals was estimated using Matthews Coefficient calculations from the CCP4 
package 272.  Calculations from all crystals were shown to contain ~57-58% of solvent 
(table 5.2).  Low Rmerge values of ~0.06-0.122 were also obtained from all the data 
sets collected.  This suggested that the overall conformations of the EcB43-ADPNP 
complex, from all the crystals, are likely to be largely similar to those of the structure 
of the original template. 
5.7 Structure refinement   
Further refinement of the model was carried out using the Refmac5 software to 
perform auto-refinement of the model, typically with ~5-10 cycles of iteration.  The 
auto-refined model was then manually processed using Coot 222 to correct small mis-
alignments of local structures, including manual examination and correction of side-
chain orientations, peptide flips, etc.  This was done using the SIGMAA-weighted 
2mFobs –DFcalc and mFobs – DFcalc Fourier electron density map as a reference 222.  
Finally, the Phenix software package 223 was used for the modelling of the solvent 
water molecules. 
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5.8 Coot modeling of M+ binding sites 
5.8.1 Unexpected discovery of a monovalent cation (M+) binding site - 
Coot modelling of ADPNP co-ordinating M+ ion binding site (site 1) 
From the data collected from the EcB43-ADPNP crystal obtained in the absence of 
K+/Na+, electron density corresponding to a water molecule was observed in a cavity 
between ADPNP, Ile94, Val97, Ala100, Gly117, and Ser121 (fig. 5.4).  A water 
molecule was subsequently inserted manually into the model using Coot.   
 
 
Figure 5.4 Electron density corresponding to the site 1 bound water at the 
ͷ.ͷσ contour level.  The density corresponding to the water is surrounded by six 
oxygen atoms from Serͷ͸ͷ, )le94, Val97, AlaͷͶͶ, Glyͷͷ7 and the Ƚ-phosphate of 
the ATP substrate in close proximity. 
 
Interestingly, we were also able to observe electron density in an identical position in 
the K+ co-crystal of the EcGyrB-ADPNP complex (fig. 5.5).  A manually inserted water 
molecule was rejected by Refmac5, as the actual density was regarded to be too large 
to correspond to a single water molecule.  Given that K+ was included in the 
ATP 
S121 
G117 
A100 
I94 
H
2
O 
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crystallisation condition, we manually inserted a K+ ion by Coot into the model; this 
adjustment was accepted by the auto-refinement process by Refmac5.   
In the same coordinates of the Na+ co-crystal, we discovered an unusual elongated 
area of electron density (fig. 5.6).  As the only difference in crystallisation conditions 
in the Na+ co-crystal was the inclusion of Na+ instead of K+, we assumed that the 
elongated area of electron density to arise from a relatively mobile Na+ occupying two 
slightly different positions. 
 
 
 
Figure 5.5 Electron density corresponding to the site 1 bound potassium at 
the ͷ.ͷ σ contour level.  The density corresponding to the potassium ion is 
surrounded by six oxygen atoms from Serͷ͸ͷ, )le94, Val97, AlaͷͶͶ, Glyͷͷ7 and Ƚ-
phosphate of the ATP substrate in close proximity. 
 
K
+
 
S121 
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Figure 5.6 Electron density corresponding to the site 1 bound sodium at the 
ͷ.ͷ σ contour level.  The density corresponding to the sodium ion has an 
elongated appearance, which suggested the sodium ion can occupy two positions 
at the electron density Na+1 and Na+2.  The density corresponding to the sodium 
ion is also surrounded by six oxygen atoms from Ser121, Ile94 (not shown), Val97, 
AlaͷͶͶ, Glyͷͷ7 ȋnot shownȌ and Ƚ-phosphate of the ATP substrate in close 
proximity. 
 
 
5.8.2 Discovery of a second M+ binding site - Coot modelling of ATP 
lid co-ordinating M+ ion binding site (site 2) 
 
While a M+ binding was discovered at site 1, we were also able to find a highly 
coordinated electron density in all co-crystals of EcB43-ADPNP (Na+, K+ and K+ plus 
Na+) at a second site (fig 5.7).  This electron density is coordinated by the backbone 
carbonyls of Lys103 and Asp105 and four additional areas of electron density 
resembling water molecules in an octahedral fashion.  While manual insertion of a 
water molecule, a K+ or a Mg2+ ion by Coot was rejected by Refmac5, insertion of a Na+ 
ion was accepted.  The fact that the density is situated closely (~2.3-2.4) to the 
Na
+
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coordinating atoms was also closely matched by the theoretical average Na+-O bond 
distance (2.5 Å) of an octahedrally coordinated Na+.  It is therefore highly possible 
that this electron density is in fact a highly coordinated Na+ ion, suggesting a second 
novel M+ binding site in EcGyrB, after the discovery of site 1. 
 
 
Figure 5.7 Electron density corresponding to the site 2 bound sodium at the 
ͷ.ͷ σ contour level.  The electron density corresponding to the sodium ion was 
appeared to form a complex with four oxygen atoms from four ordered water 
molecules, two oxygen atoms from backbone carbonyl of Lys103 and Asp105. 
 
5.9 Building the disordered loop in NTD GyrB 
Prior to initial molecular refinement, it became clear that regions between Asp298-
Glu317 of the EcGyrB-NTD consisted of a relatively disordered loop region.  As the 
quality of the electron density of the loop is not sufficient for auto-alignment using 
automatic refinement (refmac5), we decided to rebuild the loop manually using Coot.  
Initially, the loop region of the model generated by refmac, which aligned poorly with 
the electron density, was removed.  We then manually added amino acids back to the 
two ends of the deleted region, guided by the poor quality region of the electron 
density.  This was continued, with recurring auto-refinement using refmac5 to refine 
the new manual additions made until both ends of the deleted ends were met.  As a 
result, a loop with no secondary structure resulted (fig 5.8). 
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Intriguingly, this flexible loop was discovered to interact with the identical loop of the 
adjacent symmetric related molecule and formed a key part of the contact.  Due to the 
relatively disordered nature of the loop, a significant gain in entropic energy was 
envisaged from its stabilisation through crystal contact formation.  We therefore 
proposed that the stabilisation of this disordered loop to be the key energy driver for 
the crystal lattice formation of the P2221 crystal form.  
 
It possible that this loop contact contributed to the crystal form rigidity observed 
with EcB43-ADPNP and resulted in P2221 being the only crystal form observed.  The 
fact that this construct strongly favours the formation of this crystal form also 
prevents the formation of diospyrin-bound crystal forms.  Therefore, it is proposed 
that the deletion of the disordered loop might be necessary to encourage the 
formation of alternative crystal forms that can accommodate diospyrin binding.  
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Figure 5.8 Disordered loop in the region between Asp298 - Glu317 of the 
GyrBNTD-ADPNP structure overlaid with electron density at ͷ.ͷ σ ȋtopȌ and 
Ͷ.7 σ ȋbottomȌ.  Note the lack of density around the loop region at ͷ.ͷ σ and the 
reappearance of poor quality electron density at Ͷ.7 σ.  
K307 
V308 
R382 
S309 
K307 
V308 
R382 
S309 
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5.10 Structure validations  
Once the model of H2O, K+, Na+ soak crystal structures are fully refined in Coot, they 
were assessed using Ramachandran plots created via Molprobity (figs 5.9a & b, & 
5.10a & b).  It was clear that vast majority of residues fitted well within the plots.  
Those that were identified as outliers were mainly situated in the disordered loop 
(chapter 5.9).  The outlier are listed as below: 
 
K+-EcB43-ADPNP co-crystal structure: 
o 178 Asn 
o 303 Ser 
o 308 Val 
o 390 Glu 
 
Na+-EcB43-ADPNP co-crystal structure: 
o 178 Asn 
o 303 Ser 
o 305 Ala 
o 306 Ala 
Note that 178 Asn is listed as an outlier both in the K+ and the Na+ structure (figure 
5.9a and 5.10a), which is located in the middle of an exposed loop in a beta-sheet.  
Due to the rotatable nature of the asparagine residue as well as the exposed nature of 
its location within the structure, the electron density of this residue is not precise as 
the rest of the structure.  This might have led to the poor modelling of the 178 Asn 
residue and consequently appear as an outliner in the Ramachadran plot.  Similarity, 
the 303 Ser, 308 Val and 390 Glu of the K+ containing structure and the 303 Ser, 305 
Ala and 306 Ala of the Na+ containing structure are all located within the remodelled 
disordered loop describe in chapter 5.9.  The poor density data of this region of the 
protein structure has led to the poor modelling and subsequently contributed to the 
outliers. 
Overall, the percentage of outlier is ~1% for both sets of data and it is certained that 
the modelling process was carried out with sufficient accuracy. 
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Figure 5.9a. Ramachandran plot (general case (excluding proline, glycine and 
pre-proline) and proline) generated from the refined K+-EcB43-ADPNP co-
crystal structure.275 
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Figure 5.9b. Ramachandran plot (Glycine and pre-proline (the residue before 
proline)) generated from the refined K+-EcB43-ADPNP co-crystal structure.275 
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Figure 5.10a. Ramachandran plot (general case (excluding proline, glycine and 
pre-proline) and proline) generated from the refined Na+-EcB43-ADPNP co-
crystal structure.  275 
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Figure 5.10b. Ramachandran plot (Glycine and pre-proline (the residue before 
proline)) generated from the refined Na+-EcB43-ADPNP co-crystal structure.  275 
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K+-EcB43-ADPNP co-crystal structure 
Refinement 
 
 
Rcryst (based on 95% of data) 
 
0.2101  
Rfree (based on 5% of data) 0.2436  
Ramachandran favoured (%) 96.39% 
Ramachandran outliers 4 
Rmsd bond distances (Å) 0.026 
Rmsd bond angles (°) 2.54 
Average temperature factors (Å) 33.9 
Contents of model  
Protein residues 392 
Magnesium ions 1 
Potassium ions 1 
Sodium ions 1 
ADPNP 1 
Waters 172 
 
Table 5.3 Summary of refinement and model parameters for K+-EcB43-ADPNP co-
crystal structure 
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Na+-EcB43-ADPNP co-crystal structure 
Refinement 
 
 
Rcryst (based on 95% of data) 
 
0.2106  
Rfree (based on 5% of data) 0.2397  
Ramachandran favoured (%) 95.36% 
Ramachandran outliers 4 
Rmsd bond distances (Å) 0.028 
Rmsd bond angles (°) 2.489 
Average temperature factors (Å) 37.257 
Contents of model  
Protein residues 392 
Magnesium ions 1 
Sodium ions 2 
ADPNP 1 
Waters 139 
  
 
Table 5.4 Summary of refinement and model parameters for Na+-EcB43-ADPNP 
co-crystal structure 
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5.11 Novel M+-binding site in the GyrB N-terminal domain 
5.11.1 GyrB-NTD structure: M+ ion binding site at the ATP pocket (site 1) 
5.11.1.1 K+ bound site 1 
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Figure 5.12. Schematic diagram of the site 1 K+ coordination contacts. 
 
From the electron density data, we were able to identify a M+-binding site coordinating the Ƚ-phosphate of the ADPNP substrate analogue (site 1).  Electron 
density corresponding to Na+ and K+ ions were present in site 1 in the NaGlu- and 
KGlu-grown crystal, respectively.  Electron density equivalent to a water molecule is 
found in site 1 when no K+ or Na+ was included in the crystallisation condition.  As 
shown in Figure 5.10, site 1 when bound with K+ is octahedrally coordinated by six 
oxygen atoms contributed by Ile94 in helix 3, Val97 and Ala100 from the subsequent loop, Glyͳͳ͹ and Serͳʹͳ from helix Ͷ and the oxygen atom from the Ƚ-phosphate of 
the bound ADPNP.  The K+ ion is evenly positioned within the octahedral ǲcageǳ 
formed by the six oxygen atoms, with an average M+-O distance of 2.8 Å.  This 
correlates well with previously studied K+-binding proteins, which commonly consist 
of 4-8 M+ binding ligands with the average M+-O distance of ~2.8 Å 276.  
5.11.1.2 Na+ bound site 1 
Interestingly, when a Na+ ion occupies site 1 an unusually elongated density is 
observed (fig. 5.5).  It resembles a mobile Na+ freely shifting between two positions 
towards ADPNP and Val97 of the binding site (figure 5.12).  By assuming that the Na+ 
ion is evenly distributed between the two positions simultaneously, the average M+-O 
distance of tetrahedrally co-ordinated Na+ in position 1 (closer towards ADPNP) and 
position 2 (closer towards Val97) are 2.975 Å and 2.55 Å respectively.  This would 
suggest that Na+ is too small to fit into the site 1 M+ binding site and thus appears to 
have a more mobile mode of binding when compared to K+. 
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Figure 5.14 Schematic diagram showing details of the site 1 Na+ 
coordination contacts and distances between the coordinating O and the 
Na+.  Na+1 and Na+2 are the positions occupied by two 0.5 occupancy Na+.  
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5.11.1.3 K+ binding in site 1 confirmed by anomalous scattering signal 
While molecular refinement suggested site 1 to be occupied by K+ in the K+ co-crystal 
of EcGyrBNTD-ADPNP, we were interested in confirming this finding by detecting the 
presence of K+ via anomalous scattering.  The anomalous diffraction data were 
collected at 1.907 Å wavelength to a resolution of 3.0 Å.  The geometry of the 
anomalous density collected was then lined up with the previously solved EcGyrB-
ADPNP-K+ structure (2.04 Å).  The coordinates of the K+ were generated using the 
density from the phased anomalous maps difference map.   
 
Figure 5.16 Raw anomalous signals observed in site 1 M+ binding site.  The 
white grid depicts the anomalous signal observed in the K+ co-crystal of 
EcGyrBNTD-ADPNP at the 5.5 σ contour level.  Data were collected at 1.907 Å.  
The electron density appears to coordinate with the oxgen on the Ƚ-phosphate of 
the ADPNP substrate, carbonyl groups of ile94, Val97, Ala100 and Gly100, and 
the hydroxyl group of Ser121, which overlays with the position of site 1 K+ in 
figure 5.11.   
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Figure 5.17 Anomalous signals observed in site 1 M+ binding site. Data are 
collected at 1.907 Å wavelengths.  The Cyan sphere depicts the coordinates of the 
peak of anomalous signals detected in relation to the EcGyrBNTD structure.  It 
appears to overlay with the position of site 1 K+ observed in the crystal grown in 
the presence of K+.  Minor scattering signals (red spheres) observed are 
contributed from the phosphorus atoms of the bound ADPNP.  Structure of 
EcGyrBNTD is shown in magenta.  Figure was produced in Pymol 277. 
 
As shown in the figure 5.16 and 5.17, the white grid from figure 5.16 and the cyan 
sphere from figure 5.17 depict the position of the anomalous density observed.  This 
position completely overlays with the site 1 M+ binding site thus confirming that the 
enlarged electron density observed in site 1 of the K+ co-crystal to be a K+ ion.  Any 
additional minor anomalous signals observed belonged to the phosphorus atoms 
from the ADPNP substrate analogue, since phosphorus scatters weakly at the 
wavelength (1.907 Å) tested.  The signals from the three phosphorus ions from the 
bound ADPNP provided a secondary positional reference and further re-enforced the 
authenticity of the K+ induced anomalous signal at site 1.  The presence of anomalous 
signal, together with the difference in interatomic distances between the K+ and Na+ 
GyrB-NTD cocrystal, electron density and the ATPase activity analysis, we conclude 
that site 1 is occupied by K+ instead of Na+.  
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5.11.1.3 K+ binding is preferred in site 1 
As K+ and Na+ were both capable of binding to site 1, we decided to explore the 
preferences between K+ and Na+ binding in site 1 using x-ray crystallography.  We re-
grew the EcB-NTD-ADPNP complex crystal in the presence of 100 mM NaCl and 100 
mM KCl.  Diffraction data of the crystal were collected and processed similarly to the 
K+ containing crystal.  The electron density at site 1 M+ recorded in the K+/Na+ co-
crystal exhibited a similar relative intensity to that obtained in the K+ co-crystal.  
Molecular refinement confirmed that the site 1 M+ in the K+/Na+ co-crystal to be K+.   
This is possibly due to a difference in affinity between the K+ and Na+ ions towards 
site 1.  This demonstrated that site 1 has a preference for K+ binding over Na+.  
Previous studies on M+ binding proteins showed that selectivity between Na+ and K+ 
binding are established by geometric constraints of the enzyme and thereby resulting 
in a change in entropic cost of accommodating M+ ions of difference sizes.  We would 
therefore argue that site 1 of E. coli GyrBNTD is geometrically configured to 
accommodate K+ over Na+.  We propose that this constraint is imposed by the ǲoctahedral cageǳ formed by oxygen atoms from protein backbone carbonyls, a serine 
residue and Ƚ-phosphate of the ATP substrate.  Detailed analysis of the geometric difference in the ǲoctahedral cageǳ between K+/Na+/H2O bound site 1 and the 
resultant ion selectivity would be discussed in chapter 5.11.1.4. 
 
5.11.1.4 Structural differences between EcB43 with K+/Na/water bound site 1 
There is no significant difference in the overall conformation of EcB43 with 
K+/Na+/water bound at site 1.  Nevertheless in a closer examination, we were able to observe slight differences in size of the ǲoctahedral cageǳ formed by the oxygen atoms 
that coordinate with the M+ ion (fig. 5.18).  As the coordinate errors for the Na+-
ECBNTD and K+-ECBNTD structure are 0.17A and 0.1A accordingly, it is unlikely that 
the observe differences in bond distances are the result of data inaccuracies.  When 
K+ is bound at site ͳ, the ǲoctahedral cageǳ is found to be significantly smaller than 
when Na+ or H2O is bound at site 1 (fig. 5.18 & .19).  The reduction in the ǲcageǳ size 
possibly indicates that K+ is able to establish good contacts with the six-coordinates in site ͳ and is able to ǲpull the cageǳ towards it. 
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In the case of the Na+-bound site 1, while the theoretical Na+-O bond distance is 
expected to be shorter than the K+-O bond due to its smaller ionic radius, the cage is 
bigger for the Na+-bound site 1.  This is possibly due to Na+ not being able to make 
sufficient contact with the coordinating oxygen atoms within site 1 and as a result was not able to pull the ǲcageǳ as well as K+ does.  This notion is supported by the 
apparent elongated density observed in Na+-bound site 1 that suggest a relatively 
mobile Na+.   
 
The fact that K+ binding is preferred at site 1 as observed in the anomalous data, 
together with the evidence above provide strong evidence that Na+ does not bind to 
site 1 as well as K+.  While K+ and Na+ binding in site 1 is only differentiated by their respective ion sizes and charge density, this suggests that the ǲoctahedral cageǳ is 
possibly conformationally restricted and could not form a smaller cage that can 
comfortably accommodate the Na+ ion. 
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ADPNP ;Pα=OͿ - Val97 
(O=C) 
Ile94 (O=C) - Gly117 
(O=C) 
Ser121 (-OH) - Ala100 (C=O) 
K+ 5.8 Å 5.4 Å 5.6 Å 
Na+ 6.3 Å 5.6 Å 6.1 Å 
H2O 6.2 Å 5.7 Å 
5.8 Å 
 
 
Figure 5.18 Dimensions of the Octahedral cage of site 1 M+ binding site 
between the K+/Na+/H2O bound EcB43-ADPNP structures.  
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5.11.2. GyrB-NTD structure: site 2 M+ ion binding site 
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In all of the EcB43-ADPNP structures where the crystals were grown in the presence 
of no salt, NaGlu, and KGlu, an electron density corresponding to Na+ was found in the 
centre of both of the ATP lid of GyrB (fig. 5.20), a flexible loop that forms a major part 
of the ATP pocket in present in GHKL ATPases.  The presence of this novel M+ site 
(site 2) was not envisaged as, unlike site 1, there was no previous indication of this 
site in other GHKL ATPases.  Although this site has particular amino acid residues 
that are conserved across the bacteria kingdom (fig. 5.22) (Lys 103 and Asp 105), 
there are also a range of other conserved amino acids close to the site that are highly 
conserved.  The highly conserved nature around this site might be driven by the 
needs to accommodate the ATP rather than the need for Na+ ion binding.  Similar to 
site 1, the site 2 M+-binding site is octahedrally coordinated by oxygen atoms.   Two of 
the oxygen ligands were contributed by the backbone carbonyls of Asp105 and Lys 
103 from the ATP lid and interestingly four ordered water molecules were also 
involved.  The coordinating water molecules form an extensive hydrogen bond 
network with backbone carbonyl and side chain groups of nearby residues, including 
Tyr109, Arg110 and Ser112 of the ATP lid, Pro328 and Glu329 of the transducer 
domain, and Arg22 of the adjacent GyrB monomer (figure 5.21 & 5.22).  While 
traditionally water is regarded as a mobile molecule that rapidly exchange in and out 
of the protein surface 276, it is rather common to find 1-4 water molecules stably 
bound to M+ and amino acids around the M+ binding sites in M+ activating proteins. 
 
In other M+ activating proteins, the M+-coordinating water molecules would typically 
form a stable hydrogen bonding network around the amino acid residues around the 
M+ binding site 278-279, supporting the function of the enzyme by acting as an 
important structural feature of the protein scaffold.  While bulk Na+ exchanges its 
surface water with the bulk solvent at a high frequency 276, the enclosed environment 
created by the ATP lid could shield the Na+ from freely exchanging water molecule.  
This restriction on the movements of the coordinating water molecules subsequently 
creates the framework that provides the six oxygen atoms crucial for the octadentate 
binding of the Na+ ion (fig. 5.21). 
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The hydrogen bond network links together functionally important interfaces between 
the ATP lid, the transducer domain and the conserved Arg22 from the adjacent GyrB 
monomer.  While the ATP hydrolysis in ATPase domain and the movement in the 
transducer domain in type IIA topoisomerase have been suggested to be closely 
linked during strand passage 280, the GyrB-NTD dimer interface determines the 
integrity of the N-gate, which is crucial to the proposed 2-gate strand passage 
mechanism 85,281.  
 
This network of interactions created by the presence of Na+ could potentially stabilise 
the flexible ATP lid, assist GyrB dimerisation and coordinate movements between the 
ATPase domain and the transducer domain. 
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As Na+ binding was observed in the absence of Na+ supplement in the crystallisation 
condition, it is possible that Na+ contamination from the protein stock was sufficient 
to occupy the site.  Interestingly, only a water molecule was observed in site 1 in the 
same crystallisation condition, which indicates that the affinity of Na+ to site 2 is 
much stronger than it is to site 1.  Additionally, crystals grown in the presence of 100 
mM K+ did not displace the Na+ ion bound and therefore suggests that site 2 has a 
strong if not a complete preference for Na+ binding over K+.  
 
5.12. Discussion 
5.12.1 Biochemical function of the M+ sites in GyrB-NTD 
While divalent ion binding and function in proteins is well understood 282-284, the 
roles of monovalent ions on protein structure and function is not as well elucidated.  
Many proteins are known to require Na+/K+ ion for their activity but there is little 
understanding on the role that Na+/K+ has on their functions 276.  As the Na+ ion 
electron density closely resembles a well-ordered water molecule, it is often not 
easily identified in crystal structures.  In the case of E. coli GyrB-NTD, stable crystals 
were obtained readily in the absence of K+ and Na+ in the past46,60.  Due to the 
prevalence of a M+ site among GHKL ATPase, there were previous suggestions that 
the M+ site could exist in GyrB (a GHKL ATPase). 
 
Here two novel M+ binding sites have been identified in the NTD of GyrB, where site 1 
can accommodate both K+ and Na+ (with a preference for K+), and site 2 has an 
explicit preference for Na+.  It is suggested that the minimum size of M+ ion that can fit 
into site 1 is restricted, which leads to Na+ being less well fitted with the smaller ionic 
radius and shorter M+-O distance.  Intriguingly, the differences in ATP hydrolysis rate 
of E. coli GyrB in the presence of K+ is marginally higher than in Na+ from the 150-600 
mM range (fig. 3.24), which could be the result of K+ being better fitted to site 1 M+ 
site.   In addition, supplementing E. coli gyrase with both Na+ and K+ (described in 
chapter 3.8, fig. 3.17) also increases their supercoiling activity, with K+ showing 
significant stimulation over Na+. 
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The fact that site 2 does not accommodate K+ yet K+ was able to stimulate both 
ATPase and supercoiling activity of E. coli gyrase, provides a clear indication that the 
concentration-dependent stimulation by M+ is likely to originate from site 1 but not 
site 2. 
 
5.12.2 Site 1 and 2 M+ belong to type I and II M+ activation, respectively 
In the review of M+-activating proteins assembled by Cera et al 276,285, the enzymatic 
mechanisms of M+ activation among these proteins were carefully grouped into type I 
and type II.  He described that type I activating M+ behaves as a co-factor, where the 
absence of the M+ completely abolishes enzyme activity276.  Type II activating M+ 
behaves as an allosteric effector and stimulates baseline activity upon binding276.  
From analysis of the structures of M+ activating enzymes285, it is found that type I M+ 
typically coordinates with the substrate and directly influences its binding.  Type II 
M+ however does not have direct contact to the substrate and instead would bind to 
regions where enzyme activity could be influenced indirectly285.  Structurally, under 
this system of classification, site 1 and site 2 M+ binding site of GyrB would belong to 
type I and type II M+ respectively. 
 
Furthermore, type I M+ activation can be further divided into type Ia and Ib (figure 
5.23 & 5.24).  Type Ia enzymes would require the binding of M+ for substrate binding, 
while type Ib enzymes allow substrate binding in the absence of M+ but cannot 
catalyse the reaction without the M+.  As a result, despite the absolute M+ ion 
requirement of type I enzyme, type Ia activation is not dependent on M+ 
concentration.  Whereas in a type Ib enzyme, its kcat would increase with the increase 
in M+ concentration as the enzyme becomes saturated with M+. 
 
In the case of GyrB, the M+ concentration-dependent stimulation profile of ATPase 
and supercoiling strongly resembles that of a type Ib (fig. 3.24).  Indeed, 
crystallographic evidence also supports the idea that GyrB is capable of binding 
ADPNP in the absence of a monovalent metal cation (M+) 46,60, which accords with 
substrate binding behaviour of type Ib. 
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Figure 5.23 Schematic diagrams showing the kinetics of M+ activation for 
type Ia, type Ib and type II.  Enzyme (E) freely complexes with the monovalent 
cation (M+) and the substrate (S) in all the listed type of M+ activating enzyme.  
However, in the case of type Ib, M+ binding is only possible in the absence of the 
substrate.   
 
 
Figure 5.24 Typical profile of kcat versus monovalent alkali metal ion 
concentration ([M+]) of type Ia, Ib and II M+ activating enzymes.  
Reproduced from Page & Cera 2006 276 
Chapter 5   X-ray protein crystallography 
 
191 
 
 
Although we were able to observe baseline ATPase activity from E. coli GyrB in the 
absence of K+/Na+ supplement (fig. 3.23, fig. 3.24), we proposed that it could be the 
results of the stimulation from low-level M+ contamination in the enzyme stock.  
Overall, the evidence further enforces the suggestion that M+ binding in site 1 is 
crucial to ATPase activity and supercoiling activity of DNA gyrase. 
 
5.12.3 Structural role of site 1 M+ ion in Gyrase – evidence from the 
conserved M+ ion binding site in GHKL ATPase 
 
 
Figure 5.25 Position of monovalent ions (purple and red) in relation to the 
ADPNP substrate (green) in various GHKL ATPases: position of Mg2+ is 
indicate as a cyan sphere 61.  Top left – branched-chain Ƚ-ketoacid 
dehydrogenase (BCK); top right – DNA mismatch repair protein MutL; bottom 
left – heat shock protein 90 (Hsp90); bottom right – CheA histidine kinase (CheA). 
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The existence of site 1 M+ was previously predicted 61  as other members of the GHKL 
ATPase family were found to possess an M+ binding site in a similar region (fig 5.25).  
These M+ sites in other related GHKL ATPase are found to be crucial to their ATP 
hydrolysis activity 61,286-287.  Moreover, the positioning of the M+ binding site in site 1 
coincides with the predicted position of the putative M+ site suggested in Gubaev et al 
281.  This putative M+ site was suggested as B. subtilis gyrase requires K+ but not Na+ 
for its supercoiling activity.  Subsequent single molecule experiments showed that the 
complete closure of the N-gate requires the presence of K+ ion.  K+ binding to this 
putative site in B. subtilis gyrase was suggested to be crucial to establishment of GyrB-
NTD dimer contacts281. 
 
5.12.4 GyrB N-terminal Strap – the link to site 1 M+ function 
On re-examining the Single-Molecule Fluorescence Resonance Energy Transfer (SM-
FRET) data from Gubaev et al.281, narrowing of the N-gate is found to be almost 
unaffected by the replacement of K+ by Na+ as the distance between E17C (B. subtilis 
gyrase) residues of the two GyrB monomer is almost identical in the presence of 
potassium or sodium ions.  Yet there is a major difference in the distance between 
S7C residue residues of the two GyrB monomers, located in the N-terminal strap.  
Surprisingly, given that E. coli gyrase has been the subject of molecular study for the 
past 30 years, there is little biochemical understanding on the function of the N-
terminal strap of GyrB (fig. 5.26).   
 
Structural information on GyrB suggested that the N-terminal strap forms contacts 
with the ATP lid of the adjacent GyrB monomer, this includes a crucial contact in the 
form of an antiparallel Ⱦ-strand, with three backbone H-bonds formed between Kͳͳ’ 
and G101, L13′  and H99 (′  indicates amino acids groups from adjacent monomer).  
This is interesting as A100 (its carbonyl group forms one of the six oxygen atoms that 
originates site 1 M+ site), sits in between residues G101 and H99 (fig. 5.27).  This 
close proximity of the M+ binding site to the dimer-forming interface for the N-strap 
provides strong indication that the M+ binding in site 1 results in the difference 
observed in the N-terminal strap in the presence of K+ and Na+ in B. subtilis gyrase 281. 
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Figure 5.26 (Top) Top view of the EcGyrBNTD-ADPNP-Mg+-K+-Na+ dimer complex, 
with opposing monomers in blue and red.  Position of ADPNP (cyan stick), K+ (purple 
sphere), Mg+ (green sphere), Na+ (cyan sphere) in relation to the GyrB dimer are 
depicted.  Positions of the N-terminal straps are indicated by the red arrows and dashed 
line boxes.  (Bottom) Side view of the EcGyrBNTD-ADPNP-Mg+-K+-Na+ dimer 
complex.  Positions of the N-terminal straps are indicated by red/blue arrows and 
dashed line boxes.   
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Figure 5.27 Antiparallel β-strand contacts between the N-terminal strap of 
GyrB (Red), and the ATP lid of the adjacent GyrB monomer (Blue) in an 
assembled GyrB dimer: Lys11-NH-OC-Gly101, Lys11-CO-HN-Gly101 and 
L13-NH-OC-His99.  The figure also illustrates the proximity of the strap contacts 
to site 1 M+ bound. 
 
Although it is clear that K+ and Na+ are likely to influence the inter-dimer contact in 
the N-terminal strap, we currently do not understand how the binding of M+ would 
contribute to this effect.  As depicted in the structure (fig. 5.27), the region between 
Leu98 and Gly102 would lack secondary structure in the absence of the adjacent 
monomer.  The binding of M+ ion on site 1 could act as an anchor and support correct 
positioning of the loop region between Leu98 to Gly 102 in relation to the rest of the protein, enforcing a conformation that allows crucial Ⱦ sheet contacts to be made with 
the N-terminal strap of adjacent GyrB monomer. 
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5.12.5 M+ specificity of site 1 - implication on K+ specificity in S. aureus 
and B. subtilis gyrase 
When the crystals were grown in presence of equimolar of K+ and Na+, K+ was found 
to occupy site 1.  In addition, the electron density resembles the K+ density observed 
in the K+-only crystal and is bigger than the Na+ in site 1 of the EcGyrBNTD-ADPNP 
crystals grown in NaCl only.  This ultimately suggested that K+ is the preferred ion in 
site 1 and it is quite possibly the result of a large Kd difference between K+ and Na+ 
binding in site 1. 
 
As Na+ is able to replace the function of K+ in E. coli gyrase by supporting ATP 
hydrolysis and supercoiling, it is apparent that the Na+-binding is stable enough to 
maintain the function of the site 1 M+ site in E. coli GyrB despite the ill fit.  No major 
conformational difference was observed between the GyrBNTD-ADPNP complex with 
water, K+ and Na+ bound in site 1, despite the obvious activity difference between the 
presence and the absence of K+/Na+.  This is not surprising, as previous structures, i.e., 
MutL (GHKL ATPase) in complex with Na+, K+ and Rb+ in the equivalent site, showed 
little structural difference despite the difference in the enzyme stimulation between 
the ions 61.  This overall indicates that K+/Na+ does not influence GyrB conformation 
but perhaps functions as a structural stabiliser which ensures the integrity of the N-
gate during supercoiling. 
 
In the case of S. aureus and B. subtilis gyrase, they both exclusively require K+ for their 
supercoiling activity 224,231.  Sodium ion (Na+) supplementation could not stimulate 
the supercoiling activity of S. aureus and B. subtilis gyrase in the absence of K+ 224.  If 
M+ binding in site 1 is indeed the origin of this ion preference, deriving from the 
observation that Na+ is less tightly fitted in site 1 and that site 1 M+ binding might be 
size dependent, we hypothesised that M+ binding site 1 of S. aureus and B. subtilis 
gyrase might not support Na+ binding and therefore only K+ can support its activity.  
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5.12.6 Number of site 1 M+ ions required for gyrase supercoiling and 
ATPase activity 
Mutagenesis studies 288 suggested that hydrolysis of ATP in only one of the GyrB 
monomers was sufficient to support a single round of DNA strand passage in gyrase.  
However, as the mutant enzyme studied was able to bind to ATP 288, it can be argued 
that the binding of a second ATP is potentially important to gyrase supercoiling and 
ATPase activity.  The discoveries of the novel site 1 M+ binding site located in the ATP 
pocket therefore raised the question of whether M+ binding on one or both of 
monomer(s) of the GyrB dimer is required for gyrase activity.   
 
On closer examination, we found that stimulation of DNA-independent ATPase of S. 
aureus gyrase by low concentration of Na+ and K+ (0-700 mM) (fig. 3.23) show 
characteristics of sigmoidal kinetics.  In addition, both S. aureus gyrase supercoiling 
also showed weak evidence of sigmoidal stimulation by K+ (fig. 3.8).  This sigmodial 
concentration-dependent stimulation by K+ and Na+ could be signs of a cooperative 
binding event from K+.  However it would certainly require evidence from more detail 
kinetic studies in order to support the claim and prove the existence of the sigmodial 
relationship between K+ concentration and enzyme activity. 
 
5.12.7 Possible function of site 2 M+ – the key to ion specificity in S. aureus 
and B. subtilis gyrase 
It is interesting to note that Gross et al 289 discovered a mutant gyrase with a point 
mutation at Lys103 has intact ATPase, yet defective supercoiling activity.  This 
phenotype is consistent with both S. aureus and B. subtilis gyrase in the presence of 
Na+ only.  Interestingly, Lys103 is one of the two residues coordinating the site 2 M+ 
ion in the EcB43 structure.  If the defective supercoiling activity observed in Na+-
supplemented S. aureus and B. subtilis gyrase is indeed contributed by site 2 M+, it is 
possible that the K+ specificity is the result of site 2 preferences in K+ binding in S. 
aureus and B. subtilis gyrase. 
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Currently there is no clear evidence that could suggest the distinction in function 
between the two M+ binding sites and which of these sites leads to the K+ dependency 
and specificity of S. aureus and B. subtilis.  The transitional mechanism of gyrase 
between closing of the N-gate and the opening of the DNA gate during the strand 
passage event is one of the least understood steps within the dynamic reaction cycle 
of gyrase supercoiling.  Further understanding of the functions these two M+ have on 
supercoiling could gives us important insight of this transitional mechanism. 
 
5.12.8 Biological implication of M+-binding sites and K+-dependent 
supercoiling activity stimulation 
The latest evidence of a structural mechanism of M+ binding on supercoiling activity 
of DNA gyrase enables further suggestion that the intracellular concentration of 
K+/Na+ could affect the DNA supercoiling activity of gyrase in vivo.  It is known that 
intracellular concentrations of K+ and Na+ varies in S. aureus to counteract osmotic 
stress asserted by the extracellular environment 290.  Such variation in K+ and Na+ is 
known to affect global DNA topology of the bacterial chromosome, as DNA stacking 
and supercoiling is sensitive to the ionic environment 291-292.  It would therefore be 
expected that a cellular mechanism has been evolved to swiftly adjust the 
supercoiling state of the bacterial chromosome in response to the osmotic changes. 
 
There is a previous proposal of intracellular ATP/ADP concentration ratio being the 
primary control of intracellular gyrase activity and that DNA topology would be 
attuned by this mechanism to react to metabolic activity of the bacteria and 
availability of nutrient.  In E. coli, a salt shock induced by 0.5 M NaCl increases both 
negative supercoiling as well as intracellular [ATP]/[ADP] ratio 293.  It is not known if 
the increase in negative supercoiling is the result of the changes in [ATP]/[ADP] ratio 
or vice versa.  There is a secondary mechanism which regulates DNA topology by 
adjusting expression level of gyrase via the Leu500 promoter that is up-regulated 
when the chromosome becomes positively supercoiled 294.  Both of these mechanisms 
could be slow to respond to rapid environmental changes e.g., osmotic changes, which 
could exert instant changes on DNA topology intracellularly295. 
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Based upon the finding that gyrase supercoiling is sensitive to the concentration of 
the M+, possibly via the novel M+ binding sites discovered, we propose a third possible 
mechanism, in which DNA gyrase activity and DNA topology are directly regulated by 
changes in K+/Na+ intracellular concentration as a result of external osmotic changes.  
As DNA topology could temporarily collapse when halotolerant bacterial are 
subjected to sharp changes in osmotic stress 296-297 , DNA interacting proteins e.g., 
DNA and RNA polymerase could stall under the intense DNA torsion 297-298.  Under 
these circumstances, this newly proposed mechanism could provide a kick start to 
these processes by restoring DNA topology swiftly, by the increases in gyrase 
supercoiling activity as a result of M+-dependent stimulation.  In the case of S. 
typhimurium and E. coli, the subsequent changes in DNA topology could trigger up-
regulation of the proU locus, which produce components of the glycine betaine 
transport system to counteract the osmotic stress 296.   It is envisaged that this 
mechanism would be particularly important in bacteria capable of adapting to a wide 
range of osmotic environment e.g., the halotolerant S. aureus.  
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Chapter 6 General Discussion 
6.1 Advances in understanding the S. aureus DNA gyrase 
mechanism 
S. aureus DNA gyrase has been known for its unique dependency on relatively high 
concentrations of KGlu for its ability to negatively supercoil DNA 199,224.  This 
interesting phenomenon has led us to believe that there are unknown mechanisms 
and features of the enzyme that is responsible for the difference in KGlu dependency 
between S. aureus gyrase and other gyrases studied in the past.  Here, we have 
utilised an array of mutagenesis and biochemical assays to probe and elucidate the 
origin of the KGlu dependency of S. aureus DNA supercoiling activity in detail.   
Deriving from the results of the mutagenesis study on the domain swap SaNTD-
EcCTD GyrA mutant, we successfully demonstrated that the CTD of Sa GyrA have 
partially contributed to the KGlu dependency.  Primary sequence analysis and 3D 
protein model predictions did not reveal possible structural differences in the 
SaGyrA-CTD.  However, analysis of surface electrostatic charges of the protein model 
of S. aureus gyrase indicated a reduction in positive charges on the DNA contact 
surface when compared with E. coli gyrase.  We proposed that this change on the DNA 
wrapping surface reduces the ability for S. aureus gyrase to wrap DNA, thereby 
leading to its characteristic salt dependency. 
Although we noticed an extended C-terminal acidic tail located in GyrA, deletion 
mutant did not show any reduction in salt dependency and therefore proving that the 
C-terminal tail did not contribute to the KGlu dependency at all. 
Since ATPase activity is vital to supercoiling ability of gyrase, we also investigated the 
effects of KGlu, NaGlu and KCl on ATPase of Sa gyrase.  We found the ATPases of both 
Sa and Ec GyrB to be significantly stimulated by KGlu/NaGlu/KCl at lower ranges of 
concentration (~150-200 mM), thereby showing a K+/Na+ dependent stimulation of 
ATP hydrolysis in both Sa and Ec GyrB.  This would also explain the less than optimal 
supercoiling activities in E. coli gyrase with no salt. Despite the KGlu-specific nature of 
supercoiling stimulation, replacement of Glu- with Cl- as a counter ion to K+ did not 
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have significant affect on ATP hydrolysis of Sa and Ec gyrase.  We proposed that the 
differential behaviour in the DNA wrapping by GyrA-CTD in S. aureus gyrase is 
responsible for the KGlu-dependent stimulation at high salt concentration (600-900 
mM), whilst ATPase also contributes to the salt-dependent supercoiling at lower 
concentrations (150-450 mM). 
Through structural data of GyrB obtained from X-ray protein crystallography.  We 
have discovered two novel M+ ion binding sites in the NTD of GyrB.  One of the M+ 
sites directly coordinates the non-hydrolysable ADPNP substrate and the ATP binding 
site, while the second M+ site is found under the ATP lid, in the structurally crucial 
interface between the ATPase domain, the transducer domain and the adjacent GyrB 
monomer.  As the second M+ binding site in E. coli gyrase explicitly accommodates 
Na+, we proposed that M+ binding site 1 is responsible for the K+/Na+ ability to 
stimulate ATPase activity in a concentration dependent manner.  Intriguingly, both K+ 
and Na+ are able to stimulate ATPase activity of B. subtilis gyrase, while K+ but not Na+ 
is specifically required for the closure of its N-gate 281.  We therefore anticipated that 
one/both of these M+ site(s) has/have two mechanistically different roles; both of 
them are vital to the function of DNA gyrase: 
1. Activation of ATPase activity; 
2. Maintaining the integrity of the N-gate (possibly via the GyrB ǲN-terminal strapǳȌ 
Whilst it has been more than 30 years since the discovery of DNA gyrase, it is exciting 
that we are still able to unearth novel mechanisms that underpin its dynamic reaction 
cycles.  This is another addition to the mechanistic complexity of DNA gyrase, which 
employs numerous strategies to ensure good coordination between the intermediate 
steps within the reaction cycles. 
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6.2 Novel chemical scaffolds, novel inhibition mechanisms and 
potentially novel drug leads from naphthoquinone gyrase-
inhibitors 
Herein, we have established that natural naphthoquinones are both inhibitors of S. 
aureus bacterial growth in vivo and inhibitors of S. aureus gyrase and topo IV in vitro. 
We found that one of the natural naphthoquinones tested, diospyrin, displayed a 
novel mode of inhibition of gyrase by binding to an unidentified region within the 
NTD of GyrB.  Diospyrin, unlike other known GyrB inhibitors, inhibits the activity of 
gyrase without competing with the binding of ATP.  Furthermore, it also inhibits the 
DNA cleavage activity of DNA gyrase.  The overall characteristics of diospyrin-gyrase 
inhibition concluded that it is an inhibitor that inhibits gyrase in a novel mechanism. 
We believe that naphthoquinone could become a useful chemical scaffold for the 
design of novel gyrase inhibitors owing to the simplicity of their chemistry and 
potential ease to synthesise.  Overall, we believe that diospyrin exhibits the potential 
to be an ideal drug lead, and naphthoquinone as a potential gyrase-inhibiting 
antibacterial agent merits further investigation. 
6.3 Future work 
6.3.1 M+ ion binding kinetics, its role in enzyme coordination and 
potential for drug design 
Following the discovery of the two novel M+ binding sites in EcGyrBNTD, it would be 
of interest to investigate the binding kinetics of these two M+ binding sites 
individually using calorimetric methods (e.g., ITC).  It is also believed that the binding 
of one or both of the M+ can have a crucial influence on the ATP binding kinetics of the 
GyrB subunit.  The generation of mutant gyrase bearing modifications surrounding 
the two M+ sites to alter its M+ binding affinity, could be useful in dissecting the 
individual roles of the two M+ ions on gyrase function.  However, as most of the direct 
contact between GyrB and the two M+ ions involves backbone carbonyls, it is 
envisaged that binding affinity of these M+ ions would be difficult to alter by simply 
mutating the amino acids in contact with the ion.  Nonetheless, it might be possible to 
Chapter 6   General Discussion 
 
202 
 
disrupt the network of connections by producing mutations around the M+ binding 
sites to create subtle differences in the distances between the six coordinating-oxygen 
atoms and the M+ ion. 
In light of the current evidence of the novel M+ binding sites and previous discovery 
on the effect of K+ on the dimerisation of the N-terminal strap of B. subtilis231, a crucial 
link between one or two of the M+ binding sites and complete N-gate closure is 
envisaged.  Experiments in a similar format to the single-molecule FRET (smFRET) 
studies conducted by Gubaev et al.231 could potentially be used to examine the 
function of these M+ binding sites using mutant gyrase with altered M+ binding 
properties.  It would also be intriguiging to study the effect of M+ on the strength of N-
gate assembly.  This can be investigated using DNA-attached magnetic tweezers to 
study the amount of force required to break open the N-terminal gate in the presence 
and absence of K+ or Na+ ions. 
6.3.2 The possible role of M+ in gyrase activity regulation in vivo 
The role of M+ on DNA gyrase in vivo can be examined, by exploring the hypothesis of 
the gyrase-dependent mechanism that adjusts DNA topology of the cell in response to 
osmotic pressure and intracellular K+/Na+ concentration.  This could involve 
replacing wt gyrase with a mutant gyrase that shows reduced or increased affinity to 
K+/Na+ in vivo.  As the potency of the gyrase-targeting antibiotics is closely linked to 
the activity of gyrase, it would be important to understand the relationship between the osmolarity of the bacteria’s external environment and the enzymatic activity of 
gyrase.  
6.3.3 Identification of the diospyrin-binding pocket 
As we are confident of the potential of naphthoquinones as gyrase-inhibiting 
antibiotics, it would be vital to identify the binding pocket of diospyrin in order to 
understand molecular details of the contacts between the enzyme and the drug.  Our 
failed attempts to co-crystallise diospyrin with the GyrBNTD construct suggests that 
alternative constructs may be required for the production of diospyrin-GyrB co-
crystals.  Flexible regions within the GyrBNTD construct can be deleted in order to 
improve the ability for the construct to be crystallised.  Alternatively, alanine 
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scanning of the surface residues in the NTD of GyrB could possibly reveal the binding 
location of diospyrin, should diospyrin-GyrBNTD protein crystals prove to be 
unattainable. 
Diospyrin is the only known inhibitor that is able to inhibit DNA cleavage of gyrase.  
We believe that a more comprehensive understanding of the mechanism, involving 
diopsyrin inhibition, could further enhance our knowledge on the molecular events 
crucial to the initiation of the DNA cleavage process. 
6.3.4 Development of naphthoquinones as novel antibacterial 
agents 
With the lack of attention on developing new classes of Gyrase-inhibiting 
antibacterial, gyrase is a proven antibacterial target that has been under-exploited.  A 
new class of Gyrase inhibitors could be the ǲlow hanging fruitǳ that pharmaceutical 
companies have been searching for.  The discovery of diospyrin as a novel gyrase 
inhibitor and its in vivo activity as an anti-S. aureus agent in this study showed a 
promising starting point of a novel anti-bacterial.  In order to further develop 
naphthoquinones, aside from the further information needed for its mode of binding, 
it is crucial to explore new naphthoquinone entities from a medicinal chemistry view 
point.  This study has showed limited yet crucial pharmocophore information, which 
provides guidance for the medicinal development for a more effective 
naphthoquinones.  In the future, it would be crucial to confirm and extend the current 
pharmcophore model to develop nathphquinones with improved affinity. 
During the development process of a new reagent, whilst it is important to improve 
its affinity towards its cellular target, the success of an antibacterial agent will also 
depend heavily on its ability to penetrate bacterial and human cells, as well as its 
toxicity profile.  In order to achieve this, further studies have to be conducted to 
assess the properties of naphthoquinones through in vitro cellular assays.  This will 
need to be carried out in conjunction with medicinal modifications to improve 
naphthoquinones cell permeability (logP) profile as well as improving toxicity by 
reducing the occurance of secondary targets interactions in human cells. 
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Recently, various two ǲheadedǳ reagents with two separate pocket-binding moieties 
with excellent gyrase inhibition properties has been found 168.  This ignites the 
potential of designing new reagents with improved potency, capable of binding 
multiple pockets on the surfaces of DNA gyrase.  Previously we speculated that 
binaphthoquinones, such as diospyrin and Neodiospyrin, may bind to multiple 
binding pockets simultaneously.  It may be possible to further improve the potency of 
naphthoquinones by altering the ǲheadsǳ or the ǲlinkerǳ region via medicinal 
chemistry.  
6.3.5 Further understanding the gyrase supercoiling mechanism 
The complexity of DNA gyrase reaction steps and the interplay between the gyrase 
and the DNA substrate has captured the curiosity of scholars in the past 3 decades.  
Due to the complex nature of gyrase, scientists are still yet to fully understand the 
mechanism of this DNA machinery.  Although great advances have been made to 
understand the static structure of gyrase and its subdomains, the dynamic 
movements of these subdomains in relation to each other, during the reaction cycle, 
are poorly understood.  Recent efforts from the Klostermeier group 299-301 and other 
single molecule studies 88,302-303, have shed light on the dynamics of some of these 
processes.  All of these studies have been carried out in native DNA gyrase, therefore 
potential studies using gyrase mutants with altered properties using these single 
molecule techniques may provide further clues to its dynamic properties. 
6.4 Concluding remarks 
Antibacterial resistance is a long battle that would endure with the continuous use of antibiotics for bacterial infection treatments.  )t is clear that there is no single ǲmagic bulletǳ for the combat the resilience of these bacteria, supported by the most 
successful biological process, evolution.  Antibiotics are urgeably one of the most 
important types of drug and is the pilar of the western health care system, not only 
providing a safety net to the range of bacterial infections encountered but also to 
ensure the safety and recovery of all open wounded surgery operations.  Currently, 
pharmaceutical companies are opting to invest on therapeutic areas with greater 
financial return, such as cancer, pain and inflammation and mental illnesses, rather 
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than bacterial infection 231.  Therefore improvement in the progress of antibiotics 
discovery can only be instigated with a radical change in the currently dysfunctional 
financial model of antibiotics funding, perhaps with governmental backing.  Moreover 
the daunting technical prospect to sustain the continual fight against the worsening 
antibacterial resistance would certainly require a concerted effort of scientists, 
medics, drug developers and the government.   
Whilst novel anti-bacterial therapy such as phage therapy, antibody-based therapy, 
quorum sensing and other preventive therapy such as vaccination offer glimpses of 
hope towards improving prospects of antibacterial treatment, much of these 
approaches are in their infancy and each of them presents their own unique 
challenges.  It will be a long time until they are ready to replace the convenience, 
immediacy and efficacy of current antibacterial treatments.  Although it would only 
be a matter of time these new technologies will become viable treatment options, 
antibacterial-resistance development will not cease and patients suffering daily from 
reoccurring bacterial infections will be desperate for the new treatments.  Given the 
urgency of tackling the global problem of antibiotics resistance, we truly believe that 
old and reliable antibacterial targets, such as DNA gyrase would provide the perfect target for the next generation of ǲgolden bulletsǳ. 
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